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Abstract 
Orally administered therapeutic agents need to cross the mucosal epithelial membrane in the 
intestine to reach the systemic circulation. This intestinal epithelial membrane is covered by a 
biopolymer barrier, namely, mucus which protects the underlying layer through trapping or 
degrading of foreign particles and macromolecules. Thus, mucus can restrict the systemic 
absorption of some therapeutic agents such as peptides by enzymatic degradation. Nanoparticles 
(NPs) could serve as a carrier for these peptides to protect them from environmental conditions 
in the mucus and to increase their bioavailability. However, these NPs can be trapped 
themselves by the mucus, hence, a proper nano-strategy should be selected to deliver these 
peptides orally. NPs delivery through intestinal mucus barrier has been studied extensively, 
where various in vitro tests and mucus models were investigated to mimic the in vivo test. In 
this thesis, two mucus models were assessed for their suitability as intestinal mucus barrier 
through which NPs diffusion can be studied. Also, multiple particle tracking (MPT) technique 
was exploited to study the diffusion and interaction of nanoparticles through pig intestinal 
mucus barrier. This technique (MPT) was used to understand the factors affecting the diffusion 
through mucus of NPs representing various nano-strategies such as PEGylated NPs and 
mucolytic NPs. Based on data obtained for the diffusion of NPs, we adopted a nano-strategy 
mimicking the capsid shell virus in which the NPs surfaces are densely covered with oppositely 
charged groups but with overall neutral charge. To do so, polyelectrolyte (PEC) NPs based on 
the self-assembly of (+) chitosan and (-) polyacrylic acid (PAA) were synthesized and the 
diffusion of these densely charged NPs was studied. After proving the concept, RAFT technique 
was used to synthesize zwitterionic densely charged NPs in which butyl methcrylate (BMA) 
was used as the lipophilic core and sulfobetaine as the shell of NPs.  
Native mucus prepared by our group was found to be a proper model to study NPs diffusion 
through it by the MPT technique. Study of diffusion of NPs representing various nano-strategies 
through mucus revealed the impact of various properties of these NPs on their diffusion. For 
example, particle size, zeta potential, type and molecular weight of the polymer, type and 
concentration of the diffusion enhancer and method of synthesis of NPs were detected to affect 
the diffusion of these NPs. For PEC NPs, the data obtained showed a relation between the zeta 
potential of NPs and their diffusivities through the mucus, where the highest diffusivity was 
obtained for the neutrally charged PEC NPs. Accordingly, sulfobetaine NPs were highly 
efficient NPs in term of their stability, charge density, particle size and importantly their 
diffusivities through the mucus barrier which was significantly higher as compared with all 
other tested NPs and related to the ratio of the sulfobetaine polymer in the NPs. This indicates 
that densely charged viral like NPs can be promising carriers to improve the mucus permeation 
of some therapeutic agents.  
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1. INTRODUCTION 
1.a The Mucus Barrier in the Gastrointestinal tract  
Generally, a drug molecule exerts its systemic therapeutic effect only after reaching into 
the systemic circulation. If the injection route is not applicable, then drug molecules 
should be administered either trans-dermally, meaning that the molecules have to cross 
the epidermis, or they may be administered by other routes where the drug molecules 
need to cross the mucosal epithelium layer. The mucosal epithelium layer is covered 
with a biological barrier, namely, mucus which drug molecule need to permeate through 
before crossing the epithelial membrane. For example, therapeutic agent needs to 
permeate the mucus barrier covering the epithelial membranes in the gastrointestinal 
tract (GIT), urogenital tract, pulmonary system, oral cavity or nasal cavity. The 
thickness of this barrier varies depending on the site in the body. For example, it is 
0.578 µm thick in the eye [1], 0.1–50 µm in the trachea [2] and 15-150 µm in the colon 
[3]. 
Functionally, the main roles of mucus are lubricating, hydrating and protecting against 
mechanical stress of the underlying epithelial membrane [4,5]. Moreover, mucus 
represents the body’s first line of defence against harmful particles such as pathogens 
and microorganisms [6,7]. This defensive mechanism, however, extends to include all 
types of foreign particles including therapeutic macromolecules and nanoparticles 
(NPs), meaning that mucus is the key limiting barrier preventing the delivery of various 
macromolecular therapeutic agents [8].  
In the respiratory system and the middle ear, mucus plays the major regulatory role of 
water balance, ion exchange and clearance of foreign particles, while in saliva, mucus 
                                                                                                                                                   Chapter One 
 
3 
 
served as an anti-microbial layer [9]. Mucus in the cervical system has additional 
functions include being a reservoir and transporting medium for sperm [9].   
In the GIT, mucus can be found as either a gel layer or a viscous slippery fluid 
depending on the location within the GIT [10]. The GIT is the part of the body where 
most types of microorganisms and foreign particles are in contact with. Hence, mucus in 
the GIT is thicker and has higher mechanical strength [11,12] compared to other mucus 
barriers in the body,  this helps to prevent the passage of any foreign particles [13]. The 
thicker GIT mucus is not only important to avoid the permeation of foreign particles but 
works together with the bicarbonate buffering system of the GIT mucus to  protect the 
underlying epithelial membrane against the high acidity in the lumen [14,15]. 
Additionally, mucus avoids the permeation of pepsin enzyme that is secreted to digest 
food, hence, by this mean, mucus protects gastric epithelial membrane from auto-
digestion [16].  
Thus, mucus in the GIT serves as a semipermeable membrane that allows nutrients and 
small drug molecules to be absorbed provided these molecules are not affected by the 
GIT environment, such as pH and enzymes [17]. So, therapeutic agents that are small 
enough to permeate through mucus, should not be hydrolysed in the GIT environment; 
otherwise they need to be protected from this environment. This mostly happens by 
incorporating drugs into a colloidal system, like NPs, which in turn will have to cross 
the mucus barrier. Due to their degradation in the GIT environment, peptides and genes 
are the main therapeutic agents that need to be encapsulated into a proper nano-delivery 
system when they are delivered orally [18]. Although these NPs will protect peptides 
from the GIT environment, they will, however, themselves be trapped by the intestinal 
mucus [19]. Difficulties involved with diffusion of macromolecules and NPs through 
the intestinal mucus barrier has been described in many review articles [20–22]. 
                                                                                                                                                   Chapter One 
 
4 
 
Since the trapping mechanism of mucus is mainly correlated to the composition of the 
mucus barrier; it is important to study the composition of mucus in order to arrive at a 
better understanding of how the mucus trapping mechanism might be circumvented.  
GIT Mucus Composition 
Generally, mucus contains 90-95% water regardless of its location in the body,  with 
various ratios of  glycoprotein, electrolytes, lipids, DNA, sloughed epithelial membrane 
and bacteria [23,24]. In most parts of the body, mucus contains around 0.5–5% of 
glycoprotein and lipids, around 1% of mineral salts and 1% of free protein [9]. 
Although the water content usually doesn’t change in response to diseases or position in 
the body, the other components are highly affected by the location and healthiness of 
the mucus [25]. Larhed et al. (1998) [26] found that dry pig intestinal mucus (mucus 
was dried prior to the measurement) encompasses 5% glycoprotein, 37% lipids, 39% 
proteins and 6% DNA.  
The high DNA content was linked to the high rate of slaughtering of epithelial cells into 
the intestinal mucus. The high DNA content (4%) in the intestinal mucus has also been 
reported in another study [27]. Accordingly, high lipid content was attributed to the 
release of the lipid after the digestion of food. This intestinal lipid is removed when 
mucus is purified by various extraction and separation methods leaving the purified 
mucin in lack of this ingredient [28]. Lipid content plays a major role in the permeation 
of lipophilic drugs. Larhed et al. (1997) [29] studied this correlation by comparing the 
permeation of lipophilic drugs in a native pig intestinal mucus model and in a purified 
pig intestinal mucin model. In contrast to the native mucus which showed direct 
correlation, purified mucin showed no relation between drug lipophilicity and 
permeation through the mucus. Other sites in the body possess different ratios of mucus 
constituents which are supposed to exhibit different influences on drug permeation. For 
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example, the dry content of human ocular mucus comprises 29% protein, 53% 
carbohydrate and 12% lipid; bovine submaxillary glands have 31% protein, 58% 
carbohydrate and 11% lipid, while ovine  submaxillary glands exhibit 33% protein, 53% 
carbohydrate and 14% lipid [9].  
Even with the important role that other ingredients of mucus have, the key element in 
mucus is the glycoprotein content. In the 1960s, researchers agreed to refer to the 
glycoprotein units in mucus as mucin and to identify mucin as the building block of the 
mucus [30]. Mucin fibres are responsible for the formation of the mucus viscoelastic 
structure through the protein and the glycosidic residues of these units. The protein parts 
are responsible for the formation of the network and the glycosidic parts are responsible 
for the swelling of this network [31,32]. Understanding the chemical composition and 
physical properties of mucin is, therefore, the only way to understand the whole 
physicochemical properties of mucus barrier. 
2. Mucin Structure and Composition 
Mucin macromolecule is a large glycoprotein with an average molecular weight of 
2000-10000 kDa [33,34]. In electron microscopy (EM), purified mucin units are 
appeared curvilinear fibres with an average diameter of about 5–7 nm  and a length of 
about 200 to 4000 nm [35,36]. The purification process involves extraction and 
separation step to remove other components adsorbed into mucin fibres. The diameter 
of non-purified freshly collected mucin fibre is appeared thicker in EM, with a diameter 
range of 30-100 nm due to the adsorption of various mucus components such as 
lysozyme [37]. At high concentrations mucin (20-40 mg/ml), a mucus gel network is 
formed by interconnection of mucin macromolecules via various types of interactions  
[38]. 
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Mucin macromolecule is formed from 3-4 mucin monomers, each has a molecular 
weight of  3-5 x 105 Da [16]. Each of these subunits, or monomers, consists of 
glycosylated and non-glycosylated protein domains in consequent order (Figure 1.1). 
The glycosylated domains are composed of polypeptide backbones rich with threonine, 
serine and proline (PTS) amino acids (aa) [39] and are densely coated with glycosylated 
side chains (Figure 1.1). These glycosylated protein domains are separated by non-
glycosylated protein regions (Figure 1.1) which are rich with cysteine aa.  These naked 
protein regions are responsible for linking glycosylated domains by means of 
intramolecular disulphide bonds [34]. Functionally, the densely glycosylated regions are 
resistant to proteolytic enzyme, while the naked protein regions are susceptible to 
proteolysis due to the absence of the protective glyosidic side chain [40,41]. 
 
Figure 1.1: Structure of mucin subunit showing the glycosylated domain and the naked 
protein region (Cysteine domains). 
Structurally, each polysaccharide side chain is linked to the polypeptide core through an 
O-glyosidic linkage between the α -1 position of the N-acetylgalactosamine and the 
hydroxyl groups of the serine or threonine units [42,43]. The glycoprotein structure of 
mucin is unique in the body, with its polypeptide backbone that is predominantly 
formed of the hydroxyl containing aa (Serine and Threonine) and the O-glyosidic 
linkage between the peptide chain and the glycosylated side chains [44]. Moreover, 
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mucin is also unique in terms of the degree of glycosylation, where the polysaccharides 
consist 80% of the total weight of mucin and each glycosylated region is covered with 
around 160-200 glyosidic side chains [20].  
Besides the secreted mucin, there is another mucin type, known as cell associated mucin 
(Figure 1.2). This type of mucin has a transmembrane region which is responsible for 
fixing of mucin into the epithelial surface. The extracellular part of this mucin type 
possesses a unique region, namely, the SEA domain (sea-urchin sperm protein, 
enterokinase and agrin). This unique domain is responsible for splitting the extracellular 
mucin from the transmembrane part in response to any mechanical stress or auto-
proteolysis process without affecting the membrane [45].  The extracellular part of the 
cell-associated mucin is similar to other secreted mucin types in having a high PTS 
content. This extracellular part is projected 100 nm from the epithelial surface with 
around 5000 aa along the polypeptide backbone.  
 
Figure 1.2: Cell associated mucin containing the cytoplasmic region, SEA domain and 
the glycosylated polypeptide extracellular region. 
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Also, mucin can be classified depending on the encoding genes, which are known as 
MUC genes. Each mucin type is named after the same encoding gene, i.e. MUC1 is 
named after the MUC gene 1. These MUCs share almost the same structural PTS 
backbone. Up to date, various MUC gene types have been isolated and identified, for 
example: MUC1, MUC2, MUC3A, MUC3B, MUC4, MUC5AC, MUC5B, MUC6, 
MUC7, MUC8, MUC11, MUC12, MUC13 and MUC16 [46,47]. In human, MUC1 and 
MUC4 have been identified as the MUC gene for the cell associated mucin type  
[48,49]. Accordingly, regarding secreted mucin in the GIT, MUC genes are expressed 
as follows: (i) MUC5b, MUC7, MUC19 are highly expressed in the oral cavity, (ii) 
MUC5b is highly expressed in the oesophagus, (iii) MUC5ac and MUC6 are the 
predominant type in the stomach, (iiii) MUC2 is the main gene in the small intestine 
and  MUC2, MUC5b, MUC6 are the main genes in the large intestine [27]. 
MUC2 was found to be the predominant mucin type in the small intestine of human 
[50], rats [51], mice [52] and pigs [53]. Although some studies showed minor levels of 
MUC11 and MUC6 in the small intestine, MUC2, which is secreted by goblet cells, still 
has the major influence on the properties of the intestinal mucus including the barrier 
properties against the absorption of therapeutic agents [54].  
The polypeptide backbone of each MUC2 subunit consists of 5100 aa (Figure 1.3), 
which are divided into glycosylated and non-glycosylated regions and C and N 
terminals [55]. In MUC2, there are two main glycosylated regions that are separated by 
a 148 aa Cysteine rich domain [56]. The glycosylated regions can be imagined like a 
bottle brush shape, with the polysaccharide side chains being concentrated in the middle 
of the polypeptide core leaving both ends of the core un-glycosylated (Figure 1.3). In 
regards to the first glycosylated region, the polypeptide backbone mainly consists of up 
to 100 repetitive blocks. Each block consists of 23 aa in which the predominant aa, 
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threonine, is linked to N-galactoseamine unit through an O-glycosidic linkage. Each of 
these polysaccharide side chains contains up to 15 sugar units, making them a densely 
packed shield around the polypeptide backbone. Accordingly, the protein core of the 
other glycosylated domain contains 347 aa, which is rich with serine and proline, as 
well as being densely coated with polysaccharides [57].  
 
Figure 1.3: MUC2 structure, the main constituent of intestinal mucus. The Figure 
shows the main two glycosylated regions, the cysteine non-glycosylated region and the 
C and N terminal. 
 The carboxyl terminal (Figure 1.3) is composed of 984 aa in which there is a 
glycosylated peptide subdomain consisting of 139 aa and a cysteine rich subdomain of 
845 aa. The N terminal, meanwhile, contains a cysteine subdomain of 700 aa and 
another glycosylated polypeptide subdomain of 570 aa [58]. The C and N terminals are 
responsible for the end to end oligomerization of mucin subunits through intermolecular 
sulphide bonds to form a long linear chain. The protein core of mucin fibres represents 
around 20% of the total mucin fibres.  
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Conformation of Mucin in the Aqueous Phase 
Generally, there are three types of polymer solutions: dilute, semi-dilute and 
concentrated [59]. Similarly, mucin in solution can form the same three main systems.  
Identification of these systems depends on an important factor called the critical overlap 
concentration (C*), which is the concentration at which polymer molecules overlap to 
each other [60]. The dilute system is characterised by a polymer concentration less than 
the overlap concentration (c << C*), where the polymer molecules are separated from 
each other. At the Simi-dilute system, polymer concentration is equal to the C* and 
intermolecular interactions are existed among mucin fibres, at the concentrated system, 
polymer concentration is much higher than the overlap concentration (c >> C*) and 
entanglement of the polymer network is observed [61].    
A dilute mucin solution can be generated, in laboratory, by hydrolysing mucin 
macromolecules into subunits and dispersing these subunits in water [62]. These linear 
and non-branched mucin subunits are swollen in solution due to the interaction of 
glycosidic chains with water [63]. Accordingly, the mucin unit, the whole mucin fibre, 
has an extended random coil conformation in water [64,65]. However, this 
conformation varies depending on the pH of the media, that is, at pH > 4, negatively 
charged groups in the sugar units and positively charged amino group in the non-
glycosylated cysteine rich domain are interacted resulting in a coiled conformation [66]. 
Oppositely, at pH < 4, sugar carboxylate groups are protonated and the electrostatic 
interactions are broken inducing an extended conformation for mucin [67]. Accordingly, 
coiled conformation of mucin is resulted from folding and rotating of mucin fibre in the 
un-glycosylated region only, i.e. rotating of mucin fibres in the glycosylated domain is 
not possible due to the rigidity provided by the glycosylated side chains [46]. 
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Globally, the approved model of mucin macromolecule conformation is the Carlstedt 
model [64], which describes mucin macromolecule as a flexible extended linear 
filament consisting of 4-5 subunits linked together by disulphide bridges between the 
cysteine rich domains of the C and N terminals. While the glycosidic domains are 
described as swollen regions, the un-glycosylated lipophilic cysteine domains were also 
reported to have unique globular conformations (Figure 1.4), i.e.  un-glycosylated 
domains are arranged just like pearls in the mucin string [68–70]. These lipophilic 
globular regions play major role in the formation of the mucin network gel. 
 
Figure 1.4: Mucin macromolecular conformation.  
Formation of Mucin Network (Gel Formation) 
As was described earlier, mucin is a very high molecular weight polymer, and this 
means that the overlapping concentration C* is very low for these units, indeed, Bansil 
et al. (1995) [71] reported mucin gel can be formed at an average concentration of 2 
mg/ml. Accordingly, Bromberg has shown that purified human tracheobronchial mucin 
can aggregate to form a gel structure at a concentration of 15 mg/ml [72]. This 
overlapping concentration is much lower than the physiological mucin concentration 
(50 mg/ml). Hence, mucin fibres tend to be highly aggregated and entangled at their 
physiological concentration [73]. Moreover, mucin gelation and aggregation was found 
to be happened at relatively lower concentrations when pH is less than 4 than that at 
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neutral pH [74]. Imaging of mucin by atomic force microscopy (AFM) at different pH 
value showed the transformation of mucin from separated filamentous molecules at pH 
6 to an aggregate at pH 4 which followed by formation of clusters at pH 2 [75].  
The mucin network which is the building structure of the mucus gel was found to be 
constructed depending on the formation of disulphide bridges among cysteine rich 
domains [76]. Rheological studies, meanwhile, showed that the electrostatic interactions 
among glycosidic and polypeptide chains, are the main cross-linking interactions 
responsible for the formation of gel at low pH [76,77]. In these studies, it was found that 
the increase of the ionic strength in which mucin fibres are dispersed and introducing of 
thiol reduction agents restricted the formation of mucin gel at low pH levels. This  
finding is in agreement with other studies which showed that the disulphide bridges 
among the cysteine rich domains are the main cross-linking building blocks in the 
mucin gel at any pH conditions [64,78].  
Besides the covalent disulphide bonds, entanglement of glycosidic side chains is an 
essential factor for the formation of mucus gel [79]. McCullagh et al. (1996) showed a 
parallel correlation between the length of the glycosidic side chains and the formation of 
the mucin gel [80]. Another study showed that the interdigitating of the glycosidic side 
chains is another reason for the formation of a stable three-dimensional network through 
the formation of a cohesive intermolecular physical interaction [81]. This was 
confirmed by another study which showed that the destruction of the mucin network by 
proteolytic enzymes did not change the mechanical properties of mucus gel, indicating 
the essential role of the interdigitated glycosidic side chains in the formation of mucus 
gel [82]. 
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Physicochemical Properties of Mucin 
Like any other polymer, the physicochemical properties of mucin are driven by its 
chemical compositions which are the polysaccharide side chains, the cysteine rich 
domains and the disulphide bridges. Firstly, mucin has a negative charge due to the 
negative nature of the polysaccharide side chains. These  are full with sialic acid and 
galactose sulphate ester units which are responsible for the negative charge of mucin 
[83]. Sialic acid has a pKa of 2.6, so it is supposed to be totally charged at the 
physiological pH 7 [84].  In the GIT, mucin is expected to be fully charged in the 
intestine and colon but to be neutral or weakly positively charged in the stomach. On 
the other hand, apart from the glycosidic chain, the presence of aspartic acid and 
glutamic acid in the polypeptide chain is another reason for the negativity of the mucin 
macromolecules [85].  
Secondly, the high lipophilicity of the cysteine-rich domains in the protein core exerts a 
lipophilic nature on the mucin macromolecules [86]. Also, methyl groups at equatorial 
positions of the fucose units in the polysaccharide side chain are also additional 
lipophilic areas within the mucin macromolecules [87]. This structural feature of mucin 
represented by lipophilic cores and a highly charged glycosidic cover indicates 
structural similarity to the highly lipophilic polyelectrolyte particle.  Hence, it is also 
affected in the same way by the environmental conditions, such as the ionic strength and 
the pH of the media [88]. 
Thirdly, disulphide bridges are responsible for the mechanical properties of mucus since 
these bridges are the building block of the mucin network which gives the known 
viscoelastic property of mucus. However, mucin can form either hard gel mucus or 
weak viscous mucus depending on the ratios of the aa in the polypeptide cores and the 
length of the polysaccharide side chains [89]. Hence, other aa within the protein core 
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can affect the physical properties of mucin network. Figure 1.5 shows the structures of 
the main chemical moieties within mucus that are responsible for its  physicochemical 
properties. 
 
Figure 1.5: Structures of Cysteine, disulphide bond, sialic acid, fucose, glutamic acid 
and aspartic acid.  
3. Aspects of Intestinal Mucus 
Besides the physicochemical properties of mucus, there are some other important 
aspects of mucus in the GIT. Studying these aspects makes it easier to understand the 
mechanism through which GIT mucus works as a barrier for the absorption of 
macromolecules. These are as follows: 
Multi-Layered Nature of the Intestinal Mucus 
Early studies on GIT mucus identified the presence of more than one layer within the 
GIT mucus. This concept was based on the analysis of the gastric scraped mucus which 
showed that 22% of mucin was water soluble and up to 80% was insoluble [90]. The 
same researchers observed breaking down the insoluble mucin units into the same 
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subunits of soluble mucin when treated with pronase enzyme indicating that both layers 
are composed of the same subunits but with different molecular weights and solubility 
[91]. Indeed, the enzyme pronase  is able to hydrolyse the mucin network by breaking  
the peptide chains, thus leading to smaller mucin units. Later, examination of the 
colonic mucus in the mouse revealed its two layered nature, with MUC2 being the main 
building block of both layers [55]. These layers were classified as inner and outer layer, 
where the inner layer is adherent to the epithelial membrane, densely packed and 
impermeable to bacteria, conversely, the outer layer is loosely packed, colonized with 
bacteria and continuously moving down through the GIT [92,93].  
 Some studies showed the existence of the two layered mucus only in colon but not in 
the small intestine, these studies interpreted the existence of only a loose layer in the 
small intestine to allow the absorption of nutrients [94,95]. Based on this concept, the 
antibacterial defence mechanism of the small intestine was attributed to the secretion of 
antibacterial agents [96]. This concept has been contradicted by other studies which 
have showed the presence of an adherent mucus gel layer with variable thickness along 
the small intestine  [97,98]. Since this layer is unstirred and adhered to the epithelial 
membrane, it is either called adherent or unstirred layer [99]. 
It is believed that this layer adheres to the intestinal epithelial membrane through the 
entanglement of mucin with the cell associated mucin anchored into the cell membrane  
[100,101]. The cell associated mucin fibres with some of the entangled adherent layer 
form a densely packed layer called glyocalyx. This layer is densely packed with a 
thickness range of 0.1-0.5 µm [102,103]. Glycocalyx is not only a physical barrier or a 
hook to clasp the adherent layer but is highly responsible for the hydrolysis of orally 
administered peptide due to the high enzymatic content [104]. 
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Researchers have studied the difference in the compositions and functions of each 
mucus layer in the small intestine. Since both layers consist mainly of MUC2, gradual 
hydrolysis and dilution of MUC2 as moving away from the secretion sites has been 
proposed as an explanation for the difference between the two layers [105]. 
Accordingly, the presence of high levels of bacteria in the loose layer is argued to be 
responsible for the degradation of mucin by secreting glycosidase enzymes [106]. 
Degradation of glycosidic side chain works together with proteolytic enzymes to break 
down the mucin network producing weaker mucus in the loose layer. The hydrolysed 
mucus in the loose layer is further diluted and weakened by the chyme containing water 
in the intestinal lumen [107].  
Thus, the function of each layer is related to the mechanical strength of this layer. So, 
the unstirred inner layer is maintained intact in order to prevent any permeation of 
pathogens and digestive enzymes [108]. Accordingly, the loose layer, meanwhile, is 
continuously moving in order to wipe and clear bacteria and foreign particles. This 
lubricating effect is essential in order to prevent any quick growth of bacteria in the 
intestinal lumen [109]. Figure 1.6 shows how both mucus layers in the intestine work 
together as a defensive mechanism to prevent the reaching of bacteria and foreign 
particles to the intestinal epithelial membrane. In the eye, for example, where there is no 
adherent mucus layer, fast clearance of mucus is the main defensive mechanism [110]. 
Similarly, the high rate of clearance of the nasal mucus protects the lower respiratory 
tract [111].  Moving on, it is important to understand the rheological behaviour mucus 
so as to realize how the two distinct mucus layers are dynamically retained. 
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Figure 1.6: Defence mechanism of intestinal mucus to prevent permeation of bacteria 
and other particles into the intestinal epithelium by moving the particles away with the 
loose layer. 
Rheological and Mechanical Properties of Intestinal Mucus  
As was described in the previous section, lubricating effect of the intestinal loose mucus 
layer is important to keep the body safe. This lubricating effect is directly correlated to 
the general rheological and mechanical properties of the mucus. Generally, mucus is 
characterised by  a shear thinning behaviour in response to high physiological stress like 
swallowing and coughing [112]. Upon the passage of food or particles, two processes 
occur concurrently. First, mucus forms a very sticky slug (Figure 1.5) around the 
particles due to the formation of many low affinity bonds between various lipophilic 
and hydrophilic domains of mucin network and particles [113]. These bonds are 
continuously deformed and reformed between the flexible mucin fibres and the particles 
so as to keep sticking to the particles. Concurrently, passage of particles exerts a shear 
force onto the planes of the loose mucus layer that is in contact with the particle 
resulting in a shear thinning response and reduction of viscosity [10]. This lower 
viscosity allows the loose layers to slide over each other to form a slippage plane to 
lubricate the movement of the slugged particles.  
                                                                                                                                                   Chapter One 
 
18 
 
The other important rheological property of mucus is its viscoelastic behaviour which 
gives mucus the flexibility to adhere to moving particles [114,115]. Thus, at small shear 
stresses, mucin fibres stretch rather than split apart, followed by spring back. This 
elasticity and flexibility is very important in helping the mucin fibres to rearrange 
around the particles, which in turn keeps the particles stuck in the mucin slug [101]. 
Mucus viscoelasticity is controlled by water and ion content [116], as well as the lipid 
content [117].    
Thickness of Intestinal Mucus  
The thickness of each of the mucus layers varies throughout the whole GIT system 
[118]. Mucus thickness at each site in the body is a consequence of the function of 
mucus at that site as well as the rate of turnover. Mucus is secreted and removed 
continuously either by digestion, recycling or by shedding with a short lifetime [119].  
For example, mucus in the pulmonary system is exchanged in less than 20 minutes 
(min) to ensure quick movement of any harmful particles [120]. Indeed, continuous 
mucus secretion is the origin of the defensive mechanism against irritants since it is the 
source for the shedding of the loose layer and replacement of the unstirred layer. 
Accordingly, it has been found that goblet cells increase their mucus secretion in 
response to intestinal inflammation [121].  
Generally, 1 litre of mucus is secreted into the GIT every day with variable turnover 
times of up to few hours (hr) [122]. In the stomach, secretion should be fast enough to 
avoid the permeation of pepsin enzyme into the epithelial membrane [15]. Lehr et al. 
(1991) [123] measured the rate of mucus secretion and turnover in the rat intestine, 
showing the rate of secretion to be 0.16 µl min-1 cm-1, the volume of adherent mucus to 
be 7.7 µl cm-1, and the rate of turnover to be between 47 to 240 min. Accordingly, a 
comparative study between the rate of turnover of mucus in the jejunum and proximal 
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colon of rats showed that mucus turnover in the small intestine is 2.2 times higher than 
in the colon, with turnover rates of 1.1 and 0.5 µg min-1 cm-1, respectively [124]. 
The thickness of mucus within the GIT has been studied extensively. It is well known 
that gastric adherent mucus layer is the thickest in the GIT system with an average of 
180 μm and a range of 50–450 μm in the human stomach [125]. The adherent mucus is 
thinner in the small intestine with an average thickness of 28 and 93 μm in the 
duodenum and jejunum of rat, respectively [126]. Accordingly, the thickness of the 
colonic mucus in the mouse was found to be 150 μm, with the adherent layer being 
around 50 μm and the loose layer to be 100 μm [93].  
Although many studies have been carried out to measure thickness of intestinal mucus, 
Atuma et al. (2001) [127] study on the GIT of the rat is the most often referred to in 
most review articles discussing this subject. Figure 1.7 was modified from Atuma et al. 
(2001) which shows the thickness of each mucus layer in the GIT rat model. This 
Figure illustrates the thickness of the unstirred layer, which is 154 μm in the stomach, 
15-29 μm in the small intestine and 116 μm in the colon. On the other hand, the loose 
layer is shown to be 120 μm in the stomach, 108-447 μm in the small intestine and 715 
μm in the colon [127].  
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Figure 1.7: Thickness of the mucus along the GIT tract. Yellow area represents the 
loose mucus layer, brown area is the unstirred layer and black area is the glycocalyx 
layer. This Figure is modified from Atuma et al. (2001). 
Intestinal Mucus pH 
As was explained earlier in this chapter, pH plays a role in the aggregation and gelation 
of mucus [10]. The pH varies from site to site along the GIT specifically, intestinal pH 
changes from  the lumen up to the mucus attaching the epithelial membrane where it 
reaches the neutrality [128]. Trials to detect the pH of the intestinal mucus were initially 
conducted by sacrificing the animal (dog) and collecting the mucus from the GIT to 
measure the pH [129]. Average pH in the sacrificed dog was found to be 3.68 in the 
stomach, 5.9 in the duodenum, 6 in the Jejunum, 6.3 in the ileum, 6.5 in the cecum and 
6.8 in the colon. Talley et al. (1992) used the pH microelectrode technique to measure 
the pH in the stomach and to identify the gradient change in the pH of mucus from the 
gastric lumen to the mucosal epithelial membrane [130]. In Talley’s experiment, pH 
microelectrode was inserted endoscopically into human volunteers’ stomach, where the 
pH difference between the gastric lumen and mucosal membrane was found to be 5.3 
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indicating the bicarbonate neutralization mechanism to prevent self-digestion of the 
stomach. 
In the small intestine, reaching of the chyme to the duodenum is accompanied by a 
sharp reduction in the neutral luminal pH [131], thus, luminal pH in the duodenum can 
be reduced down to 2 before being quickly neutralized by mixing with the bicarbonate 
secretions in the duodenum [98]. The large intestine, however, is too distant to be 
affected by the high acidity of the stomach contents. For example, in the large intestine 
of the guinea pig, the pH was found to be neutral [132]. 
Evans et al. (1988) [133] used pH sensitive radiotelemetry capsules to measure the pH 
at each site within the GIT of 66 normal humans. The pH was found to be highly acidic 
in the stomach, with a range of 1 to 2.5, neutral in the small intestine, with an average of 
6.6 in the more proximal part of the intestine and 7.5 in the ileum. The pH was reduced 
in the caecum to 6.4 and raised again in the colon to 7.0 [133].  The same technique was 
used to measure the pH in the GIT of 14 normal children. In the stomach, the pH was 
found to be 1.5, rising to 6.4 in the duodenum and 7.4 in the ileum, the pH was reduced 
in the caecum to 5.9 but increased again to 6.5 in the rectum [134].  
4. Barrier Properties of Intestinal Mucus  
As was described above, mucus completely covers the intestinal epithelial membrane. 
Mucus forms an efficient barrier based on its physical and chemical nature. Physically, 
the mucin network works as a size-based exclusion barrier that prevents the diffusion of 
particles by steric repulsion. Chemically, the defensive mechanism of mucin is based on 
its lipo- and hydro-philic regions, which form low affinity bonds with any particulates 
that come in contact with it, so as to immobilize their movements [135]. Mucus allows 
the free permeation of nutrients and small drug molecules. Early study, however, 
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showed that permeation of some drugs could be highly restricted through the intestinal 
mucus barrier as compared to their permeation in the PBS. This restriction was found to 
be 45% for phenylalanine, 37% for a-methyl-glucoside, 38% for aminopyrine, 40% for 
antipyrine, 46% for benzoic acid and 51% for urea [136].    
Olmsted et al. (2001) [137] used the fluorescent recovery after photo-bleaching 
technique (FRAP) to study the correlation of protein particle sizes to their diffusion 
through the mucus. The Olmsted’s study revealed the following: (i) peptides as small as 
4.1 nm, exemplified by chicken lysozyme, and 4.5 nm, exemplified by porcine pepsin, 
showed almost 100% diffusion in the mucus. (ii) Human immunoglobulin G and A, 
with particle sizes of 11 nm, showed free diffusion in mucus. (iii) Norwalk and human 
papilloma viruses, which have particle sizes of 38 and 55 nm respectively, had also free 
diffusion. (iv) However, human lysozyme (3.5 nm) and cholera toxin B subunit (5.4 
nm) exhibited diffusions of 74% and 68% respectively indicating a non-specific cut off 
particle size and the importance of the surface chemistry of particles in their permeation 
through the mucus [137]. 
Accordingly, using of chamber model to examine the diffusion of a protein with a 
molecular weight range of 126-186000 Da through porcine gastric mucus showed no 
cut off limit, even though a reduction of diffusion was prominent at a molecular weight 
of 30000 Da and above [138]. A similar study in which the permeation through the 
intestinal mucus of peptides with molecular weight range of 3.4 to 66 kDa was studied 
using various peptides such as  bovine serum albumin, myoglobin, lysozyme, 
cytochrome c and aprotinin [139]. This study showed that diffusion was only around 
1% for all peptides molecular weight ranges between 12.4 to 66 KDa, while peptides 
with molecular weight of 3.4 and 6.5 kDa had relatively higher diffusion through the 
mucus (2% and 3% respectively).  
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The trapping of particles has been linked to the multi interactive nature of mucus [140]. 
On this basis, the immobilized diffusion of Herpes simplex virus, having a size of 180 
nm, was explained on the basis of the interaction of the mucus lipophilic domains with 
the lipophilic envelope of the viruses rather than the steric trapping [141]. Comparison 
of mucus permeation of hydrophilic and lipophilic drug models revealed the high 
tendency of pig intestinal mucus to trap lipophilic agents [142]. Thus, the lipophilic 
molecule, testosterone, showed a 6.8 fold reduction in permeability through caco-2 cells 
covered with mucus compared to cells covered with PBS. The same study showed a 
varied reduction in permeability of hydrophilic agents, with a maximum reduction of 
three times for the biggest hydrophilic macromolecules. The retardation of lipophilic 
agents permeability through the mucus secreting cells (HT29) has also been reported in 
many other studies [143,144].  
Accordingly, Larhed et al. (1997) [29] finding is consistent with previous studies on the 
permeability of hydrophilic and lipophilic drugs through the pig intestinal mucus. 
Larhed found that the lipophilicity of drugs is the crucial factor in limiting drug 
permeability through intestinal mucus, while the retardation of hydrophilic agents’ 
permeability through mucus was more apparent for the very high molecular weight 
large peptides. Similarly, Boegh et al. (2015) tested the permeability of various 
lipophilic and hydrophilic drugs through a bio-similar mucus model consisting of 
reconstituted gastric pig mucin containing cholesterol, linoleic acid and BSA [145]. 
This study showed that the lipophilicity and the ability to form H bonds were the 
reducing factors for the permeability of lipophilic drugs, while for the hydrophilic 
peptides, cationic groups was found to be the reductive factor on their permeability 
[145]. The limitation of the permeability of lipophilic drugs through mucus was also 
reported by Meaney et al. [146]. 
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The first evidence that NPs (submicron in size) can diffuse through the mucus barrier 
was shown by Saltzman et al. (1994) [147],  who reported muco-diffusive antibodies 
and particulates in the size range of 30-60 nm. Subsequently, Frey et al. (1996) [103] 
showed that cholera toxin (CTB)-fluorescein isothiocyanate NPs with a size of 6.4 nm 
can penetrate the mucus layer and adhere to the enterocytes of both an in vitro (Caco-2) 
cell line model and within an in vivo intestinal model. In the same study, 28 nm gold 
NPs conjugated with CTB lacked the ability to cross the thick mucus barrier indicating 
the trapping of these relatively small particles by the mucus barrier. Sanders et al. [148] 
demonstrated steric hindrance of the intestinal mucus barrier to the permeation of NPs, a 
hindrance which was dependant on the size of the  particles. They found that 520 nm 
polystyrene NPs were totally trapped by the 220 µm thick cystic fibrosis (CF) sputum 
layer, however the same type of particles but at a smaller size of 124 nm were found to 
readily cross the same barrier. 
The abovementioned outcomes have been used as the basis for the design of nano-
strategies to overcome the mucus barrier (Chapter Three). Thus, the inert surface is 
identified as the hydrophilic surface that is completely covering the internal lipophilic 
core of the particle, so as to prevent any lipophilic interaction of the particles and 
cysteine domains of the mucus. Also, the hydrophilic surface should not form any H-
bonds or electrostatic interactions with the glyosidic domain of the mucin network 
[149]. Particles that are densely covered with a PEGylated shell have been studied 
extensively. The first such study, conducted by the John Hopkins University, revealed a 
very high permeability through the mucus barrier [150]. PEGylated NP have shown a 
high mucus permeability through cervicovaginal mucus [141], CF sputum (pulmonary 
unhealthy mucus) [151], pulmonary mucus (healthy mucus) [152] and through various 
other mucus barriers [153]. In addition to PEG, other surface chemistries were 
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examined for the ability to form an inert surface that does not form  lipophilic, 
electrostatic or H-bond interactions. 
5. Techniques to Measure Particle Diffusion through the Mucus Barrier 
The measurement of particle diffusion through a dynamically active biological fluid 
such as mucus is challenging. Studies should be planned carefully in order to avoid 
misleading permeation data. In this thesis, a multiple particle technique (MPT) will be 
used to measure the diffusion of NPs through the intestinal mucus barrier. Other widely 
used techniques that are very often reported to measure particle diffusion will be briefly 
described.  
Transwell Chamber Technique 
This outdated technique is still the most widely used method to measure particle 
permeation across a static mucus layer. This method involves a donor and receptor 
compartments arranged in parallel or vertically to each other and separated by a layer of 
mucus sandwiched between two membranes. Drugs or particles are applied in the donor 
compartment and the amount of drug that crosses the mucus layer is measured in the 
receptor compartment which is filled with a suitable buffer [138,154]. As well as being 
an easy method, mucus components can be easily altered during the experiment to 
mimic various physiological and pathological conditions [9]. For example, Boegh et al. 
(2015) modified a technique in which the caco-2 cell layer is grown on the membrane 
separating two transwell vertical compartments, then, mucus or bio-similar mucus gel 
consisting of pig gastric mucin is added onto the cell layer and drug permeation through 
this mucosal membrane was measured [140,145].  
This method, however, measures only the average permeation of the bulk sample 
without measuring the behavioural movement and interaction of particles in the mucus 
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[9]. It is also a time consuming method since samples need a long time to cross the 
mucus layer which could be enough time to change the mucus integrity by enzymatic 
degradation or by dilution resulting in clogging of filters or leaking of mucus contents 
into the receptor compartment [8].  
Fluorescence Recovery after Photo-Bleaching (FRAP)    
This method is widely used to measure particle diffusion through highly concentrated 
solutions and bio-gel samples like mucus [155]. In this method, fluorescently labelled 
particles are added into the mucus sample and placed under fluorescence microscopy. A 
confined area of the mucus sample is bleached by exposing to a high intensity laser 
beam which bleaches the fluorescently labelled particles. Then, the unbleached 
fluorescently labelled particles start to move to the previously bleached area, resulting 
in the recovery of the fluorescent intensity of that area. The diffusion of particles 
through mucus is measured from the time at which fluorescent recovery happens [156]. 
Olmsted et al. (2001) used the FRAP technique to measure the diffusion of the 
fluorescently labelled viruses and polypeptides through mucus [137]. Similarly, 
Saltzman et al. (1994) [147] used this technique to measure the diffusion of antibodies 
through the cervical mucus. 
The FRAP technique was also used to study the effect of mucin on particles’ 
aggregation. According to Afdhal’s concept [157], the increase in the sizes of 
cholesterol vesicles was attributed to the interaction with mucin, resulting in particle 
aggregation. Other techniques like Pulsed-gradient spin-echo NMR (PGSE-NMR) and 
small angle neutron spectroscopy (SANS) have also been reported to measure particles 
diffusion through mucus barrier [158,159].  
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MPT Technique to Measure Particles’ Permeation through the Intestinal Mucus  
MPT involves the video microscopy and post-acquisition analysis of time-resolved 
particle trajectories within the particular matrix under study, e.g. cell cytoplasm, mucus, 
etc. As a technique, it allows for the dynamic measurement of the movement of 
individual particles within a heterogeneous matrix [160], and as such, contrasts to static 
techniques which quantify only the bulk movement of particles [161]. MPT is not only 
capable of the accurate assessment of the diffusion for hundreds of particles both 
individually and simultaneously [162] but also provides ‘behavioural’ or qualitative 
information for hundreds of particles both individually and simultaneously about the 
environment in which the particles are moving. In particular, it can reveal information 
about particle-matrix interactions e.g. interactions of particles with mucin fibers or the 
steric trapping of particles within the mucus mesh network [163]. Such qualitative 
information is obtained through  the more in-depth analysis of the time-resolved particle 
trajectories to determine the different modes of particle diffusion [164] (see also below).  
The Hanes group have been prominent early pioneers in using MPT  to assess particle 
diffusion through heterogeneous matrices [165]. The group subsequently applied the 
technique to understand and quantify particles, including NPs, to transport them through 
a range of heterogeneous biological samples [160,161].  For example, the group used 
MPT to study the transport of amine and carboxylated modified polystyrene NPs 
through the sputum of cystic fibrosis patients and related the respected transport to the 
micro-viscosity and macro-viscosity characteristics of the sputum [166].  The group has 
also used MPT to quantify, for example, the intracellular transport of non-viral 
polyethylene-imine/DNA nano-sized polyplexes [167].  
MPT involves the simultaneous capture of the movement of hundreds of individual 
particles within a particular matrix, the basic principles of which include: 
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 Labeling of the particles with a fluorescent dye whose physicochemical properties 
are appropriate for the particle under study, and which will provide a high signal to 
noise ratio in the biological matrix under investigation.  Issues such as high 
background auto-fluorescence of the matrix itself can compromise image quality and 
particle tracking [168].  Although not essential, a confocal microscopy platform may 
allow for an improved signal to capture noise data as more defined excitation and 
emission sources can be selected (see below). 
 Inoculation of particles within the matrix. Clearly the pre-experimental preparation 
of the matrix will impact on the efficiency and effective distribution of particle 
inoculation. Similarly, the concentration of the particle inoculum itself can cause 
particle aggregation within the matrix [150]. In mucus samples (0.5 g) it was found 
an inoculum of a 25 µl 0.002% NP suspension to consistently lack aggregation 
problems. Particle distribution within the matrix also requires a period of 
equilibration following inoculation and prior to the video capture of the experiment. 
Typically, mucus samples are equilibrated with particles at 37°C for 2 hr prior to 
experimentation. 
 Video-microscopy capture of particles’ movement within the matrix.  This will 
involve the maintenance of the matrix under the appropriate physiological 
conditions, e.g. 37oC, and the use of a high speed camera to capture the particle 
movements. Typically, camera speeds of  at least 30 frames per second are used with 
videos of generally 10-20 seconds in length; the short collection periods are 
sufficient to collect robust data and help to minimise sample degradation issues, e.g. 
as discussed for mucus [9].  
 The microscope itself may be either a standard wide-field Epifluorescence or a 
confocal type. Nevertheless, for mucus samples, particle movement is most 
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commonly captured in 2-dimensions (X-Y), principally due to the isotropic nature of 
the matrix, i.e. particle movement in X=Y=Z.  Furthermore, 2-dimensional capture 
avoids inaccuracies in subsequent data and trajectory analysis that may be introduced 
by the process of Z-sectioning through the sample.  
The basic principles involved the post-acquisition analysis of particle movement and 
particle trajectories include: 
 Use of appropriate software, e.g. Fiji Image J, which can track the video movements 
of the particles at resolutions as high as 4 nm [169]. The software converts the 
movement of each particle as captured by high-speed video microscopy into 
individual particle trajectories. Appropriate rules need to be applied to the analyses 
e.g. videos capturing particle movement in 2-dimensions should show that any single 
particle eligible for analysis must remain within the same X-Y plane throughout all 
the frames of the entire video capture period.  
 The movement of particles is translated into individual particle trajectories which are 
initially represented as numeric pixel data. This data is then converted from pixels 
into metric distance based on the microscope and video capture settings. From this, 
the inter-frame distances moved by each particle in the X-Y plane are expressed as a 
squared displacement (SD). The mean square displacement (MSD) of one particle 
represents the geometric mean of the sum of all of that particle’s square 
displacements throughout its transport trajectory [170]. Typically, in a single 
experiment, MSD data is calculated for at least 120 particles of each NP species 
under study, and the average of these MSD values (ca. 120 values) represents an 
“ensemble mean square displacement” defined by <MSD>.  The ensemble Effective 
Diffusion Coefficient <Deff> of a particular NP species  can then be determined  by  
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<Deff> = <MSD>/(4*frame rate), where 4 is a constant relating to a 2-dimensional 
mode of video capture and the frame rate relates to the speed of video capture  [151].  
The MPT technique tracks the change in movement of each single particle as a function 
of time.  Unlike particle diffusion in water, which is non-restrictive and unchangeable 
with time, particles will undergo varying degrees of hindrance during their diffusion 
through a polymeric gel matrix such as mucus.  Here the mucin fibres are undergoing 
continuous association  and disassociation and the network as a whole undergoes elastic 
behaviour  resulting in the formation and collapse of aqueous cages surrounded by 
mucin fibres  [101]. As such, there will be significant  potential for particle-gel 
interactions within mucus, the probability of which increases as a function of time 
[171]. Accordingly, how the diffusion of individual particle changes with time not only 
provides information on the kinetics of movement but also the nature of movement, e.g. 
changes in time from unrestricted to restricted movement, e.g. the “pearl on string 
trajectory”, may be indicative of the successive binding-unbinding of particles to the 
mucin network [172]. Such interactions captured by MPT have helped to reveal 
information on the structure of the  mucus mesh network [141] as well as on the mucus 
micro-rheology [173].     
The analysis underpinning studies on the nature or mode of particle diffusion can be 
undertaken by calculating the <MSD>  for each particle over successive time scales, 
with a change <MSD> over this time period revealing the mode of particle motion 
which is represented in the literature by an exponential anomalous (α) [174].  Particle 
transport in water is described as ‘freely diffusive’ and α is equal to 1, while in an 
accelerated mixing environment α can be greater than 1 with the movement  described 
then as ‘active diffusion’.  Particle diffusion in mucus is often restricted and the α value 
is less than 1 with diffusion then generally described as ‘sub-diffusive’ [175] and where  
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α values are between 0.2 and 0.9, it reflects varying degrees of hindrance to particle 
movement [150]; particles with an α value of less than 0.2 are then considered to be 
completely immobilized.  A nuance building on such an analysis of individual particle 
behaviour is profiling the distribution of diffusive properties for the entire population of 
particles studied. Such information can provide a unique assessment of the 
heterogeneity of particle movement and the  presence of outlier sub-populations 
indicative of distinctive pathways of diffusion through the matrix [176]. 
In summary, MPT allows the dynamic measurement of the movement of individual 
particles and sub-populations within heterogeneous biological and non-biological 
matrices.  The information it provides complements that obtained by static approaches 
to assess particle diffusion. The main technical challenge for any investigator wishing to 
use the approach will be their ability to undertake high-speed fluorescent video 
microscopy.  
Dynamic Light Scattering for Measurement of Particle Sizes 
Throughout this thesis, Malvern Nano ZS was used to measure particle sizes of NPs 
which is based on the principles of dynamic light scattering (DLS). In this technique, a 
laser light beam is passed through a suspension of NPs and the intensities of the scattered 
light by particles are detected by an image detector which processes the data to determine 
and record the particle size. That is, the intensity of the scattered light corresponds to the 
velocity of particle movement in the suspension, i.e, the diffusion coefficient of these 
particles in the suspension. Particle size is measured by using the Stock-Einstein equation 
(Chapter 2). The limit of detection of this technique is ranged between 10 nm to 1 µm 
[177].  
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The instrument determines the change in the intensity of scattered light over time rather 
than the intensity itself. This is driven by the fact that the intensity of the scattered light is 
fluctuates over time depending on how fast the particle is diffusing. For the Malvern 
instrument, a digital auto correlator device is used to correlate the intensity of the 
scattered light of same particles at sequential time scales. This correlation is presented as 
an autocorrelation curve (correlogram) for which the correlation within time decays faster 
as the particle diffusion speed increases. Thus, the time at which the correlation is 
decayed is proportional to the size of the particle measured. 
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6. Aim and Overview of the Studies in this Thesis 
This study was performed in collaboration with the Alexander European Consortium 
aiming to produce muco-diffusive nano-particulate system that can improve the 
diffusion through the intestinal mucus barrier of some therapeutic agents like peptides. 
Alexander is a large collaborative group within the 7th European Framework 
programme. This group is responsible for research upon mucus permeating 
nanoparticulates. It includes 14 industrial and academic partners within Europe that 
have expertise in chemistry, biochemistry, pharmacy, chemical engineering, 
pharmaceutical technology, molecular physiology, biopharmaceutics, toxicology, drug 
development and project management. 
This thesis can be divided into two main parts. In the first part (chapter 2 and 3), we run 
a validation and comparison studies on the interaction to and diffusion through the 
intestinal mucus barrier of various nano-particulate systems that synthesized by the 
partners in the Alexander consortium. Thus this part involves the studying of: 
(i) Physicochemical properties of the intestinal mucus and how these properties 
are changed in response to the processing procedures and how these changes 
affect the barrier properties of intestinal mucus. 
(ii) NPs diffusion by the MPT technique including the validation and assessment 
of this technique to be used for the dynamic analysis of the transport through 
the intestinal mucus of NPs synthesized by the Consortium. 
(iii) The factors affecting the diffusion and interaction of NPs through the 
intestinal mucus.  
Based on the findings in the first part, the second part of this thesis (chapter 4 and 5) 
involves the synthesis of novel NPs having high diffusivity through the intestinal 
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mucus barrier so as to be the nano-carrier for the oral delivery of certain therapeutic 
agents. 
The overall objectives of this work can be summarized in four main objectives: 
 Identification of a suitable pig intestinal mucus model to be used as a barrier to 
study particles interaction and diffusion through it.  
 Use MPT to study particle diffusion/interaction through the pig intestinal mucus 
barrier. 
 To study the diffusion of NPs representing various nano-strategies through the 
pig intestinal mucus model to identify the factors and properties enabling high 
diffusivity of NPs through the intestinal mucus barrier. 
 Based on data acquired from objective three, is to synthesize a novel NP with 
certain physicochemical properties enabling the high diffusivity through the pig 
intestinal mucus barrier. 
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1 INTRODUCTION 
1.a Mucus Models 
As was described in Chapter 1, mucus is a biopolymer lining the intestinal epithelial 
membrane which serves as a barrier to limit the permeation of macromolecules from the 
intestinal lumen into the blood circulation.  Hence, the permeation of macromolecules 
through the intestinal mucosal membrane needs to be studied in the context of their 
permeation through mucus. Intestinal mucus has always been described as a gel barrier 
due to the structural nature of the mucin network  [1]. The properties of the mucus gel 
varies between different regions in the intestine depending on the main MUC gene  
product that constitutes the respective mucin network [2,3]. To this end one of the most 
common models is to use the purified mucin itself isolated from the intestine.  
Among commercially available mucins, dried porcine gastric mucin (PGM) from Sigma 
Aldrich has been widely used [4–6]. This has been rationalised on the basis of  
similarities between the pig and human intestinal mucin, where both types are MUC 2 
tetramer structures [7] and possess the same amino acid sequences [8]. The dried PGM 
can simply be re-suspended in an aqueous phase to form a gel representative to some 
extent of the native intestinal mucus.  However, it was found that some physicochemical 
properties of natural intestinal mucus gel cannot be reproduced by gel formed from re-
suspending of the sigma PGM. For example, Kocevar-Nared et al. (1997) [9] showed 
that the rheological properties of natural intestinal mucus gel are different from that of 
the re-suspended gel-Sigma´s dried PGM. This was attributed to the degradation of the 
commercially available mucin fibres during the initial isolation step which damaged the 
disulfide-bridges crosslinking the mucin subunits. Despite concerns over reconstituted 
mucin, various models of either a reconstituted mucin gel or a native mucus sample 
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have been used to study the permeation of NPs through the ‘intestinal mucus barrier’ 
[10,11]. 
1.b Biophysical Properties of Mucus 
Mucus is a complex biological polymer with unique properties that provides a rich 
material for biophysical and biochemical  analyses, which extend from the dynamic and 
chemical properties of the mucin basic unit to the rheological and structural properties 
of the mucus gel itself [12].   For example, the physical appearance of gastric, cervical 
and bronchial mucin macromolecules in diluted solutions was studied by electron 
microscopy revealing these units have linear conformations with a diameter of ca. 5 nm 
and length of  ca. 5000 nm [13]. Electron microscopy has also been used to measure the 
size of mucin subunits revealing an average length of 400 nm [14]. While electron 
microscopy has allowed researchers to build up a comprehensive picture of mucin 
morphology,  light scattering techniques have informed  the molecular weight of mucin 
units, subunits and domains [15,16]. Chemically, the polypeptide and polysaccharide 
content of  mucus has been examined by the nuclear magnetic resonance (NMR) 
technique [17,18]. 
In this chapter, AFM and rheology will be used to study the biophysical properties of 
intestinal mucus:  
Rheological Studies on Mucus  
Rheology is the study of the deformation and/or flow-ability of material when stress is 
applied. Rheological testing is used to classify material into a solid, semisolid or fluid 
according to its flow-ability in response to the applied rheological stress [19]. The most 
important rheological system is the semi-solid which is a system that possesses the 
characteristics of both solid and fluid systems [20].  In other words, this system 
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although defined as a fluid contains solid components which build structure to deliver 
properties consistent with a solid material. As an example, a gel is a semisolid system 
where the polymer concentration in the fluid is high enough to build a structured 
network to behave like a solid. When the gel sample is subjected to shear stress, the gel 
structure will change in response to the level of shear stress. These changes can be 
expressed in terms of  the degree of fluidity (“loss modulus”) versus degree of solidity 
(“storage modulus”)  [21].  Since mucus is a gel system, rheological analysis is of 
significance in the study of its structure. Moreover, rheology is important in terms of 
delivery of agents through mucus as it can reveal  the effect of variables such as mucus 
components and the interaction of mucus with particles [22]. 
A decade ago, the rheological properties of native pig gastric mucus and purified mucin 
gel was reported by the Taylor group [23]. Both of these models have shown shear-
hardening behaviour, where viscosity increases as the applied stress is increased up to a 
particular level (“low stress level”). When the applied stress is further increased, these 
mucus models flowed and behaved as shear thinning systems [23]. This shear-
thickening behaviour of the mucus might explain the resistance of mucus to the small 
mechanical strength like stresses applied through intestinal motility.  Although recently, 
Nordgård and Draget  (2015) [24] showed  the shear-hardening behaviour of pig 
intestinal mucus in response to levels of mechanical stress encountered in the  intestine. 
In their study a stress of 1 Pascal, which is the same as the stress applied by the gut 
wall, was applied to native intestinal mucus and a hardening response was obtained.  
Moreover, rheological tests have the capacity to show the effect of NP interactions on 
mucus structure.  For example, in the study the interaction of muco-adhesive polymers 
with gastric homogenised mucus, Madsen et al. (1998) [25] showed that the mixture of 
mucus and muco-adhesive polymer has a higher mechanical strength than that of mucus 
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alone indicating the formation of an entangled cross-linked gel between the mucus 
network and the polymer network. This interaction of muco-adhesive polymer with 
mucus resulted in what is termed ‘rheological synergism’, where the resistance to the 
shear stress is much higher for the mucus-polymer mixture than the resistance of both 
systems measured separately [26]. However, another study showed that muco-adhesive 
modified polystyrene NPs has no effect on the bulk rheological behaviour  of mucus 
[27]. The concept of no effect of NP on the bulk rheology of the mucus was used to 
indicate the free permeation of particles through the mucus [28]. 
AFM Studies to Examine Mucus Structure 
Electron microscopy techniques for imaging biological samples involve destructive 
procedures such as sample drying. In contrast, AFM provides a non-destructive  
procedure where the biological sample can be imaged in its hydrated form and with a 
resolution at the sub-nanometer level [29]. Unlike other microscopy techniques which 
depend on visualising a fixed sample, AFM depends on sensing the surface architecture 
and anomalies of samples through a sharp tip ‘stylus’ which is attached to a flexible 
cantilever. The sharp tip stylus scans the sample surface either through direct contact, 
non-contact or tapping mode. The movement of this stylus are transmitted via the 
flexible cantilever leading to specific bending profile of the cantilever that is related to 
the structural properties of the sample. Through the laser deflection technique, this 
bending profile can be expressed as an image of the sample [30]. 
The late 1990s witnessed the use of AFM to image the molecular structure of hydrated 
ocular mucin.  Mucin was collected from human conjunctiva, and then purified and 
hydrated in a physiological pH buffer [31]. This early study showed that hydrated 
mucin has a variable range of lengths from a 100 nm up to a few microns. Accordingly, 
purified gastric mucin, dispersed in 0.1 M sodium acetate buffer, showed a long linear 
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filamentous structure when observed by AFM [32]. Deacon et al. (2000) [32] also used 
AFM to indicate the muco-adhesive properties of chitosan when it is mixed with mucin, 
where the aggregation of chitosan-mucin was imaged by the AFM. Similarly, AFM was 
used to identify the muco-adhesive  properties of pectin polymer when it is mixed with 
mucin dispersed in deionized water [33].  
Moreover, the effect of environmental pH on the structural behaviour of the porcine 
gastric mucin was studied by the AFM [34]. It was found that both of the diluted and 
concentrated gastric mucin aqueous solutions at pH 2 showed as big as 3000 nm2 
clustered aggregations. The same study used AFM to image human gastric mucus 
collected by endoscopy which appeared as a ‘pearl and necklace’ in which the pearl size 
is similar to that of the clustered aggregates which was observed in the dispersed gastric 
mucin (3000 nm2).  This finding is in accordance with the suggested aggregation 
behaviour of mucin in low pH media.  
Processed Intestinal Mucus “Consortium Mucus Gel“ Model 
The work in this thesis was supported by the FP7 Alexander European Consortium.  
The mucus gel model introduced by the Alexander European Consortium as the groups’ 
principle model aimed to mimic the intestinal mucus barrier in term of its rheological 
gel structure. This model was designed to form a gel layer with high mechanical 
strength to study NP permeation, and in particular NP permeation across the intestinal 
mucus gel that had been coated upon Transwell semi-permeable membrane filter-
chambers. This mucus model was obtained by squeezing (‘milking’) the luminal content 
from longitudinally intact pig intestine sections (cut cross-sectionally into 25 cm length 
pieces). Given the method of collection, the harvested product contained not only the 
mucin and other mucus constituents but also food debris and significant water content. 
The mucus model was processed to remove any food debris and as much excess water 
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as deemed appropriate in order to form a more compacted structural product. The 
processing procedures included multiple washing and high speed centrifugation of the 
harvested intestinal luminal content followed by removal of the supernatant.  This 
centrifugation step resulted in a gel with high mechanical strength that formed an intact 
layer in the Transwell semi-permeable membrane filter-chambers. 
There were two main drivers for the centrifugation of mucus in this model. First, is to 
form a stiff gel layer of mucus for the Transwell experiments. Second,  is to retain the 
other structural features of mucus such as a mucin mesh spacing involving physical 
cross-linking of the mucin network, but with cross-linking that is capable of  forming 
reversible attaching/detaching interactions [35] involving electrostatic interactions [36], 
hydrophobic interactions [37] and/or calcium interactions [38]. Such reversible 
viscoelastic properties should enable the mucus to retain its other features by re-
annealing upon removing of the applied stress [39]. However, the Yudin and co-
workers (1989) [40] demonstrated that imposing upon mucus any physical stretching 
such as centrifugation results in a change in the mucus mesh spacing (network’s 
microstructural properties). As such, retaining the native mesh properties of mucus that 
has been subjected to high speed centrifugation is questionable. In this chapter, the 
effect of processing on the physicochemical properties of mucus will be studied 
extensively.  
Native Pig Intestinal Mucus “Cardiff Native Mucus” Model 
The Cardiff team introduced  another mucus model to the consortium which simply 
comprised freshly isolated mucus  gently scraped from pig intestine  without any 
significant  processing procedures such as centrifugation [10]. This model was 
introduced to represent the native intestinal mucus as close as possible in terms of mesh 
spacing and the content of water, lipid, and protein.  The collection of the native mucus 
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involved gentle scraping of the mucus layer lining the epithelial membrane after 
removing of any food debris. This mucus should retain the same network structure of 
the mucus in the intestine [10]. This mucus model was used by our group to compare 
the biophysical properties of various mucus models and to study the dynamic 
permeation of NP by the MPT technique.  
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1.c Aim of the Study 
The aim of this chapter was to characterise an appropriate intestinal mucus model that 
closely mimics the in vivo mucus system, and one that afforded the conduct of multiple 
particle tracking (MPT) for the  analysis of  NP diffusion.  
The objectives of this study are as follows: 
 Preparation of various pig intestinal mucus models the “Consortium mucus-gel 
model” and the “Cardiff native mucus model’ and assess the suitability of these 
models for MPT analysis of NP diffusion.  In particular this chapter focused on the 
use of some standard NPs of Poly(lactic-co-glycolic acid) (PLGA) and PEG- PLGA 
NPs.  
 Assess each of the mucus models in terms of  mechanical strength, microscopical 
structure and water content, and characterise these properties such as to allow their 
use in future (later chapters) interpretations of NP permeation.  
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2. MATERIALS AND METHODS  
2.a Materials 
Glass bottom imaging dishes (35 mm diameter dish with a glass coverslip at 1.5 mm 
thick and 10mm diameter) were from MatTek Corporation (USA).  Other standard 
chemicals such as NaCl, KCl, Na2HPO4, KH2PO4, NaOH and HCL were from Fisher 
scientific (Loughborough, UK). Poly(lactic-co-glycolic acid) (PLGA) and polyethylene 
glycol (PEG)-PLGA NPs encapsulated with Lumogen red 305 were supplied by 
Nanomi, Netherland as part of the FP7 Alexander Consortium.  
2.b Collection of Mucus Models  
Native Pig Intestinal Mucus “Cardiff Native Mucus” Model 
Freshly isolated  pig intestinal ileum (2 m in length from proximal region)  was obtained 
from a local  abattoir (Cardiff) and kept in ice-cold oxygenated phosphate buffered 
saline (PBS) (no longer than 1 hr) prior to sample processing. The ileum was processed 
into 25 cm lengths with each length cut longitudinally to allow intestinal food and other 
waste debris to be gently rinsed away from the intestinal surface using ice-cold PBS. 
The mucus was then harvested by an approach described previously [41], and one 
recognised to optimise the yield of not only the loose mucus layer but  critically also a 
high content of the adherent mucus layer.  Simply, it involved gentle scraping of the 
mucus from the intestinal surface using a wooden spatula while at the same time 
avoiding the shedding of significant intestinal epithelial tissue. The mucus collected was 
divided into aliquots (0.5 gm) and kept at -20 °C  prior to  experimentation [42].  
Processed Intestinal Mucus “Consortium Mucus Gel“ Model 
Freshly isolated pig intestine was collected and cross-sectionally cut into 25 cm length 
pieces. The intestinal content from each of the 25 cm intestinal pieces was squeezed  or 
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’milked’ into a container.  This sample of  intestinal content was then mixed with 0.1 M 
NaCL (saline) at a ratio of  1 gm to 5 ml saline, and the mixture was gently stirred for 
one hr at 4 °C afterwhich it was  centrifuged at 10,400 g at 4 °C for one hr. The 
supernantant was discarded and the granular material (food debris) removed from the 
bottom of the tube. The process of washing and centrifugation was repeated once more 
and the supernantant and any residual food debris were removed again. The remaining 
mucus was divided into aliqouts and kept at -20 °C for further analysis.  
2.c Measurement of pH of Mucus  
The pH of both the mucus models was measured in triplicate using a pH meter (Orion 
410A, USA).  For the ’mucus gel’ model, the pH was measured before the last 
centrifugation step since the immersion of the pH probe into the mucus sample was not 
possible after the final centrifugation step due to the stiffness of this sample.  
2.d Measurement of Water Content of Mucus 
The water content was measured in triplicate for the both mucus samples. Simply, 0.5 
gram of each mucus sample was weighed and freeze-dried (Scanvac, Denmark) for 
three days. The weight of the sample was measured again after lyophilisation and the 
difference in weights (pre- vs post- freeze-drying) was expressed as a  %loss 
representing the original water content of the sample. 
2.e AFM Imaging of Mucus 
This study was carried out by the group of Dr Polina Prokopovich at Cardiff School of 
Pharmacy and Pharmaceutical sciences. AFM imaging (XE-100 Advanced Scanning 
Probe Microscope, Park Systems, Korea) was used to measure the pore size of the 
mucin network and to define the surface morphology of the mucus sample. Three 
mucus samples of each model type were scanned by the AFM non-contact mode [43]. 
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10 images were acquired from 10 different regions within the samples so as to cover the 
whole mucus sample. Images were obtained at different formats, these are: large format 
of 25x25 µm, medium format 15x15 µm and small formats 5x5 µm and 2 x 2 µm. A 
total of 100 pores were measured for each mucus sample and the overall distribution of 
pore diameters was plotted. XEI analysis software was used to measure the pore 
diameter within each image.  
2.f Rheological Studies on Mucus 
The strain sweep test was conducted by measuring the elastic modulus (‘Storage 
modulus’) and the viscous modulus (‘Loss modulus’) in triplicate using an IR550 
rheometer (TA Instruments, USA) (experiments were conducted at the University 
Ramon Llull, Barcelona, Spain).  In this experiment, a 1 gram mucus sample accurately 
weighed and placed between the parallel plates’ chamber in which the plate diameter is 
40 mm and the gap width is 1 mm. An oscillating amplitude mode was applied at up to 
95% strain in which the plateau stress curve is obtained and the Loss (G´´) and Storage 
(G´) moduli were recorded in Pascal. The phase angle (δ) was calculated by the 
equation: tan δ= (G´´/ G´) [44].  
2.g. Measurement of NP Diffusion in Mucus  by the MPT Technique 
For NPs received from the Consortium partners they were provided either as freeze-
dried powders or dispersed particles in an aqueous phase. Freeze-dried powder samples 
were re-suspended in the aqueous phase that was originally used by the partner. Simply, 
powder was weighed and dispersed in the aqueous phase to the concentration suitable to 
run the MPT experiment. Samples were dispersed either by vortex, sonication, magnetic 
stirrer or probe sonicator depending on the protocol for particles dispersion 
recommended by the respective partner. The PLGA and PEG-PLGA NPs received from 
our partner in the consortium were fluorescently labelled with Lumogen red by the 
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encapsulation method (0.1% w/w). NPs diffusion  through intestinal mucus was 
assessed by the MPT technique [45] using  both the ‘consortium model mucus gel’  and 
the ‘Cardiff native mucus model’.  Due to the varying properties of the two mucus 
models a number of methods were explored to disperse the NPs into the mucus 
matrices:  
(i) Method 1. The fluorescently-labelled NPs were inoculated onto the surface of mucus. 
Specifically, a 25 µl aliquot of the 0.002% NP suspension was added to the surface of a 
0.5 gm mucus sample (or 10 µl for 0.2 gm mucus). This dilution of NP suspension was 
confirmed to reproducibly avoid particles aggregation at the point of NP inoculation. To 
ensure effective particle distribution throughout the mucus matrix, the inoculation was 
immediately followed by a 2 hr period of equilibration at 370 C prior to capturing the 
movement of the NPs by MPT video-microscopy.  We found this approach suitable for 
the Cardiff mucus model.  
(ii) Method 2. -  The fluorescently-labelled NPs were inoculated directly into the core of 
the mucus sample. This was explored as a way to distribute particles into the 
Consortium mucus model, where the surface addition approach described above was 
simply not successful. However, following analysis of the outcome for the Consortium 
model, an additional ‘mixing’ step was then added which involved a centrifugation step 
at 10,400 g for 15 min and removal of the supernatant corresponding to the NP loading 
volume of 25 µl.   
Prior to the use with the Consortium model, some validation tests were performed using 
the Cardiff mucus model but with inoculation Method 2. Video capture involved 2-
dimensional imaging on a  Leica DM IRB wide-field Epifluorescence microscope (X 63 
magnification oil immersion lens) using a high speed camera with a 20x digital 
magnification system (Allied Vision Technologies, UK) running at a frame rate of  33 
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ms, i.e. capturing 30 frames sec-1;  each completed video film comprised 300 frames. 
For each mucus sample approximately 120 NPs were simultaneously tracked and their 
movements captured. For any distinct NP species three distinct mucus samples were 
analysed, i.e. minimum of 360 individual NP trajectories assessed. Moreover, these 
triplicates measurement was repeated on three different days so as to ensure the 
reproducibility of the data. 
Videos were imported into Fiji Image J software to convert the movement of each NP 
into individual NP trajectories across the full duration of the 10 sec videos. Then the 
movements of each particle within sequential 30 frame segments (corresponding to 1 
sec intervals) were tracked throughout the 10 sec video.  That is, the displacement of 
each particle was measured over consecutive 1 sec intervals, i.e. during the 1 sec 
continuous presence of the particle in the X-Y plane throughout the 10 sec video. The 
measurement of particles diffusion at 1 sec interval limits the impact of mucin 
movement upon the particle diffusion calculations [46]. The individual particle 
trajectories were converted into numeric pixel data (Mosaic Particle Tracker within Fiji 
Image J) which, based on the microscope and video capture settings, was converted into 
metric distance. The distances moved by each particle over a selected time interval (Δt) 
in the X-Y trajectory were then expressed as a squared displacement (SD). The mean 
square displacement (MSD) of one particle represents the geometric mean of the 
particle’s squared displacements throughout its entire 30-frame trajectory. 
MSD was determined  as follows [47]:  
MSD(Δt) = (XΔt)
2 + (YΔt)
2                   Equation 2.1  
In any single mucus sample experiment an MSD was calculated for at least 120 
individual particles with the experiment replicated a further two times for any particle 
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type, i.e. at least 360 particles studied in total.  For each NP type under study an 
“ensemble mean square displacement” (defined by <MSD>) was then determined for 
each of the three replicate studies.  The Ensemble Effective Diffusion Coefficient 
(<Deff>) for a particular NP type was then calculated by: 
<Deff> = <MSD>/ (4 * Δt)         Equation 2.2 
Where 4 is a constant relating to the 2-dimensional mode of video capture and Δt is the 
selected time interval. 
The ‘tracking resolution’ (σ) was measured for each NP species by gluing 
(cyanoacrylate-based glue) the particles to a glass bottom imaging dish followed by 
drying and setting of the glue matrix. Videos were captured and particles trajectories 
were tracked similar to the abovementioned. The σ was then calculated by two 
approaches: (i) independently determining X- and Y-direction displacements followed 
by calculating of geometric mean of the data; (ii) Calculation of the square root of 
MSD.  
In order to provide a comparison for the respective mucus diffusion data, the 
determination of NP diffusion in water made. The NP diffusion coefficient (D°) in 
water was calculated by the Stokes-Einstein equation at a temperature of  37 C° [48]:   
[D° = κT / 6πηr]                          Equation 2.3     
Where  is Boltzmann constant, T is absolute temperature, η is water viscosity and r is 
radius of the particle. The diffusions of all particles were also expressed as the 
parameter, %ratio <Deff> / [D°].  
Statistical Analysis: T test was used to compare the two mucus models for their pH and 
water content, the same t test was used to compare the % ratio <Deff>/D° of NPs added 
into the mucus by method 1 and 2 with significant value of p < 0.05.  
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3. RESULTS AND DISCUSSION   
In this chapter, two pig intestinal mucus models were assessed for their capacity to 
study NP diffusion by the MPT technique.  The first model, “Consortium model” seems 
to fits the requirement to study the permeation of particles by the transwell chamber 
model since a mucus barrier with sufficient mechanical strength is needed to separate 
the donor and receptor compartments in the transwell chamber system. In this model, 
the centrifugation at high speed should form this physical gel barrier. However, 
suitability of this mucus gel model to study particles transport by other dynamic 
methods like MPT technique is doubted for many reasons.  
First, centrifugation at high speed is expected to reduce the water content of this mucus 
model. This is an important factor that can affect particles diffusion through the mucus 
since the dynamic movement of particles through the mucus is carried out through the 
spaces filled with water in the mucin network [49]. Wine reported that reduction of 
water content can dramatically reduce the movement of particles through the mucus 
[50]. Moreover, the other effect coming from water content is the viscoelastic properties 
of the mucus since water content affect the elasticity of the systems under stress [51]. 
Regarding this point, this consortium mucus model was introduced as a gel model 
having the general viscoelastic characteristics of gel system; however, the less water 
content should have an impact on these viscoelastic properties. Lastly, processing of 
this mucus model could change the structure of the mucin network. To be more specific, 
centrifugation step involved in the preparation of this model can induce structural 
changing on the mucus network due to the bundling of mucin fibres [41]. For all the 
above mentioned, the water content, pore sizes and viscoelasticity were measured to 
assess the effect of processing steps on the properties of this mucus gel model. 
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On the other hand, the native intestinal mucus model was used in this study as a 
standard model representing the pig intestinal mucus [11]. What is more important, is 
the suitability of the native mucus model for the MPT analysis which was revealed by 
Crater and Carrier (2010) [52]. In their literature about studying of particles’ diffusion 
by the MPT technique, Crater and Carrier (2010) showed a high correlation between the 
chemical properties of the assessed NPs and the diffusion in the native pig intestinal 
mucus, whereas they found no correlation between the particles’ chemical properties 
and diffusion in the purified mucin sample (PGM) [52]. Hence, this native mucus was 
used to extrapolate the relation between the physicochemical properties of tested 
nanoparticles and their diffusion coefficients through the mucus. Also, this mucus 
model was assessed for its water content, viscoelasticity and e pore sizes.  
3.a Measurement of pH of Mucus 
This study was carried out to confirm the pH of the  mucus models were within the 
range of pH values to be expected from the small intestine, i.e. 6.5 to 7.5 [53]. The pH 
of the “Consortium mucus gel” model was 6.50 (±0.05) and for the “Cardiff native 
mucus” model was 6.70 (±0.12) (Table 2.1). This range of pH values is in agreement 
with the pH range of the mucus collected from pig small intestine [47]. As described in 
Chapter 1, the pH of intestine is usually reported in a range rather than a specific value 
due to the high variability seen between studies. The non-significant difference (ca. 0.2 
pH units) in the pH values between the “Consortium model” and the native mucus 
model may be due to the varying methods of collection and processing, i.e. the 
processing of the “Consortium mucus gel” model involving a ‘milking’ of the intestinal 
contents (food debris) should affect the final pH of the system. 
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Table 2.1: Water content and pH of the two mucus models. N = measurements taken 
from three separate experiments. (The difference in the data from each mucus model 
was compared by T test).  
Biophysical test 
Consortium model 
Mean (±s.d) 
Cardiff model 
Mean (±s.d) 
T test comparison of pH 
and water content of the 
two mucus models  
(p value) 
pH 6.5 (±0.05) 6.7 (±0.12) Non-significant (0.0561) 
Water content 81.2 (±1.4) 91.4 (±0.51) Significant (0.0003) 
3.b Measurement of Water Content of Mucus 
One of the main concerns about the processing strategy for the “Consortium mucus-gel” 
is the potential water loss due to the centrifugation and the impact of this step upon the 
structure of the mucin network.  As is shown in Table 2.1, the water content of the 
“Consortium mucus-gel” was determined at 81.2 ±1.4%, while for the “Cardiff native 
mucus” model it was 91.4 ±0.51%. The significant difference of 10% lower water 
content of the processed “Consortium mucus-gel” may be expected due to the 
centrifugation of the intestinal mucus followed by the supernatant from which was then 
discarded. In contrast, the water content of the “Cardiff native mucus model” was as 
expected higher, essentially due to the minimal processing of the material. Indeed the  
water content of the  “Cardiff native mucus model” is consistent with previous studies  
[54–56] which reported the water content of more than 90% in mucus. 
  The difference in water content between the two models is also reflected in their 
contrasting physical appearance. Figure 2.1 shows the physical appearance of the 
“Consortium mucus-gel” model (left) and the “Cardiff native mucus” model (right). The 
“Consortium mucus-gel” model appears considerably desiccated compared to the 
“Cardiff native mucus” model. The high water loss of the “Consortium mucus-gel” 
model would also likely indicate a change in the mucin network structure following 
centrifugation; therefore, structural analysis was explored by AFM below.  
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Figure 2.1: Imaging of the processed mucus gel model (left) and the native mucus 
model (right) showing the watery nature of the native mucus model and dried nature of 
the processed mucus gel model.  
3.c AFM Imaging of Mucus  
AFM was used to detect the morphology of the mucin fibre mesh within each of the two 
mucus models.  AFM imaging involves less sample processing compared to electron-
microscopy techniques and has resolving power to the  nanometre range [57]. Figure 
2.2A shows the surface morphology and the pores within the mucin network of the 
“Cardiff native mucus” model displayed as large-field (25x25 µm), medium-field 
(15x15 µm) and small-field (5x5 µm) AFM images.  Figure 2.2B shows a histogram of 
the size distribution of these pores determined from over 98% of all of the pores within 
imaged by the AFM.   
The data shown in Figures 2.2A and 2.2B show the pore population to be comparatively 
heterogeneous with an approximate 7-fold range in the pore size (diameter) between 60 
nm to 400 nm, but with a distribution defined by more than 50% of pore size below 200 
nm and a mode of 300 nm. Moreover, it can be seen that 33% of the pores sizes are 
between 300 to 400 nm. The large macro-porous spaces (above 400 nm) comprised ca. 
2% of the total size distribution. The heterogeneity is isotropic within all the areas of 
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this mucus model which has also been reported previously where the system has been 
defined as symmetrically heterogeneous [58,59]. 
As described in chapter 1, the pore characteristics in the Cardiff native mucus model are 
consistent with other mucus model in term of average pore sizes (ca. 200 nm) and the 
presence of small ratio of large pores sizes [40,60].  This may not be that surprising as 
the  mucus harvesting approach adopted for the Cardiff model is one recognised  to 
contain some of the loose layer and the adherent mucus layer [41,61] and as such, our 
approach will naturally lead to a  heterogeneous but realistic data.  
 
Figure 2.2: AFM imaging of the “Cardiff native mucus” model. (A) AFM surface 
morphology of the mucus with large (25x25 µm), medium (15x15 µm) and  small (5x5 
µm) field images of  the network of pores;  (B)  size distribution of over 98% of all 
visible pores within the mucus. 
In comparison AFM imaging of the “Consortium mucus gel model” (Figures 2.3, 2.4, 
2.5) revealed the impact of the processing steps on the mucin network. The figures 
illustrate the mucus gel model to be anisotropic system with different morphologies 
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within different sites in the mucin network. To be specific, three different morphologies 
were detected within the “Consortium mucus gel model”. Firstly, Figures 2.3A and 
2.3B show two different areas within the mucus gel at 10 x10 µm and 25 x 25 µm 
frames, respectively. These figures highlight areas within the “Consortium mucus gel 
model” in which very large pores in the mucin network are seen to dominate, with the 
size of these voids reaching up to 5 µm and 8 µm respectively. Figure 2.3 also shows 
large mucin aggregates surrounding the large pores. These aggregates may play an 
important role in the physicochemical properties of the mucus-gel. 
 
Figure 2.3: AFM imaging of the “Consortium mucus gel” model. (A) AFM surface 
morphology of the processed mucus gel model at  a scale of (10x10 µm) showing a 5 
micron pore at one site in the mucus (B)  AFM surface morphology of the mucus at a 
scale of (25x25 µm) showing 8 micron pores at another site in the mucus. 
These mucin aggregates were evident throughout the mucus gel model. For example, 
Figure 2.4 shows large mucin aggregates with sizes up to 5 µm (black arrows).  Figure 
2.4 also shows that the mucin aggregates are separated by channels and spaces (red 
arrow), the diameter of these channels are around 40-80 nm.  Figure 2.5 shows also the 
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bundling of mucin fibres into thick cables separated by channels (red arrows) with an 
average width of 100 nm.  
 
Figure 2.4: AFM imaging of the “Consortium mucus gel” model at  a scale of (15x15 
µm) showing a 5 micron aggregated mucin fibres at one site in the mucus (black arrow) 
and channels separated these mucin aggregates (red arrow). 
 
 
Figure 2.5: AFM imaging of the “Consortium mucus gel” model at a scale of (2x2 µm) 
showing the mucin fibres bundling into thick cables. 
Although small pores were evident within the mucin aggregates of the “Consortium 
mucus gel” model,   they were below the resolving power of the AFM. This inability to 
quantify pore sizes within the aggregated mucus-gel clusters will compromise the full 
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value of plotting a pore size distribution diagram similar to the one generated for the 
“Cardiff native mucus” model. Specifically, the pore size distribution produced will 
ignore the spaces that we are unable to measure.  
The structural features of the “Consortium mucus gel” model were to a large extent 
dependent upon the mucus processing methodology, specifically the centrifugation of 
the harvested mucus material. Centrifugation at high speed will lead to collapse of the 
mucin network leading to the aforementioned sizeable aggregates of compacted mucin 
fibres, within which are very small pores, but as a consequence of collapse of the 
network, the gel contained numerous large inter-fibre pores.  
Previous studies showed that these aggregates and bundles of mucin fibres are stable in 
the mucin network and not re-annealing to its original morphology due to the formation 
of hydrophobic interactions among the mucin fibres within these aggregates [62,63]. 
These interactions expected to increase in frequency as the mucin network undergoes 
external pressures such as those imposed by centrifugation to bring the mucin fibres 
close enough to form hydrophobic interactions. The above is also consistent with the 
lack of capacity to retain water content in the “Consortium mucus-gel” model. That is 
the collapse of polymeric network  forms a macro-porous spacing allowing the water to 
be more easily extracted from the mucus and hence the greater  water syneresis and loss 
from the system [64,65].  
The structural changes described above for the mucin network in both the “Cardiff 
native mucus” model and the “Consortium mucus-gel” model will likely have 
differential  effects upon the diffusion of particles, although it is difficult to predict how  
the mucin structures will affect diffusion. The studies below using MPT represent an 
excellent experimental system to reveal the effect of the large pores, clusters 
aggregations and mucin bundles on particle diffusion.  
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3.d Rheological Studies on Mucus 
The two mucus models in this study were prepared using distinctly different methods. 
While both are gels, the Consortium model was produced mainly with the aim for use 
by the Consortium as high mechanical strength gel able to be used in Transwell 
permeation chambers studies, a requirement of this model is that the mucus is able to 
serve as a layer placed upon porous polycarbonate membranes. The Cardiff native 
mucus model is a gel system also but with obvious mechanical properties that differ 
from the Consortium model [66].  This difference in the gel structure between the two 
models can be explored through study of their viscoelastic properties using rheology 
methods, and in particular conduct strain sweep tests to measure the G′ versus the G′′ in 
response to the applied oscillating strain.  
Figure 2.6 shows that both mucus samples were tested within the % strain range of 12 to 
95 across which the “Cardiff native mucus” develops a plateau response in the G′ and 
G′′ parameters.  The strain sweep test showed both models to possess a gel structure 
defined by G′ values that were higher than the G′′ values within the plateau region [67]. 
Figure 2.6A shows that the “Cardiff native mucus” displayed a plateau curve with a 
range of G′ values between 100 and 150 Pascal and a range of G′′ values between 25 
and 30 Pascal at the % strain range of 12% to 95%.  Moreover, the “Cardiff native 
mucus” model exhibited a phase angle (δ) range of 14.82 to 16.22° with an average of 
15.36, which is another indication of the viscoelastic gel property of this model; an 
elastic gel is defined as a system having a δ of less than 45° [68].  
In contrast the “Consortium mucus-gel” model was expected to have higher mechanical 
strength due to compacting of the mucin fibres. This model showed a linear viscoelastic 
region within the % strain range of 12 to 78%. Within this linear viscoelastic region, the 
set of G′ and G′' values of this mucus model were much higher than that of the “Cardiff 
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native mucus”. Specifically, the G′ values of the “Consortium mucus-gel” model were 
higher by almost 300 Pascals compared to that of the native mucus. This high elasticity 
of the processed mucus gel is due to the fibre bundling, as observed by the AFM 
imaging. Fibre bundles are reported to lead to higher mechanical and elastic behaviour 
of the mucus [62]. 
 
 
Figure 2.6:  Strain sweep test within the % strain range of 12 to 95%. (A) “Cardiff 
native mucus” which shows a linear viscoelastic region at the % strain range of 12 to 
95.  (B) “Consortium gel mucus” model which shows a critical breaking point at a % 
strain of 78.  
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Moreover, the viscoelastic region of the “Consortium mucus-gel” model is followed by 
drop off of the G′ and an increasing of the G′' until these moduli cross at a 95% strain 
indicating the breaking down of the system (Figure 2.6B). This break down of the 
mucin structure at a strain value lower than “Cardiff native mucus” model is due to 
former having a reduced water content that makes the mucin fibres less flexible and 
more susceptible to breakage when the strain level increases [69].  
3.e Assessment of Particles’ Diffusivity through the Intestinal Mucus 
This study was carried out to assess and validate the MPT technique for the 
measurement of particle diffusion through the mucus barrier, and to examine two 
distinctly different mucus models in terms of their suitability for this objective. In this 
validation work two types of particles were selected, i.e. NPs of PEG-PLGA and PLGA 
alone, which represent examples of fast and slow permeating NPs, respectively.  
Previous MPT studies have showed that PEGylation of PLGA core NPs improves the 
diffusion of the essentially non-diffusive PLGA NPs through the muco-inert nature of 
the PEG [70,71]. 
There are various elements which can affect the tracking of movement of NPs by MPT 
technique. These include, the fluorescent dye associated with the NP, the microscopy 
settings and the experimental procedures involved in the addition of the NPs into the 
biological sample (mucus).  
Selecting the appropriate fluorescent dye is obviously critical for the specific 
visualisation of fluorescently labelled particles. Specific visualisation of the particles 
enables the specific tracking of particle movement through the mucus rather than any 
other endogenous mucus components. The fluorescent dye should thus have 
fluorescence characteristics that differ from the mucus auto-fluorescence. Mucus has a 
                                                                                                                                                   Chapter Two 
76 
 
high intensity excitation-emission spectrum of 280-340 nm [72]. For this reason, 
selected NPs (PLGA, PEG-PLGA) were loaded with a dye having higher emission-
excitation spectrum.  Lumogen red 305 was selected as the dye. It has a high stable 
excitation-emission spectrum of 573-613 nm [73]. It was encapsulated into the NPs to 
eliminate as much background signal from soluble dye leaching to the mucus matrix.  
Lumogen red 305 was encapsulated at a concentration of 0.1% into the selected 
particles. Specificity and efficiency of Lumogen red 305 was tested by examining for 
fluorescence in mucus before and after the addition of the fluorescently labelled NPs. 
Mucus was placed in the glass bottom imaging dish and examined using 
Epifluorescence microscopy at the excitation-emission range of Lumogen red (573-
613nm).  
In the absence of Lumogen red 305 NPs, there was no fluorescence observed from the 
mucus sample alone. However, following addition to the mucus of fluorescently 
labelled NPs encapsulating 0.1% Lumogen red 305, the signals obtained were very 
bright against the mucus’s blank background and the signals showed high photo-
stability. Indeed, photo-stability against fluorescence bleaching for particles loaded with 
Lumogen red 305 has been reported by other groups [73,74]. 
The microscopy settings including the objective of lens, the camera speed and the 
position of sample in the microscopy have a direct impact on the temporal, spatial and 
tracking resolution.  In this study we used a lens with a 63X objective in conjunction 
with a digital magnification system of 20X as part of the high speed camera (30 frames 
per sec). With these settings, the temporal resolution was 0.033 ms and each pixel 
within the frame equal to 154 nm and each point spread function was 200 nm. This 
allows Image software to track very small particles and generate a high accurate spatial 
tracking due to the spreading of the light over more than one pixel. Spatial tracking is 
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controlled by the tracking software (Image) which can detect any change in the position 
of the fluorescently labelled particles with sensitivity of parts of pixels.  
Moreover, the tracking resolution (σ) was measured to identify the minimum detectable 
displacement resulted by wiggling of trapped particles.  The σ was measured for each 
NP type individually by gluing the particles into the glass bottom dish as described in 
the methods section and shown in Figure 2.7. The proper setting of microscopy 
produces  an σ from 5 to 10 nm [75]. In this study, the σ for the PLGA and PEG-PLGA 
NPs was found to be 5 nm. Indeed, the geometric mean of the displacements of these 
tracked particles was around 5 nm but approximated to 5 nm (5.3 and 4.2 for the PEG-
PLGA and PLGA NPs, respectively). This indicates that the microscopy setting was 
appropriate and measurement of particle diffusion could be carried out with high 
tracking resolution. 
 
Figure 2.7: Measurement of σ by gluing the particles into the glass bottom dish. 
 Experimental procedures involving the preparation of the mucus sample and the 
manner by which the fluorescently labelled NPs are added to the mucus are also 
obviously very influential factors. Use of two different mucus models requires 
individualisation of the experimental procedures for each model. As described in the 
AFM study, the “Consortium mucus gel” model showed various structural regions 
which seemed anisotropic in nature. Also, the lower water content of the processed 
mucus gel model made the sample very rigid (Figure 2.1, page 16, mucus gel model 
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seemed to have solid appearance with high rigidity). In contrast the “Cardiff native 
mucus” model is a soft gel in which the water content is high. These structural 
characteristics will not only affect particle diffusion but also the initial addition of 
particles into the mucus sample prior to imaging.   
The addition of a suspension of NPs onto the surface of the “Consortium mucus gel” 
model resulted in the formation of a precipitated layer of these particles on the surface 
of the processed mucus gel (Figure 2.8). It appeared that the particles were unable to 
penetrate the rigid mucus gel model which resulted in their precipitation rather than 
distribution into the mucus matrix itself. However, while this is totally unsatisfactory 
outcome for the performance of MPT, it appeared to satisfy the needs of the Consortium 
for conducting Transwell permeation studies across mucus.  That is, the highly compact 
nature of this mucus-gel model affords its layering onto a Transwell membrane with 
reduced a tendency  (but not totally devoid) of leakage of the material through the 
Transwell membrane pores  into the receptor chamber [76]. The low water content of 
this mucus model (81%) is balanced by the water absorbed from the receptor media in 
the chamber system. This absorbed water could be responsible to increase the water 
content of this mucus up to the normal level (> 90%) which can improve particles 
diffusion through this mucus model. Thus, in the transwell chamber system, the 
mechanism of particles movement into the receptor compartment could be a mix of 
diffusion and convection within the moving mucus downstream.  
On the other hand, for the setting of MPT method, NPs addition into the mucus sample 
was performed by 2 different methods due to the presence of 2 different mucus models. 
In the first method, NPs suspension was added onto the surface of mucus layer; hence, 
this method involves 2 processes which are: particles penetration and distribution into 
the mucus outer layer followed by particles diffusion through the mucus layer. Particle 
                                                                                                                                                   Chapter Two 
79 
 
penetration through the mucus outer layer is governed by the difference in the 
interfacial tension between the NPs suspension and the mucus which depends upon the 
particles’ charge and solubility in each media [77]. Thus after the addition of particles, 
their initial distribution within the mucus is directly related to the interfacial tension and 
not related to the diffusion of particles through the mucus which depends essentially on 
the steric hindrance and electrostatic interaction of mucus components with the particles 
[78].  
Specifically, the low water content of the "Consortium mucus gel” model negates 
penetration of the particles across the mucus layer. In contrast, the properties of the 
“Cardiff native mucus” model afforded the simple addition of a suspension of NPs onto 
the surface of the mucus (Method 1) with the subsequent diffusive dispersion of the 
particles throughout the mucus sample, as recognised by Wang et al. (2011) [63] and 
others [12]. Thus for the “Cardiff native mucus” model,  the inoculation process of NPs 
(e.g. PLGA and PEG-PLGA NPs suspensions) involved the simple surface addition of 
the NPs to the mucus sample followed by a two hr period of equilibration after which 
the fluorescent particles appeared to be distributed thoroughly in the mucus sample.   
However, as described above, the simple NPs inoculation was amenable to the “Cardiff 
native mucus” model, but was not appropriate for the “Consortium mucus-gel” model. 
Hence, for the Consortium mucus gel samples, another method (Method 2) was 
explored whereby the NPs were directly inoculated into the core of the mucus sample, 
i.e. the idea being to bypass the issues of the interfacial tension barrier in the 
Consortium model preventing access of the NPs to the core of the mucus matrix. 
Prior to use in the “Consortium processed mucus-gel” model, Method 2 was initially 
tested using the “Cardiff native mucus” model.  Specifically, the movement of PLGA 
and PEG-PLGA NPs within the Cardiff native mucus model was assessed using MPT 
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following NP inoculation by: (i) simple addition of a suspension of NPs onto the surface 
of the mucus sample “surface inoculation” (Method 1) (ii) inoculation of the NPs into 
the core of the mucus sample (Method 2). In both cases, small volumes of the NP 
suspension (25 µl) were added to 0.5 gm of the “Cardiff native mucus” sample followed 
by a 2 hr equilibration period prior to MPT. The MPT analysis revealed no significant 
difference in the diffusivity of test particles, PLGA and PEG-PLGA NPs, between the 
two inoculation methods (See below in Table 2.2).  
However, the use of the inoculation Method 2 with the “Consortium processed mucus 
gel” model resulted in the appearance (Epifluorescence microscopy) of large channels 
in the mucus through which the NPs were freely moving in a directional manner. This 
was interpreted as a lack of homogenous mixing of the NPs within the mucus sample 
especially as these channels did not disappear even after the 2 hr equilibration period.  
The channels arose due to a hydrodynamic phenomenon whereby two fluids of highly 
different viscosity are mixed. This phenomenon is called “viscosity fingering” [79] 
(Figure 2.8) with the less viscous fluid (NPs suspension) penetrating the more highly 
viscous fluid (mucus gel) due to the convective forces of the inoculation procedure 
itself.  This behaviour has been  reported in previously  in which the injection of HCL 
acid solution into a dispersion of gastric mucin formed channels of HCL solution 
throughout  the mucus sample [80]. 
In an attempt to remove these ‘viscosity fingering’ channels and to ensure a more 
uniform distribution of NPs within the mucus sample, we incorporated one more step, 
i.e. after the inoculation of NPs into the core of the mucus, the samples were centrifuged 
(as described in methods) taking care not to alter the  water content of the mucus model. 
Logically this centrifugation process would not have caused any more damage to the 
mucin network beyond that caused by the steps of centrifugation and removal of water 
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involved in the original processing of the mucus material. Examination of the mucus by 
Epifluorescence microscopy showed that the centrifugation step to disperse the particles 
more effectively resulted in a removal of the ‘viscosity fingering’ channels and with the 
particles appearing to be thoroughly distributed within the mucus sample.  
 
Figure 2.8: Formation of viscosity fingering from the low viscous NPs suspension that 
injected into the highly viscous, low water content “Consortium mucus gel” model. 
 
Following the methods development described above, the NPs trajectories were tracked 
by MPT technique. Figure 2.9 shows the tracking of a number of fluorescently labelled 
PEG NPs in mucus. It exemplifies how the particles are being tracked in 1 video for 1 
mucus sample (each NP type is examined in 3 different mucus samples, for each mucus 
sample, 20 videos are recorded in which each particle in this video is tracked 
individually).  Most of the particles in figure 2.9 show high diffusion through mucus, 
this is represented by the area that these particles move through during the time of the 
video. Very few particles in figure 2.9 are shown to have low diffusivities through 
mucus represented by particles which moved within a limited area in the video. Thus, 
for the particles with pink trajectories, the total area (MSD) moved is much higher than 
that for particles with white trajectories. Measuring the diffusion of both particles leads 
to highly different diffusion coefficients for each of these particles. Since PEG NPs are 
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known to be highly diffusive through the mucus barrier, it can be seen that the number 
of particles with a high diffusion coefficient is greater than the number of particles 
trapped in the mucus. 
 
 
Figure 2.9: Tracking of particles by the MPT technique where the trajectories of each 
particle are transformed into MSD. 
Table 2.2 shows physicochemical properties of the NPs, their <Deff> in mucus (cm2 S-1 
x 10-9) and their respective D °in water (cm2 S-1 x 10-9). The first two rows show the 
diffusion data for the NPs in the “Cardiff native mucus” model using the simple surface 
addition of NPs suspension (Method 1) and the inoculation method into the core of NPs 
(method 2). The third and fourth rows of data show the diffusion for the same NPs in 
the “Consortium processed mucus gel” model with inoculation by direct administration 
into the core of the sample followed by centrifugation (Method 2).   
Moreover, the table shows the ratio of the two diffusion parameters expressed as (% 
ratio <Deff> / D°). This ratio provides a measure of the relative efficiency of particle 
diffusion through mucus when the particles’ intrinsic free Brownian motion in water is 
taken into account.  As such it affords comparison of particle diffusion in mucus after 
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accounting for the impact of the particle’s size upon its unrestricted diffusion in 
solution.  It is essentially a measure that more directly addresses the relative impact 
between particles of differing surface physicochemical properties and the interactions 
with, and the steric hindrance of, the mucin network.  
 
  
 84 
 
 
 
  
Table 2.2: Particles’ composition, physical characteristics and diffusion behaviour of PLGA and PEG-PLGA NPs in the “Cardiff native mucus” model and 
“Consortium mucus gel” model. (PDI and S.D. are included where necessary). 
Mucus 
model 
NP Code Zeta Potential 
(mV) 
Mean  
Particle 
Size   (nm) 
Mean  
D°  (water) 
cm2. S-1 
x10-9 
<Deff>  
(mucus) 
Method 2 
cm2. S-1 x10-9 
Mean (± s.e.m) 
<Deff>  
(mucus) 
Method 1  
cm2. S-1 x10-9 
Mean (± s.e.m) 
T Test comparison of 
<Deff> from method 1 and 
2 
(P value) 
% Ratio 
<Deff>/D° 
 Method 2         
% Ratio 
<Deff>/D° 
 Method 1         
Cardiff 
Native 
mucus 
PLGA -30 161 27.91 
0.00013 
(±0.00002) 
0.00011 
(±0.00004) 
Non-significant (0.4818) 0.0005 0.0004 
PLGA-
15% PEG 
(6000) 
-8.3 54  83.22 
0.46889 
(±0.12699) 
0.48211 
(±0.09876) 
Non-significant (0.8937) 0.5634 0.5739 
Consortium  
gel mucus 
PLGA  -30  161  27.91 
0.00010 
(±0.00005) 
- 
 
0.0004 
 
PLGA-
15% PEG 
(6000) 
-8.3 54  83.22 
0.01396 
(±0.00477) 
- 
 
0.0168 
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Figure 2.10A shows the ensemble effective diffusion coefficient (<Deff>) versus particle 
size for each of the tested particles. Figure 2.10B shows the zeta potential of each 
particle versus the % ratio <Deff> / D°.  In the figures, the PEG-PLGA NPs are shown 
in red while the PLGA NP is shown in green.  Table 2.1 and Figure 2.10 illustrate in 
both mucus models the high diffusivity of the PEG-PLGA NP as compared to the 
PLGA NP.  The <Deff> values in the “Cardiff native mucus” model were 0.46889 and 
0.00013 for the PEG-PLGA NP and PLGA NP respectively, indicating a 3600 greater 
diffusion rate of the PEG-PLGA NPs.  Similarly in the same mucus model when the 
diffusivities of the particles were compared based on % ratio <Deff>/D° values, the 
diffusivity of the PEG-PLGA NPs was greater by 1200 times as compared to the PLGA. 
This much higher  diffusivity of PEG-PLGA as compared to the PLGA particles is in 
accordance with previous MPT studies [46,81]. This indicates that the MPT technique 
developed in the PhD is a sensitive one able to discriminate diffusion differences due to 
the chemical nature of a particles’ surface; the PEGylated particles possessing a 
hydrophilic surface and showing a considerably greater diffusion as compared to the 
lipophilic surface of the PLGA NPs.  
In the “Consortium processed mucus-gel” model, the PEG-PLGA NP was only x50-fold 
faster than the PLGA NP, substantiating that the two mucus models represented distinct 
properties. In the native mucus model, it is recognised that in the absence of particle 
interaction with the mucin fibres, then  particle transport involves unhindered 
movement through the water filled  spaces within the mucin network [82]. Accordingly, 
in the same native mucus model, The PLGA NP will interact with the mucin fibres 
through their hydrophobic properties which disabled their movement through the water-
filled pores [71]. Obviously, these conditions are not the same in the “Consortium 
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mucus gel” model where the difference in the diffusivity between the PEG-PLGA and 
PLGA NPs are not that high. 
 
Figure 2.10: (A) Mucus diffusion <Deff> versus particle size of PLGA and PEG-PLGA 
NP in the both mucus models. (B) % ratio <Deff>/D° versus zeta potential of PLGA 
and PEG-PLGA NP in the both mucus models. 
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The diffusion of the PEGylated NP was 35 times faster in the “Cardiff native mucus” as 
compared to the “Consortium mucus gel” model. This is due almost entirely to the 
reduced permeation of the PEG-PLGA in the Consortium mucus. In other words, the 
reduced water content and ‘collapsed’ mucin structure of the “Consortium mucus gel” 
model limited significantly the movement of PEG-PLGA NPs through this mucus 
model. However, no previous MPT studies on this type of mucus gel have been 
conducted and further studies are required to study separately the impact of water 
content and the shrinkage of the mucin network on the diffusivity of particles.   
On the other hand, it is important to note that the diffusion of the PLGA NPs was 
almost similar between the two mucus models, where the diffusivity of the PLGA NP in 
the “Cardiff native mucus model was higher by 1.3 times than that in the “Consortium 
mucus gel” model. This indicates that the diffusion of the muco-adhesive PLGA NPs 
was less influenced by the type of the mucus model. This could be due to the muco-
adhesive nature of this NP type [83,84] such that, these particles move and adhere 
preferably to the mucin fibres where they stuck within the ‘normal‘ mesh network and 
when the water content  of the mucus is high. In other words, these muco-adhesive NP 
behave similarly in both mucus models.  
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4 SUMMARY AND CONCLUSION 
In this study, two different intestinal mucus models were tested to be used as a barrier 
for study of NPs diffusion by the MPT technique. One of the mucus models, namely, 
“Cardiff native mucus” model was scraped from the pig intestine without any further 
processing steps. The other mucus model was squeezed from intestine followed by 
further washing and centrifugation step to increase the mechanical strength of this 
model. To examine these mucus models, a group of biophysical techniques including 
rheological and AFM imaging were used to identify the physical, structural and 
mechanical properties for the both models. Moreover, MPT technique was validated for 
the in vitro measurement of particles diffusion through mucus models. Validation 
technique included the assessment of suitability of the fluorescent dye (Lumogen red), 
microscopy, NPs and mucus for efficient measurement of particles diffusion.  
Biophysical studies revealed several differences between the tested mucus models 
including their water contents, structural and mechanical properties. The “Consortium 
mucus gel” model was found to have less water content, anisotropic and higher 
mechanical strength. Also, the native mucus model was more suitable for studying of 
particles diffusion by the MPT technique since no further steps were needed to 
distribute particles into the mucus samples. The MPT technique was found to be 
sensitive and representative for studying of diffusion of particles loaded with Lumogen. 
It can be concluded that centrifugation of mucus can massively change the physical, 
structural and mechanical properties of the mucus system. This indicates that mucus 
should be used with minimum processing procedures so as to be used as a model to 
study particles diffusion through it. Also, for imaging of fluorescently labelled particles 
in mucus, a selected dye should have higher emission wave length than the auto-
fluorescent emission of the mucus sample. The microscopy should be set carefully to 
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avoid any misleading outcomes. Finally, the MPT technique was found to be a good in 
vitro test to analyse particles diffusion through the mucus. 
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1. INTRODUCTION 
1.a Nanoparticle(s) as a Vehicle to Improve Mucus Permeability 
As described in Chapter One, while small drug molecules can permeate relatively easily 
through intestinal mucus [1], orally administered therapeutic peptides and proteins are 
highly susceptible to degradation in the intestinal mucus layer by various protease 
enzymes such trypsin, chymotrypsin, and carboxypeptidase [2]. The incorporation of 
such therapeutic agents into a nano-delivery system can provide protection against 
enzymes and other environmental factors [3] [4]. However, the mucus barrier can 
adhere to these NPs through electrostatic or hydrophobic interactions, or simply by 
spatial entrapment  in the mucin network [5,6]. Therefore, an appropriate NP for peptide 
or protein delivery should protect the cargo from mucosal enzymes [7] but not itself be 
trapped by the mucus [8].   
Any selected NP formulation should display rapid permeation through the loose mucus 
layer of the intestine in order to avoid rapid clearance with the loose layer as it transits 
down the intestinal tract [9]. In contrast a long residence in the unstirred layer close to 
the epithelial surface will increase the chances of the NP to permeate  the epithelial 
membrane or allow the release of the cargo in close proximity to the intestinal epithelial 
membrane [10]. As an example,  when chitosan NPs were brought in contact with the 
epithelial barrier, these particles were found to permeate the epithelial membrane by an 
endocytosis process [11]; although the exact mechanism by which chitosan NPs 
permeate epithelial barriers is controversial.  One delivery strategy that exploits some 
elements  of the above involves the muco-adhesion of NPs that have been engineered to 
interact with the mucus either through electrostatic interactions (chitosan, 
polyethyleneimine, polylysine and polycarbophil),  hydrogen bonding or simple van der 
Waal’s forces (Eudragit) [12]. The muco-adhesion increases the residence time of the 
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particle close to the absorption barrier and as such the chances of increased absorption 
of released cargo that would have otherwise been transited down the intestinal tract.  
The more specific adhesion and interaction into the intestinal mucosa has emerged 
through the targeting of M cells which cover the peyers patches (lymphatic follicles) in 
the ileum.  This strategy is mainly to avoid the particles becoming trapped in the mucus 
since these cells are covered with only a 30 nm glycocalyx layer [13]. Various ligands 
such as lectin, tomato lectin, invasin and wheat germ agglutinin lectin have been used 
so as to target the NP to M cells through the interaction to the specific carbohydrate 
residues at the M cells [14].  
The importance of targeting M cells vs. Enterocytes was significant when the absorption 
of 300 nm polystyrene NP was improved 500 folds when cultured Caco-2 cells were 
converted to follicle associated epithelium like cells  so as to express the M cells 
predominantly [15]. Lectins Ulex europaeus was found to be very efficient ligand to 
bind the mouse Peyer's patch M-cells in the mouse gut loop model. The binding 
efficiency of 500 nm carboxylated microspheres to M-cells was higher by 100 times as 
compared to the BSA-coated microspheres [16]. Moreover, the coating of 500 nm 
polystyrene NP with invasin-C192 showed a high improvement of the uptake of 
particles through the rat intestinal epithelium [17].  
Mucus  not only serves as a physical barrier to trap particles by steric hindrance but a 
selectively permeable barrier interacting with particles depending on the surface 
chemistry of the particle [18]. Hence NPs designed for their mucus permeating 
properties are also classified depending on the nature of their surface chemistry and the 
mechanism of their permeation through mucus. 
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1.b Alexander Consortium strategies for Mucus Permeable NPs  
The primary aim of the Alexander European Consortium is to produce mucus 
permeable NPs able to improve the intestinal bioavailability of therapeutic agents, such 
as polypeptides or DNA-based drugs, whose exposure to the intestinal milieu would 
otherwise lead to degradation. Such NPs should have the following characteristics: (i) 
prolonged residence time at the mucosal barrier, (ii) enhanced mucus permeation, (iii) 
ability to protect the cargo against enzymatic degradation, (iv) improved uptake of the 
NP or release of cargo at the epithelial surface.  
The key requirement for particles is to be muco-diffusive, hence  researchers have 
approached this problem using various strategies, some of which have been previously 
described [19]. The high diffusion of particles through mucus is afforded by escape of 
the particles from entrapment by either hydrophobic or hydrophilic bonding to the 
mucus components. This may be achieved through: (i) particles bearing an ‘inert 
surface’ that does not form any bonds with mucus, or (ii) through the reversible 
destruction of the mucus structure by the NP [20]. 
1.c Alexander Nano-Strategies to Overcome the Mucus Barrier  
The following strategies were adopted by various partners within the consortium: 
Slippery Surface Nano-Carriers  
The concept of the slippery particles is based on previous findings demonstrating 
positively charged NPs form electrostatic interaction with the mucin fibres, while 
negatively charged NPs, while not undergoing electrostatic interaction with the mucin 
fibres, can form H-bonding interactions with mucus components.  As a result a  neutral 
surface presents an inert character that should afford enhanced mucus permeation [21]. 
An example from nature of a neutral particle surface is that of certain viruses such as the 
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poliovirus, the Norwalk virus and the human papilloma virus which appear to be freely 
permeable through  mucus [22]. These viruses have no lipophilic membrane but only 
the capsid cover which comprises a densely-charged coat containing almost equivalent 
positively and negatively charged groups  each separated by only a short 5 Å distance 
[23]. Laboratory synthesized viruses such as the cowpea mosaic virus have also shown 
a very high oral bioavailability [24]. However, the synthesis and stability of these 
viruses are associated with numerous difficulties [25,26] such that drug delivery 
strategies may be better developed around synthetic particles bearing similar surface 
characteristics to be above classified viruses.  
To deliver  the ‘slippery surface’ strategy, three techniques were utilised by Consortium 
partners; (1) Polyelectrolyte (PEC) NPs with densely charged surface based on the co-
precipitation of oppositely charged polymers such as alginate (-ve) and chitosan (+ve); 
(2) PEGylation of various polymeric NPs such as PLGA, with the PEGylation carried 
out using different techniques and with the aim of achieving a complete coating of the 
selected particles by the hydrophilic PEG coat; (3) copolymerization or coating of a 
lipophilic polymer with a hydrophilic polymer to obtain particles in which the lipophilic 
core is covered with muco-inert hydrophilic electrically-neutral surfaces. 
Self-Mico-Emulsifying Drug Delivery (SMEDD) Systems 
Besides solid NPs, the Consortium partners investigated the appropriateness of the oil-
in-water SMEDD systems.  A SMEDD system forming droplets of less than 100 nm can 
form spontaneously when the oil phase, surfactant(s)/co-surfactant(s) and an aqueous 
phase are mixed together [27,28]. Friedl et al. (2013) [29] showed the influence the 
ingredients of the SMEDD system can have on their diffusion through mucus . The 
Alexander Consortium aimed to investigate the effect of different oils, surfactants and 
co-surfactants mixtures on the diffusion of SMEDD systems. Moreover, other mucus 
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permeable agents, like thiomers, were loaded into the SMEDD systems to study the 
potential synergistic effects with respect to mucus diffusion.  
Nano-Carriers Loaded with Mucolytic Agents  
Mucolytic agents released from NPs can have a significant benefit within pathological 
conditions adversely affecting mucus properties such as Cystic Fibrosis or Chronic 
Obstruction Pulmonary Disease (COPD), where the mucus may display abnormal 
viscoelasticity or water and DNA content [30]. There are three types of mucolytic 
agents that are used for the management of mucus abnormalities. These are disulfide 
breaking agents, proteolytic agents and DNA hydrolysing agents which work, 
respectively, through: the cleavage of the mucin disulfide bond, the hydrolysis of 
peptide bonds within the mucin fibre or the hydrolysis of the DNA responsible for 
mucin entanglements [31,32]. The resulting improvement of NP permeation through 
mucus is due to the disruption of the mucus network by the released mucolytic agents 
[33].  
Mucolytic agents such as N-acetyl cysteine (NAC), dithiotreitol and glutathione 
(disulfide breaking strategy), bromelain, trypsin and papain (proteolytic enzyme), have 
previously been used to improve the permeation of NP through the mucus barrier [34], 
however, the Alexander Consortium sought to develop this strategy with by the loose 
release of mucolytic agents released from the ‘diffusing’ NPs themselves which 
contrasts with the established approach of exogenous parallel application of mucolytic 
agent which disrupt the entire mucosal tissue. The approach by the Alexander partners 
was exemplified through loading of NPs such as PLGA or PAA with disulfide breaking 
agents, in which NPs were designed to deliver a sustained release of mucolytic agents as 
the particles move through the mucus. Other approaches included the immobilization of 
proteolytic enzymes (papain and bromelain) on the surface of NPs by carbodiimide 
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chemistry to enable these surface attached mucolytic agents to cleave mucin fibres 
which come in contact with NPs. 
Thiomer-Nanocarriers 
This is an aligned strategy in which thiomer NPs are claimed to have mucolytic activity 
through the sulfhydryl molecules which interact with mucin disulfide bonds resulting in 
the destruction of the mucus network [9]. In the Consortium various thiol NPs and 
SMEDD systems were studied for their enhanced diffusion through the intestinal mucus 
barrier. 
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1.D Aim of the Study 
The primary aim of this section of work was to provide quantitative and some 
mechanistic data on the mucus diffusion of the wide range of different NPs produced by 
the Alexander Consortium in order to make recommendations for in-vivo evaluation 
that could be done on these NPs. The MPT analysis validated in Cardiff and described 
in Chapter Two, became the most reliable approach within the Consortium to assess 
particles diffusion. Both of pig intestinal mucus models, the “Cardiff native mucus” 
model and the “Consortium mucus gel” model, were utilised.  However, in this thesis 
chapter due to the enormity of NPs investigated, the focus on detailed reporting was 
restricted to studies using the “Cardiff native mucus” model. Appendix B, reports the 
diffusivities of NPs through the alternative “Consortium mucus gel” model.  
A secondary aim was to see if across the wide range of particle types, some global 
particle parameters could still predict NP mucus permeating efficiency.    
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2. MATERIAL AND METHODS 
2.a Materials 
Glass bottom imaging dishes (35 mm diameter dish with a glass coverslip at 1.5 mm 
thick and 10mm diameter) were from MatTek Corporation (USA).  All other reagents 
and solvents were purchased from Fisher Scientific (Loughborough, UK). In order to 
image NPs by MPT, all the NPs studied in this chapter were loaded with Lumogen red 
by encapsulation. The NPs were supplied by the partners in the Alexander consortium 
and are detailed in the respective tables in Results and Discussion section.  
2.b Methods 
The collection and preparation of the mucus models and the implementation of MPT 
were undertaken as described in Chapter 2.     
Particle Preparation 
Particles were received from the Consortium partners either as freeze-dried powder or 
as particles dispersed in an aqueous phase. Samples of freeze-dried powder were re-
suspended in the aqueous phase as defined by the respective partner. Physicochemical 
properties of these NPs (particle sizes and zeta potential) were measured by the partners 
using the DLS technique and were confirmed by our group when necessary.  
Diffusion Coefficient of Particles through the “Cardiff native mucus” Barrier 
The diffusion of the NPs was studied in both the “Cardiff native mucus” and the 
“Consortium mucus gel” models. The detailed data for the latter is reported in Appendix 
B, while the data for the Cardiff model is presented here but, where approached, some 
general comparisons made between the two models. The NPs were classified into six 
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groups depending on the strategy adopted to enhance NP diffusion through the mucus 
barrier:  
1.  Slippery-PEGylated strategy: involving particles coated or copolymerized with PEG.  
2.  Slippery-Amphiphilic polymer strategy: involving particles comprising amphiphilic 
polymers with the hydrophilic polymer at the surface and the lipophilic polymer at the 
core. 
3. Slippery-PEC strategy: involving particles comprising +ve and -ve charged polymers.  
4 Self-microemulsifying drug delivery (SMEDD) systems: involving microemulsion 
systems in which the effects of the various ingredients were studied.   
5. Mucolytic NPs strategy: involving particles loaded with mucolytic agents. 
6. Thiolated NPs strategy: involving particles loaded with thiomers.  
To identify and compare the diffusion of each particle and to highlight the effect of their 
varying surface chemistries independent of particle size,  the particles were ranked from 
the fastest to the slowest depending on their calculated % <Deff>/D° data.  Moreover, 
NPs within each nano-strategy were further sub-classified into sub-groups representing 
ostensibly the same particles made by the same partner in the Consortium but 
containing some formulation variables. Due to the confidential nature of the 
technologies made by the Consortium partners, only the variable ingredients or classes 
of the ingredients subject to the experiments have been mentioned.  
The diffusion of NPs within each strategy was used to identify factors enhancing or 
reducing diffusion. Moreover, after comparison of diffusivities of NPs within each 
strategy, a general comparison was carried out for all NPs representing all strategies. 
This general comparison was done to identify the best strategy that can be used to 
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improve particle diffusion through the mucus.  (The structures of all the polymers used 
by the partners in this chapter are presented in Appendix B). 
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3. RESULTS AND DISCUSSION 
The data obtained for the diffusivity of each particle through intestinal mucus was 
presented in two ways. First, the <Deff> of each particle was referred against particle 
size to highlight the effect of size per se. Second, to normalise for particle size, the 
particle diffusion data in mucus was referenced to the particle respective data in water.  
In other words, by measuring the % <Deff>/D°, we normalise for the effect of particle 
size on the diffusion of particle through the mucus. The % <Deff>/D° of each particle 
was presented against the zeta potential of that particle to highlight the effect of particle 
surface charge (surface chemistry) on mucus diffusion.   
3.a Slippery-PEGylated NP Strategy 
The strategy of PEGylation of NPs has previously been found  to be promising to 
improve the mucus permeability of NPs through normal cervicovaginal mucus [35], 
abnormal cystic fibrosis sputum [36,37] and pulmonary mucus [38]. The improved 
mucus permeability was attributed to the polyethylene units of the PEG polymer. This 
agrees with studies involving the coating of particles with polymers having structural 
similarity with PEG and which resulted in an enhancement of particle diffusion through 
mucus. For example, coating of PLGA NP with a low molecular weight pluronic 
surfactant bearing hydrophilic polypropylene oxide units  generated  highly mucus 
permeable NPs [39,40]. Hence, it is not surprising that a PEGylation strategy was 
adopted by a number of Consortium partners. The term (coated with PEG) is used 
throughout this chapter to describe all the surface modified PEGylated NPs. 
Table 3.1 shows particles that were surface modified with PEG.  The Table details the 
following: Consortium Partner; NP code (as defined by the partner); chemical 
composition of the particle (where known including the chemical core of the particle, 
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PLGA etc.); physico-chemical properties of the particle (Zeta potential and particle 
size); MPT diffusion data [cm2 S-1 x 10-9] in the Cardiff mucus model. The latter 
included D° water (calculated by Stocks Einstein equation), < Deff> and the % ratio 
<Deff>/D°; finally the rank order of the particle diffusion (i.e. 1= fastest) based on 
%<Deff>/D° amongst the entire screening exercise of 102 different NPs. Figure 3.1A 
shows the < Deff> versus the particle size data for the respective PEGylated NPs.  
Figure 3.1B shows the %<Deff>/D of each of the PEGylated NPs versus zeta potential. 
The PEGylated NPs prepared by the different partners are represented in the Table and 
Figures by different colours i.e. Nanomi is Red; LEK is Blue; Thessaloniki University is 
Green for the 50:50 PLGA: PEG formulation; Thessaloniki University is brown for the 
25:75 PLGA: PEG formulation; Nevara University is Pink. For reasons related to 
absence of detailed formulation issues, the Evonik data is not reproduced in the Figures.  
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Table 3.1: Particles’ composition, physical characteristics and diffusion behavior of various PEGylated NPs. (PDI and S.D. are included where necessary). 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean 
Particle Size   
(nm) 
Mean  
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% <Deff>/ 
D°          
Ranking  
Fastest =1 
and slowest 
102 
Nanomi 
PLGA Poly(D,L-lactide-co-glycolide) (50:50) -30 161 27.91 
0.00013 
(±0.00002) 
0.0005 99 
PLGA-15% 
PEG (5000) 
PLGA coated with 15% methoxy PEG 
(MW: 5000). 
-18   35  127.8 
0.16823 
(±0.09498) 
0.1317 19 
PLGA-15% 
PEG (6000) 
PLGA coated with 15% PEG (MW: 
6000). 
-8.3 54  83.22 
0.46889 
(±0.12699) 
0.5634 4 
PLGA-10% 
PEG (5000) 
PLGA coated with 10% methoxy PEG 
(MW: 5000). 
-26   41  110.7 
0.06458 
(±0.01566) 
0.0583 32 
LEK 
PEC- 22.5% 
PEG 
 
(70:30) Negatively charged polymer+ 
Positively charged polymer conjugated to 
75% PEG (Total ratio of PEG is 22.5%) 
-28 250  17.98 
0.03351 
(±0.00557) 
0.1864 15 
PEC- 52.5% 
PEG 
(30:70) Negatively charged polymer+ 
Positively charged polymer conjugated to 
75% PEG (Total ratio of PEG is 52.5%) 
-12 250 17.98 
0.05472 
(±0.00620) 
0.3045 8 
PEC- 15.0% 
PEG 
(70:30) Negatively charged polymer+ 
Positively charged polymer conjugated to 
50% PEG (Total ratio of PEG is 15%) 
-27 250  17.98 
0.01883 
(±0.00230) 
0.1048 20 
PEC- 35.0% 
PEG 
(30:70) Negatively charged polymer+ 
Positively charged polymer conjugated to 
50% PEG (Total ratio of PEG is 35%) 
-15 250  17.98 
0.04937 
(±0.00719) 
0.2747 10 
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Table 3.1 (Continuation): Particles’ composition, physical characteristics and diffusion behavior of various PEGylated NPs. 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean  
Particle Size   
(nm) 
Mean  
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% <Deff>/ 
D°          
Ranking  
Fastest =1 
and slowest 
108 
AUTH 
RG502H- 
PEG2000 
Acidic PLGA (50:50) coated with 25% 
methoxy PEG (MW:2000) 
-20 300  15.01 
0.00368 
(±0.00113) 
0.0245 42 
RG502H- 
PEG5000 
Acidic PLGA (50:50) coated with 25% 
methoxy PEG (MW:5000) 
-14 287  15.64 
0.00079 
(±0.00019) 
0.0050 74 
RG752H- 
PEG2000 
Acidic PLGA (75:25) coated with 25% 
methoxy PEG (MW:2000) 
-11 301 14.91 
0.00142 
(±0.00034) 
0.0096 64 
RG752H- 
PEG5000 
Acidic PLGA (75:25) coated with 25% 
methoxy PEG (MW:5000) 
-9 261 17.21 
0.00081 
(±0.00011) 
0.0047 75 
Nevara 
G-15% PEG 
(2000) 
Lipophilic polymer coated  with 15% 
PEG (MW: 2000)  
-45 178  25.21 
0.00166 
(±0.00051) 
0.0066 71 
G-15% PEG 
(6000) 
Lipophilic  polymer  coated  with 15% 
PEG (MW: 6000)  
-47 230  19.54 
0.00035 
(±0.00001) 
0.0018 93 
Evonik 
Mix 3 PLGA-PEG  120 37.45 
0.03084 
(±0.00771) 
0.0824 26 
 
Mix 4 
 
PLGA-PEG  342 13.13 
0.00016 
(±0.00003) 
0.0013 96 
Mix 10 
 
PLGA-PEG  424 10.58 
0.06343 
(±0.01313) 
0.5997 3 
Mix 18 PLGA-PEG  183 24.56 
0.02551 
(±0.00527) 
0.1039 22 
Mix 19 PLGA-PEG  171 26.28 
0.11984 
(±0.02907) 
0.4560 6 
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Figure 3.1: (A) Mucus diffusion <Deff> versus particle size of various PEGylated NPs 
in the “Cardiff native mucus” model. (B) % ratio <Deff>/D° versus zeta potential of 
various PEGylated NPs in the “Cardiff native mucus” model.  
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As can be seen from Table 3.1 and Figure 3.1, most of the PEGylated NPs in this study 
possessed a lipophilic PLGA core coated with PEG. PLGA is a hydrophobic 
biodegradable poly α-hydroxy acid polymer [41], consisting of either 50:50 or 75:25 
(lactic: glycolic), respectively [42]. PLGA is widely used in the synthesis of NPs due to 
its capacity to load high molecular weight lipophilic drugs and for the safety of its 
hydrolytic components [43]. However, PLGA NPs have low diffusion through mucus 
due to lipophilic interactions with mucin. Hence, PLGA is often either copolymerized 
[44] or coated [45] with a hydrophilic polymer to improve its diffusion through the 
mucus barrier. Therefore, it was not surprising that the uncoated PLGA NP (red 
coloured symbols) showed a lower diffusivity through the mucus as compared with 
PLGA NPs coated with PEG (Figure 3.1).   
Figure 3.1 A shows a very general trend only for increased <Deff> as the PEG particles 
get smaller. Indeed the impacts of the various PEG subtypes seem to have a greater 
effect on <Deff> however.  Figure 3.1B also shows there is no global correlation 
between diffusion (when normalised to particle size; <Deff>/D°) and particle zeta 
potential. However, within each subgroup such distinctions may occur but the number 
of different formulations is not great enough to make any such conclusions.  
A key point to make is that the variation in the diffusion of particles amongst the 
various sub-groups of PEG-coated NPs will also reflect differences between the 
pegylation chemistries between the different partners. As such for this particular mucus 
permeation strategy inter-laboratory comparisons should be made with caution and must 
be deliberately limited. For example, there is no real way for the Cardiff team to 
confirm the actual density of Pegylation.  Previous studies have showed that the density 
of PEG at the surface of NPs is very influential on the diffusion of particles through 
mucus. Hanes et al. (2008) [46] studied the effect of the PEG density at the surface of 
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polystyrene NPs on their diffusion through the cervico-vaginal mucus They showed that 
a reduction in density of PEG polymer on the surface of polystyrene NPs from 65% to 
40% resulted in a x700-fold reduction in the diffusion coefficient.   
Further, it has been reported that the density of PEG coating at the surface of PLGA 
NPs varies depending on the conditions of coating [47].  A study by Xu et al. (2013) 
[48]  showed that the type of the emulsifier used to coat the particles impacts upon the 
subsequent diffusion of the coated particles. Specifically, an increase in the molecular 
weight of the emulsifier resulted in a reduced diffusive capacity.  Similarly, the type of 
particle core and the cargo itself has an effect on the efficiency of coating with PEG 
[49].  Nevertheless, of particular note Figure 3.1B highlights the impact of the type of 
PEG polymer on diffusion.  Specifically, the Nanomi particles (Red symbols) show the 
negative influence of the methoxy functional group upon the diffusion of PLGA 
particles coated with PEG or methoxy-PEG.  The reduced  <Deff>/D° ratio for the 
methoxy PEG is likely due to the higher lipophilicity of methoxy –PEG polymer which 
can form hydrophobic interactions with mucin [50]. Indeed, Gref et al. (2012) [51] 
reported that conjugation of methoxy PEG polymer onto the surface of PLGA particles 
resulted in the positioning of the methoxy groups at the terminal position of the PEG 
chain which was considered to result in increased contact of the methoxy group with 
mucus components. 
It was also noted that for the NP sub-groups represented by Brown, Green and Pink 
coloured symbols (Figure 3.1B) showed that the lower molecular weight PEG (2000) 
was at least x2-fold  higher (% <Deff/D°) compared to its corresponding NP coated 
with higher molecular weight PEG (5000 or 6000).  Previous studies on the effect of 
PEG molecular weight upon particle diffusion through mucus can appear contradictory. 
Hanes’ group showed that NPs coated with low molecular weight PEG (PEG2000) 
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display the highest permeation compared with higher  molecular weight PEG [52]. In 
contrast another study by the same research group showed that NPs coated with PEG 
5000 possesses slightly greater diffusion than that of PEG2000 which in its own right 
was greater followed by PEG1000 [48,53]. On the other hand, a recent study showed no 
significant difference between the permeation of particles coated with either PEG 2000 
or PEG 5000 [54]. 
The debate about the effect of the molecular weight of PEG on particle diffusion 
through the mucus was clarified by Cu and Saltzman (2010) [55]. Their study showed 
that PLGA when coated with at a low density of PEG (low ratio of PEG at the surface 
of particle) then the higher molecular weight PEG (PEG 10 KDa) showed the higher 
diffusivity through the mucus as compared to particles coated at the same density but 
with a lower molecular weight PEG polymer.  Moreover, when PLGA particles were 
coated at a high density the particle with the lower molecular weight PEG (PEG 2KDa) 
exhibited the highest diffusivity through the mucus. It seems that higher molecular 
weight PEG is able to form a more complete  layer on the surface of the particles at a 
lower PEG concentration, whereas at a higher PEG concentration, the high molecular 
weight PEG forms tethered chains at the surface of the NP which inter-penetrate with 
the mucin bio-polymer network leading to particle trapping by the mucus [56,57].  
With respect to low molecular weight PEG (PEG2000) then at a high concentration of 
coating the PEG totally covers the particle surface by efficient positioning around the 
curvature of the particle [55]. Further, it appears that at very high concentrations PEG 
2000 also forms tethered chains but these do not inter-penetrate with the mucin fibers 
and only form very weak  H-bonding with the mucin  [58]. Therefore at a high density 
of surface PEG, the PEG 2000 would show a higher diffusivity through the mucus as 
compared to PEG5000 or PEG 10kDa.  
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3.b Slippery-Amphiphilic Polymers Strategy 
The slippery amphiphilic (co)polymer strategy involves the use of hydrophilic polymers 
rather than PEG to copolymerize or coat a hydrophobic core. Previous work by Beloqui 
et al. (2014) [59] has shown the impact of hydrophilic polymers such as dextran on the 
diffusion of lipophilic particles through a mucus barrier such as that represented by  the 
combined Caco-2/HT29-MTX monolayers mucus model cells. Beloqui et al. (2014) 
showed a significant increase in the mucus permeability of solid lipid NP when it was 
coated with the near neutrally charged polymer mixture of dextran–protamine.  
In this section of work, the polyanhydrides polymer (Gantrez) was served as the source 
of the hydrophobic nanoparticle core. Gantrez is a co-polymer of methyl-vinyl-ether and 
maleic anhydride, and it is classified as a lipophilic biodegradable poly α-hydroxy acids 
[41]. It was introduced as a muco-adhesive polymer due to the high capacity to form H-
bonds to the mucin glycosidic chains [60]. There are many advantages for the usage of 
Gantrez as NP for oral delivery. These advantages are: (i) non-toxic degradation 
products; (ii) ease of preparation [61], and (iii) good nano-carrier capacity for various 
ligands and proteins [62,63]. Hence, this polymer was selected by the Alexander 
consortium partner (Nevara) to be used as the lipophilic core. Moreover, the hydrophilic 
polymers, D-mannosamine hydrochloride (D-M), low methoxylated pectin (LMPEC) 
and high methoxylated pectin (HMPEC) were selected to form the hydrophilic shell of 
the Gantrez lipophilic core by either coating to or copolymerization with the Gantrez 
polymer.  
Table 3.2 shows particles that were surface modified with hydrophilic polymer, i.e. D-
M, LMPEC or HMPEC.  The Table details the following:  Consortium Partner; NP code 
(as defined by the partner); chemical composition of the particle where known including 
the chemical core of the particle, Gantrez etc.; physico-chemical properties of the 
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particle (Zeta potential and particle size); MPT diffusion data [cm2 S-1 x 10-9] in the 
Cardiff mucus model including also D° water (calculated by Stokes Einstein equation), 
the <Deff>  and the ratio of % <Deff>/D°; finally the rank order of  the particle 
diffusion (i.e. 1= fastest) based on %<Deff>/D° across the entire screening exercise of 
102 different particles). All the codes for particles are described in the Table and will be 
used throughout the section.  
 Figure 3.2A shows the <Deff> versus the particle size data for the respective 
amphiphilic polymer NPs coated or copolymerized with, i.e. D-M, LMPEC or HMPEC. 
Figure 3.2A shows no essentially effect of particle size on the diffusion coefficient of 
these particles through the “Cardiff native mucus” model. The optimum range appeared 
to be between 250 nm to 350 nm. The hydrophilic polymer associated with the highest 
<Deff> was G-5%LMPEC.   
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Table 3.2: Particles’ composition, physical characteristics and diffusion behavior of slippery amphiphilic polymers NPs. (Gantrez NPs Coated or 
Copolymerized with   D-mannosamine hydrochloride) (PDI and S.D. are included where necessary). 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean  
Particle Size   
(nm) 
Mean  
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% <Deff>/ 
D°          
Ranking  
Fastest =1 
and slowest 
102 
Nevara 
NPA-L-L Gantrez NP -53 217 20.71 
0.00167 
(±0.00032) 
0.0081 66 
G-1% D-M Gantrez coated with 1% D-mannosamine 
hydrochloride 
-40 242  18.56 
0.00273 
(±0.00060) 
0.0147 56 
G-2.5% D-M Gantrez coated with 2.5% D-
mannosamine hydrochloride 
-35 271  16.56 
0.00092 
(±0.00019) 
0.0055 72 
G-5% D-M Gantrez coated with 5% D-mannosamine 
hydrochloride 
-45 263  17.09 
0.01105 
(±0.00276) 
0.0647 30 
G-7.5% D-M Gantrez coated with 7.5% D-
mannosamine hydrochloride 
-49 332  13.54 
0.01247 
(±0.00220) 
0.0921 23 
G-10% D-M Gantrez coated with 10% D-mannosamine 
hydrochloride 
-39 367  12.25 
0.00203 
(±0.00040) 
0.0166 53 
G-1% CO-
DM  
Gantrez copolymerized with 1% D-
mannosamine hydrochloride 
-37 265  16.96 
0.00433 
(±0.00069) 
0.0255 41 
G-2.5% CO-
D M 
Gantrez copolymerized with 2.5% D-
mannosamine hydrochloride 
-31 249  18.05 
0.00133 
(±0.00027) 
0.0074 69 
G-5% CO-
DM  
Gantrez copolymerized with 5% D-
mannosamine hydrochloride 
-37 242 18.57 
0.00354 
(±0.00064) 
0.0190 50 
G-7.5% CO-
DM  
Gantrez copolymerized with 7.5% D-
mannosamine hydrochloride 
-45 254 17.69 
0.00037 
(±0.00006) 
0.0021 91 
G-10% CO-
DM  
Gantrez copolymerized with 10% D-
mannosamine hydrochloride 
-39 243  18.49 
0.00364 
(±0.00069) 
0.0197 47 
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Table 3.2 (Continuation): (Gantrez NPs Coated or Copolymerized with   low methoxylated pectin (LMPEC). 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean  
Particle Size   
(nm) 
Mean  
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% <Deff>/ 
D°          
Ranking  
Fastest =1 
and slowest 
102 
Nevara 
 
G-1% 
LMPEC 
Gantrez coated with 1% low 
methoxylated pectin 
-49 340  13.22 
0.04625 
(±0.00882) 
0.3499 7 
G-5% 
LMPEC 
Gantrez coated with 5% low 
methoxylated pectin 
-59 237  18.96 
0.10683 
(±0.02458) 
0.5634 5 
G-5% 
LMPEC - 0.5 
BSA 
Gantrez coated with 5% low 
methoxylated pectin and loaded with 
0.5% BSA 
-47 174  25.83 
0.00063 
(±0.00003) 
0.0025 86 
G-5% 
LMPEC- 1 
BSA 
Gantrez coated with 5% low 
methoxylated pectin, loaded with 1% 
BSA 
-43 161  28.00 
0.00507 
(±0.00030) 
0.0181 52 
G-5% 
LMPEC- 1.5 
BSA 
Gantrez coated with 5% low 
methoxylated pectin and loaded with 
1.5% BSA 
-41 174 25.90 
0.00790 
(±0.00046) 
0.0305 38 
G-5% 
LMPEC- 2 
BSA 
Gantrez coated with 5% low 
methoxylated pectin and loaded with 2% 
BSA 
-42 163 27.62 
0.00200 
(±0.00012) 
0.0072 70 
G-10% L 
MPEC 
Gantrez coated with 10% low 
methoxylated pectin 
-53 251 17.90 
0.05246 
(±0.00235) 
0.2930 9 
G-1% Co-
LMPEC 
Gantrez copolymerized with 1% low 
methoxylated pectin 
-49 221 20.34 
0.00676 
(±0.00133) 
0.0332 36 
G-5% Co-
LMPEC 
Gantrez copolymerized with 5% low 
methoxylated pectin 
-35 221 20.34 
0.00305 
(±0.00097) 
0.0150 55 
G-10% Co-
LM PEC 
Gantrez copolymerized with 10% low 
methoxylated pectin 
-39 175 25.68 
0.00075 
(±0.00032) 
0.0029 83 
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Table 3.2 (Continuation): (Gantrez NPs Coated or Copolymerized with  high methoxylated pectin (HMPEC) and other Amphiphilic polymer mixture NPs 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean  
Particle Size   
(nm) 
Mean  
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% <Deff>/ 
D°          
Ranking  
Fastest =1 
and slowest 
102 
Nevara 
 
G-1% 
HMPEC 
Gantrez coated with 1% high 
methoxylated pectin 
-45 239 18.80 
0.00142 
(±0.00030) 
0.0076 67 
G-5% 
HMPEC 
Gantrez coated with 5% high 
methoxylated pectin 
-52 261 17.22 
0.02707 
(±0.00720) 
0.1572 17 
G-10% 
HMPEC 
Gantrez coated with 10% high 
methoxylated pectin 
-46 274 16.40 
0.00034 
(±0.00006) 
0.0021 92 
G-1% Co-
HMPEC 
Gantrez copolymerized with 1% high 
methoxylated pectin 
-43 178 25.25 
0.00798 
(±0.00190) 
0.0316 37 
G-5% Co-
HMPEC 
Gantrez copolymerized with 5% high 
methoxylated pectin 
-47 157 28.63 
0.00075 
(±0.00017) 
0.0026 85 
G-10% Co-
HM PEC 
Gantrez copolymerized with 10% high 
methoxylated pectin 
-36 168 26.75 
0.00065 
(±0.00012) 
0.0024 88 
Nevara 
 
CG-O-TH Gantrez copolymerized with thiamine 
(spray dried NP) 
-29 231 19.46 
0.00008 
(±0.00001) 
0.0004 101 
G-OA-NSD  Gantrez copolymerized with  octadecyl- 
amine (spray dried NP) 
          -57 227 19.80 
0.00033 
(±0.00006) 
0.0017 94 
G-NIC Gantrez copolymerized with  nicotin- 
amide  (spray dried NP) 
-40 297 15.13 
0.00054 
(±0.00012) 
0.0036 81 
HPCD Gantrez copolymerized with  2-
hydroxypropyl-beta-cyclodextin (spray 
dried NP) 
-57 245 18.34 0.00041 
(±0.00008) 
0.0022 90 
TH-SD Gantrez coated with thiamine NP 
(lyophylised) 
-41 240 18.75 0.00017 
(±0.00004) 
0.0009 97 
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Figure 3.2: Diffusion behaviour of 
various slippery amphiphilic polymers 
NPs in the “Cardiff native mucus” 
model. (A) Diffusion <Deff> versus 
particle size of all amphiphilic polymers 
NPs (B) The % ratio <Deff>/D° versus 
zeta potential of coated amphiphilic 
polymers NPs (■) versus copolymerized 
amphiphilic polymers NPs (□)  (C) The 
% ratio <Deff>/D° versus zeta potential 
of amphiphilic polymers NPs coated 
with D-M (blue particles), amphiphilic 
polymers NPs coated with LMPEC 
(Red particles) and amphiphilic 
polymers NPs coated with HMPEC 
(brown particles) (D) The % ratio 
<Deff>/D° versus zeta potential of 
Gantrez NPs coated with 5% LMPEC 
(○) versus the same particles loaded 
with different concentration BSA(●).  
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Each of the Figures 3.2B, 3.2C and 3.2D shows the %<Deff>/D° ratio versus zeta 
potential of amphiphilic polymer NPs. Specifically, Figure 3.2B shows the %<Deff>/D° 
ratio of the Gantrez particles coated with either hydrophilic polymers or copolymerized 
to hydrophilic polymers. The technique by which NPs were synthesized showed a 
crucial effect on the diffusion of the NPs through the mucus. NPs synthesized by 
coating of Gantrez with D-M, LMPEC or HMPEC polymers exhibited higher 
diffusivities than NPs synthesized by copolymerization of Gantrez with D-M, LMPEC 
or HMPEC polymers. This is true even for the relatively low diffusing NPs coated with 
10% hydrophilic polymer. This finding has not been discussed in the literatures 
previously and it could be related to the conditions of the synthesis of these NPs 
species. However, this difference in the diffusion of NPs consisting of same polymers 
but synthesized by coating or copolymerization could be due to the resulting differences 
in surface chemistry of the NPs. 
Figure 3.2C shows the effect of concentration and the type of the coated hydrophilic 
polymer on the diffusivity of the NPs through mucus barrier. These NPs are represented 
in Figure 3.2C by different colours depending on the type of the hydrophilic polymer 
coat, i.e. Gantrez NPs coated with D-M are Blue, Gantrez NPs coated with LMPEC are 
Red and Gantrez NPs coated with HMPEC are Brown. NPs coated with LMPEC (Red 
symbols) showed higher diffusivities than particles coated with HMPEC (Brown 
symbols) or D-M (Blue symbols). The high diffusivity of LMPEC particles as compared 
with HMPEC could be due to the lower methyl content of this polymer which resulted 
in lower lipophilicity at the surface of the NPs and lower interaction to the mucus [64].  
Moreover, the ratio of the hydrophilic polymer exhibited an impact on the diffusivities 
of the particles, the influence is however complex. Specifically, for each of the coating 
type, there appeared to be an optimum coating concentration that confers the greatest 
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diffusion through mucus. Between coating concentration of 1% and 10%, the optimum 
concentration for LMPEC and HMPEC was 5% while for D-M, it was 7.5%. These 
optimum concentration happened to coincide with the NPs coating concentration 
associated with the most -ve zeta potential, i.e. 5%LMPEC had the most –ve zeta 
potential among all the of the coated LMPEC particles. This zeta potential association 
with the diffusion of NPs is same for NPs coated with HMPEC and D-M.  
This kind of relationship is not dissimilar to that observed for PEG coating. For 
example, the optimum coating concentration of the Gantrez particles may be due to the 
formation of an efficient inert hydrophilic shell at the surface of the particles [45]. 
Concentration either lower or higher than the optimum may simply represent 
respectively an inefficient coating or the production of a thick layer at the particle 
surface that can interpenetrate with the mucin fibres  [56].  
Lastly, Figure 3.2D shows the effect of loading of BSA on the diffusivity of G-
5%LMPEC. The Figure shows the unloaded NP to display higher diffusion than 
particles loaded with 0.5%, 1%, 1.5% and 2% BSA. Although G- 5% LMPEC showed 
the highest % ratio <Deff>/D° through the pig intestinal mucus among all the Gantrez-
hydrophilic NP, the loading of G-5% LMPEC NP with BSA resulted in sharp drop in 
the % ratio <Deff>/D°. It was also noticeable that BSA loading resulted in a less 
negative zeta potential than the unloaded particles.  
Other hydrophilic polymers were used to coat Gantrez particle, however, the effects of 
these polymers were not studied thoroughly by the partner in the Consortium .As 
consequence, only one particular formulation of a given particle type was synthesized 
by the partner. Hence, such particles are presented in Table 3.2 but without any further 
discussion.  
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3.c Slippery-PEC NP Strategy 
This strategy was selected by the consortium to mimic the capsid shell of freely 
permeable viruses through the mucus. Such viruses are characterized by a high density 
of positive and negative charges at their surface yielding a net neutral charge [65]. This 
surface property enables these viruses to permeate freely through the mucus barrier 
[66]. Capsid shell viruses inspired researchers to synthesize particles having the same 
surface properties [52]. Self-assembled PEC NPs are synthesized by mixing positively 
and negatively charged polymers to form electrostatically complex particles with the 
aim of achieving a high charge density at the surface. The charge at the surface can be 
modified to be neutral to mimic the muco-inert surface of capsid virus. Laffleur et al. 
(2014) [67] studied the permeation of PEC NP composed of poly(acrylic acid) (PAA) 
and poly(allylamine) (PAM) through pig intestinal mucus layer using the Ussing 
chamber technique. The study showed that the neutral PEC NP had a 2.5-fold and 1.8-
fold higher permeation than that of the positively and negatively charged NP 
respectively, and indicating the promising nature of this strategy to overcome a mucus 
barrier.  
Table 3.3 shows the diffusion of various PEC NPs. The Table details the following: 
Consortium Partner; NP code (as defined by the partner); chemical composition of the 
particle, where known, including the chemical core of the particle, chitosan etc.; 
physico-chemical properties of the particle (Zeta potential and particle size); MPT 
diffusion data [cm2 S-1 x 10-9] in the Cardiff mucus model including D° water 
(calculated by Stokes Einstein equation), the <Deff>  and the % ratio of <Deff>/D°; 
finally the rank order of  the particle diffusion (i.e. 1= fastest) based on %<Deff>/D° 
amongst the entire screening exercise of 102 different particles. All codes for particles 
are described in the Table and will be used throughout the section.  
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 Figure 3.3A shows the <Deff> versus particle size data for the respective PEC NPs.  It 
shows that particle size had no real effect on the <Deff> of all the tested PEC NPs 
described in Table 3.3.  Figure 3.3 B shows that the diffusion behavior of the PEC NP 
made by LEK (Table 3.3) using either alginate or chondroitin as the negatively charged 
polymer complexed at varying ratios with the unknown +ve charged polymer. From the 
limited study design, it is hard to conclude why L1011 should be close to 3-fold greater 
diffusion compared to L1010. Although the poor diffusion associated with the +ve 
charge NP is clear. The zeta potential of the LEK particles is also shown in figure 3.3A 
and demonstrated the positive charged particles to be much slower compared to the 
negative species.  
Moreover, Figure 3.3B shows the Sagetis PEC-NPs, all of which used an unknown 
PBAE polymer as the source of –ve charges, and either chitosan (CS) or again unknown 
polymer (CR, CH) as the source of positive charge. What is clear is that despite a 
positive zeta potential, the new sagetis polymer (CR, CH) provided a high % <Deff>/D° 
then particles made from chitosan. More interestingly, whatever the particle type, these 
particles conjugated with peptide resulted in superior diffusion characteristics compared 
to the respective particles conjugated with DNA. It can be seen that this case was 
irrespective of zeta potential and clearly was not determined by this particular physico-
chemical property, i.e. CR and CH PEC NPs all displayed the same zeta potential of + 
10 mV. Without knowledge of actual components of the NPs, it is difficult to consider 
why the peptide formulations were consistently better than that of DNA formulation.  
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Table 3.3: Particles’ composition, physical characteristics and diffusion behavior of various PEC NPs. (PDI and S.D. are included where necessary). 
Partner NP Code Compositions Zeta Potential 
(mV)       
Mean  
Particle Size   
(nm)         
Mean 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% <Deff>/ 
D°          
Ranking  
Fastest =1 
and slowest 
102 
Lek 
L1009 
[90:10] (+ve) polymer unknown / (-ve) 
polymer alginate 
16 250  17.98 
0.00004 
(±0.00001) 
0.0002 102 
L1010 
[30:70]  (+ve) polymer unknown / (-ve) 
polymer chondroitin 4-sulfate  
-22 250  17.98 
0.00022 
(±0.00003) 
0.0012 96 
L1011 
[40:60]  (+ve) polymer unknown / (-ve) 
polymer  chondroitin 4-sulfate  
-18 250  17.98 
0.00063 
(±0.00012) 
0.0035 82 
 
Sagetis 
CS/CEF3.5 
[ratio unknown]  (+ve) polymer chitosan / 
(-ve) polymer poly(β-amino esters) 
(PBAEs) conjugated to peptide. 
5 194  23.17 
0.00327 
(±0.00021) 
0.0141 57 
CS/CDF3.5 
[ratio unknown]  (+ve) polymer chitosan / 
(-ve) polymer poly(β-amino esters) 
(PBAEs) conjugated to DNA. 
5 194  23.17 
0.00098 
(±0.00006) 
0.0042 77 
CR3/CDf3.5 
[ratio unknown]  (+ve) polymer unknown 
/ (-ve) polymer poly(β-amino esters) 
(PBAEs) conjugated to DNA. 
10 499  9.01 
0.00617 
(±0.00035) 
0.0685 28 
CR3/CEf3.5 
[ratio unknown]  (+ve) polymer unknown 
/ (-ve) polymer poly(β-amino esters) 
(PBAEs) conjugated to peptide. 
10 499  9.01 
0.00747 
(±0.00040) 
0.0829 24 
CH3/CDf3.5 
 
[ratio unknown]  (+ve) polymer unknown 
/ (-ve) polymer poly(β-amino esters) 
(PBAEs) conjugated to DNA. 
10 499  9.01 
0.00112 
(±0.00006) 
0.0124 59 
CH3/CEf3.5 
[ratio unknown]  (+ve) polymer unknown 
/ (-ve) polymer poly(β-amino esters) 
(PBAEs) conjugated to peptide. 
10 499  9.01 
0.00179 
(±0.00013) 
0.0198 46 
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Figure 3.3: (A) Mucus diffusion <Deff> versus particle size of PEC NPs in the “Cardiff 
native mucus” model. (B) % ratio <Deff>/D° versus zeta potential of PEC NPs in the 
“Cardiff native mucus” model.  
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3.d SMEDD System Strategy 
Previous in vivo studies of orally administered SMEDD systems have shown promise in 
term of enhancing the bioavailability of loaded drugs [68,69]. SMEDD systems were 
selected by the Alexander Consortium as one of the muco-diffusive nano-strategies. A 
SMEDD system is aimed at having a muco-inert droplet surface due to the hydrophilic 
nature of the surfactant/co-surfactant shell at the surface of the oil droplet [70]. 
Table 3.4 shows the SMEDD systems that were made by three different partners in the 
Consortium.  The Table details the following:  Consortium Partner; SMEDD system 
code; chemical composition of the SMEDD system where known including the oil 
phase, surfactant and co-surfactant etc.; physico-chemical properties of the system (Zeta 
potential and particle size); MPT diffusion data [cm2 S-1 x 10-9] in the Cardiff mucus 
model including D° water (calculated by Stokes Einstein equation), <Deff>  and the % 
ratio of < Deff>/D°; finally the rank order of  the particle diffusion (i.e. 1= fastest) 
based on %<Deff>/D° ratio amongst the entire screening exercise of 102 different 
particles. Figure 3.4A shows the < Deff> versus the particle size data for the respective 
SMEDD systems.   
Figure 3.4B shows the %<Deff>/D of each of the SMEDD system versus zeta potential. 
The SMEDD systems prepared by the different partners are represented in Table 3.4 and 
Figure 3.4 by different colours i.e. Thessaloniki University (AUT) is Black; Nevara 
University (NEV) is Blue; Insbruck University (INS) is red.  
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Table 3.4: Particles’ composition, physical characteristics and diffusion behavior of various SMEDDS systems. (PDI and S.D. are included 
where necessary). 
 
Partner SMEDDS 
code 
Compositions 
(O/W) 
(Oil/Surf) Mixture / Co-surfactant  
Zeta Potential 
(mV) 
Mean  
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% <Deff>/ 
D°          
Ranking  
Fastest =1 
and slowest 
102 
 
AUTH 
AUT-A 
Mix1 /  Labrafil-M1944CS   (Co-
surfactant) 
-0.06 35  128.4 
0.00085 
(±0.00020) 
0.0007 100 
AUT-B 
Mix1 /  Transcut-ol P  (Co-surfactant) 
-0.09 45  99.87 
0.22873 
(±0.06054) 
0.2290 14 
AUT-C 
Mix2 / LabrafilM19444CS   (Co-
surfactant) 
0.20 25  179.8 
0.10990 
(±0.00326) 
0.0611 33 
Nevarra 
NEV-A 
Mix3 / Plurol Oleique (Co-surfactant) 
-22 167  26.88 
0.00528 
(±0.00114) 
0.0196 49 
NEV-B 
Mix4 / Span 20 (Co-surfactant) 
-16 240  18.72 
0.13846 
(±0.00601) 
0.7397 2 
Innsbruck 
INS-A  Mix5 / PEG (Co-surfactant)/ TBA–
Dodecylamine (Thiol agent)  
-2.1 44  101.18 
0.87123 
(±0.1223) 
0.8611 1 
INS-B  Mix5 / PEG (Co-surfactant)/ TGA-
Octylamine (Thiol agent)  
-2.2 53  82.28 
0.05135 
(±0.0089) 
0.0624 32 
INS-C  
Mix5 / PEG (Co-surfactant)/ -0.8 36  122.12 
0.01318 
(±0.0003) 
0.0108 61 
 INS-D  Mix5 / PEG (Co-surfactant)/ /NAC 
(mucolytic agent)  
-7.1 
 
43  102.41 
0.24624 
(±0.0376) 
0.2405 12 
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Figure 3.4: (A) Mucus diffusion <Deff> versus particle size of various SMEDDS in the 
“Cardiff native mucus” model. (B) % ratio <Deff>/D° versus zeta potential of various 
SMEDDS in the “Cardiff native mucus” model. (See Table 3.4 for compositions and 
codes). 
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The systems have two main inter-independent variables that can affect the diffusion of 
these systems through the mucus. These are: the physicochemical properties of the 
SMEDD systems and the ingredients in each system. Table 3.4 shows that SMEDD 
systems from AUTH and INS have particle sizes less than 50 nm, while the SMEDD 
systems from NEV have particle size range between 167 and 240 nm. Figure 3.4A 
shows no real correlation of particle size to <Deff>, with particles as small as 50 nm 
showing a wide range of diffusion.  
Similarly, Figure 3.4B fails to reveal any correlation of zeta potentials to % ratio 
<Deff>/D°, although almost all particles are within the range of 0 to -15 mV. Figure 3.4 
does show however that the SMEDD systems are affected by their formulation 
ingredients. This effect was observed for the all three partners contributed to this nano-
strategy.  
It is exemplified by the Innsbruck SMEDD systems where the incorporation of a thiol 
agent, either NAC, TBA Dodecylamine or TGA Octylamine (INS A,B,D)  outperforms 
the SMEDD bearing just the co-surfactant (INS C). Thiol groups can interact with the 
mucin network to break inter-molecular bonds in the fibres (see sections 3.e and 3.f).  
This section of work revealed the SMEDD bearing TBA-dodecylamine to have the 
highest diffusivity among all the Innsbruck SMEDD systems, indeed across all 102 NP 
studied from the Consortium. This is possibly the result of  the high release of this thiol 
agent into the mucus and the resultant local destruction of the mucus structure to 
increase in diffusion of the SMEDD system [71]. High release of ingredients from 
SMEDD system was reported for some (active) ingredients when they are located in the 
surfactant/co-surfactant layer rather than incorporated in the oil phase [72].  The TBA 
Dodecylamine could be subject to greater release than the other thiol or mucolytic 
agents incorporated into the SMEDD systems.  
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Another example of the formulation differences can be seen with the SMEDD systems 
AU-A and AU-B which have the same oil phase (Mix 1) but showed distinct diffusion 
differences depending on the co-surfactant. The SMEDD AU-B system used Transcutol 
as a co-surfactant and showed x327 fold greater % ratio <Deff>/D° than that of 
SMEDD AU-A system which used Labrafil M 1944 CS as the co-surfactant. This 
finding agrees with previous study which showed that the type of the oil has a high 
impact on the SMEDD system interaction with mucin [73]. This was explained on the 
basis that different oil with same surfactant shell has different capability to form a 
hydrophobic interaction with the hydrophobic domains of the mucin.  
3.e Mucolytic NPs Strategy 
Previous studies showed the impact of mucolytic agents on the diffusion of NPs through 
mucus. As example, pre-treating of cystic fibrosis mucus with NAC improved the 
diffusion of muco-inert PEGylated NP [74], oppositely, the same PEG NP that 
administered without NAC pre-treatment showed low diffusivity through the mucus 
barrier. Based on these previous studies, partners in the Alexander Consortium used 
mucolytic strategy represented by either disulfide breaking agents (NAC, thioglycolic 
acid and glutathione) or proteolytic agents (bromelain and papain agents) to improve 
NPs permeation through mucus. Consequently, the synthesized NPs by the consortium 
were designed for the purpose of careful disintegration of the mucus layer that come in 
contact with mucolytic NPs. This contrasts with studies by other groups which showed 
massive destruction of the entire intestinal mucosal tissue in Sprague Dawley rat model 
[75] and in  Ussing chamber model [76]. 
Table 3.5 shows the diffusivities of NPs loaded with either proteolytic or disulfide 
breaking agents and synthesized by different partners in the Consortium. The Table 
details the following: Consortium Partner; NP code (as defined by the partner); 
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chemical composition of the particle where known including the chemical core of the 
particle, polyacrylic acid (PAA)  etc.; physico-chemical properties of the particle (Zeta 
potential and particle size); MPT diffusion data [cm2 S-1 x 10-9] in the Cardiff mucus 
model including also D° water (calculated by Stokes Einstein equation), the <Deff>  
and the ratio of % <Deff>/D°; finally the rank order of  the particle diffusion (i.e. 1= 
fastest) based on %<Deff>/D° across the entire screening exercise of 102 different 
particles). All the codes for particles are described in the Table and will be used 
throughout the section.  
Figure 3.5A shows no correlation between the particle size and the <Deff> of respective 
mucolytic particles. This absence of correlation is obvious and exemplified by 
observing that PAA-BRO NP with particle size of 304 nm showed 7 times higher 
<Deff> than CSGSH188/CD3 NP with particle size 299 nm (table 3.5). Similarly, Table 
3.5 shows no correlation between the zeta potential and the % ratio <Deff>/D° of 
mucolytic NPs, for example, NPs with same zeta potential (3 mV) represented by 
CSGSH188/CD3 and CSTGA360/-CD3 showed 7-folds difference in their % ratio 
<Deff>/D°. Each of the Figures 3.5B, 3.5C and 3.5D shows the %<Deff>/D° versus 
zeta potential of mucolytic NPs in which one variable affecting the diffusion of particles 
is illustrated. 
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Table 3.5: Particles’ composition, physical characteristics and diffusion of various NP loaded with mucolytics. (PDI and S.D. are included where necessary). 
Partner NP Code Compositions 
Zeta Potential 
(mV) 
Mean 
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% <Deff>/ 
D°          
Ranking  
Fastest =1 
and slowest  
Innsbruck 
PAA-PAP 
PAA NP loaded with  25% Papaine 
(proteolytic agent) 
-27 352  12.77 
0.00389 
(±0.00077) 
0.0305 39 
PAA-BRO 
PAA NP loaded with   25%  Bromelain ( 
proteolytic  agent) 
-20 304  14.78 
0.04029 
(±0.01280) 
0.2725 11 
 
Sagetis 
CSTGA360/-
CD3 
Chitosan-thioglycolic acid+ unknown (-) 
charged Poly(β-amino ester)s (PBAEs) 
(disulfide breaking agent). 
3 137 32.80 
0.00079 
(±0.00006) 
0.0024 89 
CSNAC177/
CD3 
Chitosan-NAC+ unknown (-) charged 
Poly(β-amino ester)s (PBAEs) (disulfide 
breaking agent). 
6 156 28.81 
0.00384 
(±0.00015) 
0.0133 58 
CSGSH188/
CD3 
Chitosan-Glutathione + unknown (-) 
charged Poly(β-amino ester)s (PBAEs) 
(disulfide breaking agent). 
3 299 15.03 
0.00671 
(±0.00043) 
0.0447 33 
Nevarra 
0.3P-NPA-L-
L 
Muco-adhesive NP loaded with papain 
(0.3 %) (lyophilized NP)  
-45 315 14.27 
0.03326 
(±0.00600) 
0.2331 12 
0.3P-NPB-L-
L 
Muco-adhesive NP loaded with papain 
(0.3 %)  (spray dried NP) 
-46 216  20.80 
0.00057 
(±0.00018) 
0.0028 84 
20NAC-NPA 
-L-L 
Muco-adhesive NP loaded with NAC (5 
%) (lyophilized NP) 
-53 189  23.77 
0.03513 
(±0.00216) 
0.1478 18 
20NAC-NPB 
-L-L 
Muco-adhesive NP loaded with NAC (5 
%) (spray dried NP) 
-28 231  19.49 
0.00753 
(±0.00072) 
0.0386 34 
200NAC-NP 
A-L-L 
 
Muco-adhesive NP loaded with NAC (50 
%) (lyophilized NP) -51 145  30.95 
0.00465 
(±0.00022) 
0.0150 54 
200NAC-NP 
B-L-L 
Muco-adhesive NP loaded with NAC (50 
%) (spray dried NP) 
-23 440  10.21 
0.00098 
(±0.00006) 
0.0096 63 
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Figure 3.5: Diffusion behaviour 
of various NPs loaded with 
mucolytic agent in the “Cardiff 
native mucus” model. (A) 
Diffusion <Deff> versus particle 
size of all mucolytic NPs (B) The 
% ratio <Deff>/D° versus zeta 
potential of NPs loaded with 
proteolytic agent (■) versus NPs 
loaded with disulfide breaking 
agent (□) (C) The % ratio 
<Deff>/D° versus zeta potential 
of NPs loaded with 5% NAC 
(brown particles) versus NPs 
loaded with 50% NAC (pink 
particles) (D) The % ratio 
<Deff>/D° versus zeta potential 
of lyophilized mucolytic NPs (○) 
versus spray dried mucolytic NPs 
(●). 
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Figure 3.5B shows % ratio <Deff>/D° of NPs loaded with proteolytic agent versus NPs 
loaded with disulfide breaking agent. It can seen that NPs loaded with proteolytic agents 
represented by PAA-BRO NP synthesized by Innsbruck and 0.3P-NPA-L-L synthesized 
by Nevarra showed much higher % ratio <Deff>/D° compared with other NP loaded 
with disulfide breaking agent indicating general higher diffusion of proteolytic agents. 
However, the presence of some NPs loaded with proteolytic agent with similar 
diffusivities to NPs loaded with disulfide breaking agents limits any finding in this 
comparison.  
The “general” higher diffusion of NPs loaded with proteolytic agents is related to the 
activity of each mucolytic type at the pH (5.5-6.9) of intestinal mucus. Comparatively, 
proteolytic agent is efficient within wide range of pH including the intestinal pH [77–
79]. This makes these agents to be efficient in Cardiff mucus model with pH mimicking 
the in vivo pH of 6.7. This is in agreement with Müller et al study (2014), which showed 
extended residence time of PAA-papaine NP in the duodenum and jejunum of Sprague 
Dawley rats indicating the activity of proteolytic agents at the in vivo pH conditions 
[80]. 
On the other hand, Disulfide breaking agents require high pH (7-9) to cleave disulfide 
bridges between mucin fibres leading to more leaky mucus [31]. In literature, 
experiments on NAC mucolytic activity is accompanied by modifying the pH of the 
mucus to more than 7 [81] while the pH of Cardiff mucus model is 6.7 (Chapter Two) 
which could be a limiting factor for the maximum activity of the NAC agent. Thus, 
several studies showed that NAC was ineffective to improve NPs diffusion through the 
mucus. For example, studying of NAC mucolytic activity on CF sputum by the MPT 
technique revealed that NAC was inactive when mucin concentration increased from 
less than 1% to 2.2%  [82]. Accordingly, in vivo study by Ferrari et al. (2001) [83] 
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showed a non-significant efficiency of NPs loaded with  NAC to deliver gene 
therapeutic agent into the pulmonary tissues of mouse. 
Figure 3.5C shows the %<Deff>/D° of NPs loaded with 5% NAC (Brown symbols) 
versus NPs loaded with 50% NAC (Pink symbols). Surprisingly, NPs loaded with 5% 
NAC showed 5-10 times higher % ratio <Deff>/D° than the same particles loaded with 
50% NAC. This inverse relation could be due to the excessive destruction of mucin 
network when high concentration of NAC (50%) was used. This results in release of the 
mucin component into the mesh spaces leading to increase of the micro-viscosity of the 
water in these spaces [84]. In normal condition, these spaces should be filled with water 
through which, small enough particles can freely move through [85]. Hence, the 
increase in the micro-viscosity limits particles diffusion through these spaces. This 
effect was also observed in previous study where NPs loaded with high concentration 
bromelain resulted in an increase of the viscosity of the water in these spaces [86]. 
 Lastly, figure 3.5D shows %<Deff>/D° of lyophilized mucolytic NPs versus spray dried 
mucolytic NPs. This Figure shows that NPs dried by the spray drying technique showed 
much lower diffusivities than the same NPs but dried by the freeze drying technique. 
This indicates that spray drying method altered the surface chemistry of these NPs 
which affected the release or the stability of proteolytic agent conjugated into NPs 
surface.  This finding is consistent with a study [87] which showed that changing the 
properties of the NP surface reduced the release of the mucolytic agents and in turn 
affected its mucolytic activity and permeation though the mucus. 
3.f  Thiolated NP Strategy  
Thiomers are formed by the conjugation of a sulfhydryl group into another polymer 
[88]. These polymers can form disulfide linkages with cysteine subdomains in the 
mucin at pH range of (7.2-7.4). All the NPs in this strategy were synthesized by the 
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partners in the consortium using the same thiolated polymer source (thiolated chitosan). 
Chitosan-thiol NPs were reported widely by other groups, for example: chitosan-
thioglycolic acid [89], chitosan –cysteine [90], chitosan-4-thio-butylamidine [91] and 
chitosan glutathione [92]. It was found that adding of thiol agent into a muco-adhesive 
polymer resulted in 130 times increase of the muco-adhesivity of that polymer by [93].   
Table 3.6 shows two thiolated NPs sub-groups that were synthesized by Sagetis. The 
Table details the following: Consortium Partner; NP code (as defined by the partner); 
chemical composition of the particle, where known, including the chemical core of the 
particle, chitosan etc.; physico-chemical properties of the particle (Zeta potential and 
particle size); MPT diffusion data [cm2 S-1 x 10-9] in the Cardiff mucus model including 
D° water (calculated by Stokes Einstein equation), the <Deff>  and the % ratio of 
<Deff>/D°; finally the rank order of  the particle diffusion (i.e. 1= fastest) based on 
%<Deff>/D° amongst the entire screening exercise of 102 different particles. All codes 
for particles are described in the Table and will be used throughout the section. 
Figure 3.6A shows the <Deff> versus particle size data for the respective thiolated NPs.  
The particles for both sub-groups (Blue and Red symbols) have almost similar particle 
sizes but different <Deff> indicating no effect of particle size on the <Deff> of all 
thiolated NPs described in Table 3.3. Similarly, Figure 3.6B which illustrates the 
%<Deff>/D° versus zeta potential of the thiolated NPs shows no impact of zeta 
potential on %<Deff>/D° of these NPs indicated by different %<Deff>/D° obtained for 
NPs having same zeta potential values.  
It can be seen also that the diffusivity of the same thiolated NPs (Red symbols) was 
varied depending on the type of the attached molecule (either DNA or peptide),  i.e. the 
NP attached to peptide showed 5 times higher diffusivity than that attached to DNA. 
This is in agreement with the data obtained in the previous section for PEC NPs where 
                                                                                                                                                Chapter Three 
  
 
139 
 
the PEC NPs attached to peptide had higher diffusion than the same PEC NP attached to 
DNA. However the lack of information about the peptide or the DNA used in this study 
limited the finding in this section.  
The most important factor which was found to affect the diffusion of NPs was the ratio 
of the thiol agent attached to the NPs. It can be seen from figure 3.6 (Blue symbols) that 
the increase in the ratio of the thiol agent from 150 to 168 µmole/gm then to 300 
µmole/gm resulted in almost 2-folds increase in the <Deff> and the % ratio <Deff>/D° 
of these particles. This increase in the diffusion is attributed to the destructive effect of 
these agents on the mucus structure by forming disulfide bonds with mucin. This 
destructive effect was proven by Leitner et al. (2003) [93] who found the competitive 
destructive effect of thiomer and NAC on the porcine mucus. Moreover, Gradauer et al. 
(2013) [94] showed that thiolated agents can destroy mucus structure even if it is not 
released from NPs into the mucus. In Gradauer study, the increase in the permeation of 
thiolated liposomes was attributed to the destruction effect exerted by the population of 
the thiolated particles firstly come in contact with mucus which allows the permeation 
of the remaining particles through the already destructed mucin network.  For the above 
reasons, Thiomers were used as permeation enhancers for the oral delivery of 
hydrophilic [95] and polypeptide drugs [96].  Similarly, in vivo studies showed that 
thiomers can improve the bioavailability of peptide drugs [97].  
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Table 3.6: Particles’ composition, physical characteristics and diffusion behavior of various thiolated NP. (PDI and S.D. are included where necessary). 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean  
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% <Deff>/ 
D°          
Ranking  
Fastest =1 
and slowest 
102 
Sagetis 
CSMPAA30
0/ CD3 
Thiolated chitosan (300 thiol µmole/gm of 
polymer) +  unknown (-)  charged Poly(β-
amino ester)s (PBAEs). 
4 140  32.10 
0.00725 
(±0.00045) 
0.0226 44 
CSMBA168/
CD3 
Thiolated chitosan (168 thiol µmole/gm of 
polymer) +  unknown (-)  charged Poly(β-
amino ester)s (PBAEs). 
4 143  31.43 
0.00569 
(±0.00033) 
0.0181 51 
CSMPAA15
0/CD3 
Thiolated chitosan (150 thiol µmole/gm of 
polymer) +  unknown (-)  charged Poly(β-
amino ester)s (PBAEs). 
2 109  41.23 
0.00399 
(±0.00032) 
0.0097 62 
CSSH/CDf3.
5 
Thiolated chitosan + unknown (-) charged 
Poly(β-amino ester)s (PBAEs) attached to 
DNA. 
1 147  30.57 
0.00230 
(±0.00013) 
0.0075 68 
CSSH/CEf3.
5 
Thiolated chitosan + unknown (-) Poly(β-
amino ester)s (PBAEs) attached to 
peptide. 
1 147  30.57 
0.01050 
(±0.00060) 
0.0343 35 
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Figure 3.6: (A) Mucus diffusion <Deff> versus particle size of various thiolated NPs in 
the “Cardiff native mucus” model. (B) % ratio <Deff>/D° versus zeta potential of various 
thiolated NPs in the “Cardiff native mucus” model. 
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3.g Comparison of Mucus Diffusivity of all Nano-Strategies in the “Cardiff Native 
Mucus” Model and “Consortium Mucus-Gel” Model 
This chapter has provided comparison of six different nano-strategies for NPs diffusion 
through mucus. Each NP was ranked to allow comparison with other NPs. Tables (3.1-
3.6) show the ranking of the particles from the fastest (1) to the slowest (102) particle. 
This ranking enables identification of the nano-strategy which showed the highest 
permeation through the “Cardiff native mucus model”. This data was used by the 
consortium to select NPs for in vivo experimentation.  
Figure 3.7A shows the PEG NPs (Red symbols) and SMEDD systems (Blue symbols) 
to be generally superior in performance to most of the other nano-strategies, although, 
such particles were mostly of a small size (ca 50 nm). Hydrophilic particles such as 
those coated with PEG generally display diffusion that is inversely correlated to their 
particle size. For example some of the PEG NPs of greater than 200 nm showed 
significantly diminished diffusion. Accordingly when expressing the diffusion data in 
terms of  %ratio <Deff>/Do (Figure 3.7B) it is evident that the best performing particles 
with respect to surface chemistries remained the SMEDDs, the PEG NPs and some NPs 
from the slippery-polymer and mucolytic strategies.  
The generally high diffusivity of the SMEDD systems depends very much on the high 
hydrophilic nature of the oil droplet surface. SMEDDs require a mixture of surfactant 
and co-surfactants with a very high hydrophilic-lipophilic balance (HLB)  [70]. As 
mentioned above this high hydrophilic surface character is one determinant for the high 
diffusivity through the mucus [98] and the high bioavailability of the drugs 
administered in SMEDDs [99,100]. It is noticeable however that the highest diffusivity 
among all 102 particles was the Innsbruck SMEDD incorporating the thiomer TBA- 
dodecylamine. Clearly the collective effect of the loaded thiol agent and the hydrophilic 
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surface of the SMEDDs contributed to this high diffusivity, where the thiol agent could 
serve  a mucolytic role [71]. 
NPs representing the slippery-PEG strategy (RED symbols; Figure 3.7) and the 
slippery-polymer strategy (BLACK symbols; Figure 3.7) also showed higher 
diffusivities.  This finding is not surprising as improved diffusion of NPs by coating 
them with a muco-inert hydrophilic shell is recognised [44,101]. For example, the 
coating of PLGA- dimethyldioctadecylammonium bromide (DDAB) NP with -DNA 
showing a 10-fold increase in the diffusion coefficient of uncoated PLGA NP of the 
same size [102]. 
NP loaded with mucolytic agents (GREEN symbols; Figure 3.7) were generally less 
diffusive than slippery surface (PEGylated and polymer mixture). The diffusive 
capacity of PEGylated particles is consistent with the findings of  Hanes’ group who 
showed that the diffusion of  PEGylated  NPs through CF mucus  pre-treated with NAC 
was 40 times higher than that of PLGA NPs through the same pre-treated CF mucus  
[74]. This indicates that the slippery surface of the PEG NP still exerts a predominant 
impact even in NAC pre-treated CF mucus.  As for NPs loaded with mucolytic agents 
then the diffusive capacity will depend to a large extent on the release profile of the 
mucolytic agent into the mucus to allow the particle diffusion through the disturbed 
mucin structure [87]. Insufficient release could result in inadequate mucolytic activity. 
Moreover, with excessive destruction of mucus then the release of mucin or other 
mucus components into the spaces of mucin network will increase the micro-viscosity 
of these water-filled channels resulting in restriction of particle diffusion [103].  
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Figure 3.7: (A) Mucus diffusion <Deff> versus particle size of NPs made of various 
nano-strategies in the “Cardiff native mucus” model. (B) % ratio <Deff>/D° versus zeta 
potential of NPs made of various nano-strategies in the “Cardiff native mucus” model. 
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The PEC NP (PINK symbols) underpinning yet another slippery surface strategy 
generally showed lower diffusion capacity through mucus. The strategy represented an 
alternative easily fabricated NP approach toward mimicking the capsid virus with a 
highly charged surface with net neutral charge [21]. The low diffusion of PEC NPs 
reflects to some extent the heterogenous nature of the positive and negative polymer 
complexes resulting inevitably in polarised regions of surface charge unlike the very 
closely aligned positive and negative charges on viral capsids.  
Thiomer technology (Orange symbols; Figure 3.7) showed very low diffusion capacity. 
As was mentioned earlier, the proposed mechanism of thiomer technology to improve 
diffusion through the mucus involves mucin cleavage, however, thiolated NPs showed 
less permeation through the mucus than that of the mucolytic NPs. This is consistent 
with the finding of Leitner et al. (2003) [93] who showed a more powerful mucolytic 
activity associated with NAC able to cleave the disulfide linkage between thiolated 
PAA NPs and porcine mucin. Another factor which can limit the activity of thiolated 
polymers is their stability as these polymers are readily oxidized in the solution [104]. 
The Bernkop-Schnürch group addressed this stability issue by protecting the thiomer 
polymer with mercaptonicotinic acid [105,106]. In their work the thiol groups were also 
conjugated to chitosan in the NPs such that the thiol agents were not be released into the 
mucus but remained conjugated with the chitosan NPs which assisted their muco-
adhesive capabilities.  
Lastly, PLGA NP was used by the partners as the lipophilic core for many of the 
strategies. The NPs formed only using polymer are muco-adhesive and were used in this 
section of work as a reference particle (Grey symbol; Figure 3.7). Not surprisingly the 
PLGA NPs showed almost the lowest permeation through mucus (ranked 99, Table 
3.1). Although the low mucus permeation of PLGA is recognised [55,107], its muco-
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adhesive properties can improve the in-vivo bioavailability of some drugs. For example, 
PLGA- fumaric anhydride- iron oxide NP improved the bioavailability of zinc insulin 
up to 11.4% of the intraperitoneally administered insulin [108].  
 Besides studies in the “Cardiff native mucus”, the diffusion of all of the nano-strategies 
was also studied in the “Consortium mucus gel”  In this latter mucus model the 
diffusivities of slippery-PEGylated particles, the slippery-polymer particles, the 
slippery-PEC particles and the mucolytic particles were studied.  The diffusivities of the 
SMEDDS and the thiol particles were not studied as these particles were not stable 
under the circumstances required to undertake MPT with this “Consortium mucus gel” 
model. Specifically, this model required a centrifugation step to install particles into the 
mucus sample.  
To obtain an improved perspective of the behaviour of the particles between the mucus 
models the data is compared in Figures 3.8 and 3.9.  Figure 3.8 immediately shows that 
the diffusion of all particles was considerably more restricted in the Consortium mucus -
gel model.  Figure 3.9 shows the correlation in the ranking of diffusivities of NPs in 
both the Cardiff mucus model and the Consortium mucus-gel model. A good correlation 
was found with  NPs ranked fast in the “Consortium mucus gel” model also ranked fast 
in the “Cardiff native mucus” model.  Note the use of zero in the ranking co-ordinates, 
e.g. (0, 1) indicates the diffusion of the respective particle in the Consortium mucus-gel 
model could not be studied. The correlation indicates that particles have the same 
mechanism of diffusion and trapping in both mucus models but are slower in the 
“consortium mucus-gel” model due to the differences of the mechanical and physical 
proprties of each mucus model. 
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Figure 3.8: (A) % ratio <Deff>/D° versus zeta potential of NPs made of various nano-strategies in the “Cardiff mucus gel” (B) % ratio 
<Deff>/D° versus zeta potential of NPs made of various nano-strategies in the “Consortium mucus gel”. (% ratio <Deff>/D° were expressed in 
the same scale for both figures (A and B) to highlight the differences in the values of diffusion between the two mucus models. 
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Figure 3.9: Correlation in 
ranking order of 
diffusivities of NPs in 
“Cardiff native mucus” 
model versus diffusivities 
of NPs in “Consortium 
mucus-gel” model. 
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4. SUMMARY AND CONCLUSION 
In this chapter, NPs representing various nano-strategies to improve the diffusion 
through the mucus was studied. Within each nano-strategy, several findings were 
revealed. These conclusions can be classified for each nano-strategy as follows: 
 Slippery-PEG Strategy:  
1. NPs coated with PEG polymer have higher <Deff> and % <Deff>/D° than that 
of NPs coated with methoxy PEG. 
2. NPs coated with low molecular weight PEG (2000 Da) have higher diffusion 
through the mucus as compared with NPs coated with high molecular weight 
PEG (5000 Da). 
3. The diffusion of PLGA-PEG NPs through the mucus is highly affected by the 
method and condition of PEGylation of these NPs. 
 Slippery-Amphiphilic Polymers Strategy 
1. The diffusion of NPs in which the lipophilic core is coated with a hydrophilic 
shell increased as the ratio of the hydrophilic polymer increased to certain 
degree, this is followed by a reduction in the diffusion when the ratio of 
hydrophilic polymer further increased. 
2. NPs coated with hydrophilic polymer showed higher diffusivities than NPs 
copolymerized with the same hydrophilic polymer. 
 Slippery-PEC NP Strategy 
1. There was not enough data to relate the diffusion of PEC NPs to their zeta 
potentials. 
2. The diffusion of PEC NPs is highly influenced by the type of polymers forming 
these PEC NPs or the molecules conjugated within these PEC NPs. 
 
                                                                                                                                                Chapter Three 
  
 
150 
 
 SMEED Strategy 
1. There is no correlation between the particle size or zeta potential of SMEDD 
systems and their diffusivities through the mucus barrier. 
2. The diffusion of SMEDD systems through the mucus is influenced by the 
ingredients in the system (oil, surfactant and co-surfactant).  
 Mucolytic NPs Strategy 
1. NPs loaded with proteolytic enzymes have generally higher diffusion through 
the mucus barrier than NPs loaded with disulfide breaking agents. 
2. There is inverse relation between the concentration of NAC in the NPs and the 
diffusion of these NPs. 
3. For all NPs loaded with mucolytic agents, NP dried by freeze drying method 
showed higher diffusion through the mucus than the same NP dried by the spray 
drying method.   
 Thiomer Strategy 
1. The diffusion of the thiolated NPs increases as the ratio of the thiomer in the 
NPs increases. 
 General Conclusion 
1. Slippery surface nano-strategy represented by the PEG NPs and amphiphilic 
polymer NPs and SMEDD systems were found to have the highest diffusion 
through the “Cardiff native mucus”. 
2. PEC NPs were not covered properly in this chapter by the partners in the 
Consortium, hence, this strategy needs further studies to identify the impact of 
zeta potential on the diffusion of these NPs through mucus barrier. 
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CHAPTER FOUR 
KINETIC STUDIES ON THE DIFFUSION THROUGH THE 
“CARDIFF NATIVE MUCUS” MODEL OF 
POLYELECTROLYTE NPs 
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1 INTRODUCTION 
1.a Slippery Surface NPs: PEC NPs versus PEG Surface NPs and Adenovirus  
In Chapter three, diffusion coefficient of 102 NPs representing six different nano-
strategies were screened to identify a nano-strategy that can be adopted by our group. 
Slippery NPs strategies (especially PEG) were found to be promising nano-strategies 
where the MPT analysis showed them to have high diffusions through both “Cardiff 
Native Mucus” model and “Consortium Mucus gel” model. This strategy was utilised to 
mimic the capsid virus shell which was reported to be freely diffusible through the 
mucus. The concept of modifying surfaces of NPs by PEGylation to generate a polar 
particle surface was first described by Lai et al. (2007) [1]. The term “slippery surface 
NPs” was used to describe the polar, electrically neutral surface synthetic particle by Cu 
& Saltzman  (2009) [2]. This concept identifies the surface chemistry of NPs as the 
most influential factor on the diffusion of NPs through the mucus barrier. For example, 
Hanes’ group [3] has shown that PEGylation of a 500 nm polystyrene particle increased 
its diffusion through mucus by >1000-fold, where particle’s surface had a more 
profound impact than NPs particle size. PEGylation is preferable to mimic the surface 
characteristics of viruses since PEG NPs do not aggregate when their surface charges 
approaches neutrality [4].   
On the other hand, PEC NP which is one of the techniques to synthesize slippery 
surface nano-strategy was not widely studied in the previous chapter and PEC NPs 
synthesized by partners in the consortium were limited in term of their range of zeta 
potential. Moreover, in the literatures, there is no enough data available about the 
impact of PEC NPs on the diffusion through the mucus. Nevertheless, there is some 
evidence that a synthetic particle of near-neutral surface charge (+0.9 mV), and 
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comprising PAA (-ve) and PAM (+ve) polymers (Figure 4.1B), does show improved 
mucus permeation, at least in an in-vitro side-by-side diffusion chamber model [5]. 
Hence, PEC NPs could be another synthetic strategy that can mimic capsid viruses to 
slip through mucus.  
The process by which PEC NPs formed is called self-assembly in which, negatively 
charge (polyanions) polymer and positively charged (polycations) polymers are 
assembled spontaneously to form NPs with net charge proportional to the ratio of each 
polymer [6]. These PEC NPs are characterized by very high charge density on their 
surface, other characteristics of these NPs are determined by the polymers’ molecular 
weights and concentration, pH, ionic strength of the solvent and mixing time [7]. 
Chitosan (Figure 4.1) is an amino-polysaccharide polymer that is formed by the de-
acetylation of the naturally amino-polysaccharide Chitin which is found in the fungal 
cell walls [8]. Presence of amino group as well as the low toxicity of chitosan makes 
this polymer a good candidate as a source of the polycation polymer for the formation 
of PEC NPs [9]. On the other hand, PAA (Figure 4.2) is biocompatible non cytotoxic 
polymer possessing carboxylate group in each acrylate unit which makes it a good 
source of the negatively charged polymer [10]. For these reasons, these polymers were 
selected to be used as the source of the oppositely charged polymers to form PEC NPs 
in this chapter.  
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Figure 4.1: Chitosan polymer structure consisting of repetitive D-glucosamine unit. 
 
 
Figure 4.2: PAA polymer consisting of repetitive acrylic acid units.  
Both of the abovementioned synthetic NPs were used to mimic the capsid viruses which 
are known to freely diffuse through the mucus. For example, some viral particles are 
well adapted for efficient mucus permeation,  for example, the Norwalk virus (38 nm) 
and human Papilloma virus (55nm) appeared to penetrate intestinal mucus in an 
unrestricted manner [11]. The general features enabling the permeation of such viruses 
appear to be their small size, the lack of a hydrophobic envelope, and the possession of 
an exposed hydrophilic protein capsid shell characterised by a  high surface density of 
+/- charges giving a net membrane potential close to neutrality [11,12].  
Generally, growing of the aforementioned slippery viruses in the laboratory is 
complicated [12]. However, some other capsid viruses such as adenoviruses (AD), 
specifically AD5, can be grown and amplified safely in the laboratory. These viruses are 
characterized by a hydrophilic protein shell consisting of hexon and penton peptides 
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domains [13]. Some types of AD were found to permeate through and infect intestinal 
mucosal membrane in children resulting in  gastroenteritis [14]. Hence, these viruses are 
a good slippery surface model to be studied for mucus permeation by the MPT 
technique.  
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1.b Aim of the Study 
The purpose of the current work is to explore the impact upon NP diffusional kinetics 
through “Cardiff Native Mucus” Model of the variables of particle surface charge and 
size. To do so, PEC NPs were assembled at various ratios of (PAA:chitosan) to 
synthesize PEC NPs with wide range of surfaces’ charge extending from highly 
negative to neutral up to highly positive charge and with various particles sizes. In 
particular we sought to examine the impact of zeta potential and particle sizes on the 
diffusion of synthetic PEC NPs.  Beyond diffusion coefficients per se, we will report on 
the proportion of diffusive particles in each formulation, and the heterogeneity of 
diffusion within sub-populations of a given particle type.   
The aim of this chapter is to compare the diffusion behaviour of different slippery 
(synthetic and natural) surface NPs. To do so, the diffusion kinetics of PEC NPs will be 
compared with the diffusion kinetics of PEG-PLGA NP (non-charged hydrophilic 
particle), and with the naturally near neutral surface charge capsid virus. PLGA NPs 
was used as a reference representing a muco-adhesive lipophilic particle.   
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2. MATERIALS AND METHODS 
2.a Materials 
The chitosan polymer (low MW), PAA polymer (MW 1800) and MES buffer were 
obtained from Sigma-Aldrich (UK).  PLGA NPs, PEGylated-PLGA NPs and Lumogen 
Red-305 (excitation 573 nm emission 612 nm) were supplied by Nanomi (Netherlands). 
The amplified AD5 virus was kindly provided by the Institute of Cancer Genetics 
(Cardiff University). Alexa Fluor® 488 Protein labelling kit was from Life 
Technologies (UK). Glass bottom imaging dishes (35 mm diameter dish with a glass 
coverslip at 1.5 mm thick and 10mm diameter) were from MatTek Corporation (USA).  
All other reagents and solvents were from Fisher Scientific (Loughborough, UK). 
2.b NPs Preparation 
The polyelectrolyte NPs were synthesized by the self-assembly technique [15] in which 
0.02% w/v chitosan solution was added drop wise (1 drop/min) into 0.02%
 w/v  PAA 
solution under continuous magnetic stirring (100 rpm) for overnight. To prepare the 
stock solution of each polymer, chitosan stock solution of 1% w/v was prepared by 
dissolving chitosan in 1% glacial acetic acid, oppositely, 1% w/v PAA stock solution 
was prepared by dissolving the polymer in distilled deionised water (DDW). The dilute 
solutions of both polymers were prepared by diluting the stock solutions of them to 
0.02% w/v with MES buffer pH 6.5.  The use of MES buffer in the NP self-assembly 
process avoided precipitation issues evident when phosphate or citrate buffers were 
used. To synthesise NPs with a wide range of zeta potentials, chitosan and PAA were 
mixed at different ratios of each polymer, these ratios are described in Table 4.1.    
Lumogen Red-305 was loaded into the NPs by the co-acervation technique [16], 
whereby Lumogen Red-305  was dissolved in acetone at a concentration of 0.2 % w/v 
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then  added to the dilute solution of  PAA prior to the drop-wise addition of chitosan 
solution.  The mass of Lumogen Red-305   added equated to 75 g Lumogen Red-305   
per 30 mg of combined PAA:chitosan polymer.  The acetone was evaporated during the 
overnight mixing allowing the loading of Lumogen Red-305 to the core of the PEC 
NPs.  
2.c NPs Sonication 
Polyelectrolyte NPs displaying a neutral surface charge (i.e. PAA:chitosan mass ratios 
of 1:2.2) gave rise to large particles.  Given a key aim of the study to investigate the 
relative significance of charge and size as independent variables, these large neutral 
particles were temporarily reduced in size by probe sonication. Accordingly, 
suspensions of the neutral NPs (ca 1200 nm) were sonicated (Fisher scientific probe 
sonicator, UK) for 2 min at 20 KHz and 70% amplitude with the suspension then 
syringe-filtered through 0.45µm membrane (Millipore, UK). Particle size and zeta 
potential were measured immediately after filtration and over a subsequent test period 
(2 hr) to ensure a sufficient duration of size stability to enable the conduct of the mucus 
diffusion studies. To serve as controls for the sonication process, both positively-
charged (i.e. PAA:chitosan mass ratio of 1:8) and negatively-charged (i.e. PAA:chitosan 
mass ratio of  1:1) polyelectrolyte NPs were also subject to the sonication process and 
their diffusion characteristics (before and after) were determined.  
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2.d Characterisation of PEC NPs 
Zeta Potential Measurement 
A Malvern NANO ZS (Malvern, UK) was used to measure the zeta potential of the NP 
samples. The instrument was standardised prior to each experiment by use of calibration 
standards.  
Particle Size Measurement 
Particle size was measured by photon correlation spectroscopy (Malvern NANO ZS) 
with data collected in uni-modal setting. The instrument was standardised prior to each 
experiment by use of calibration standards.  
2.e Multiple Particle Tracking (MPT) in “Cardiff Native Mucus” Model 
Diffusion coefficients in mucus and water were measured following the same 
procedures and method described in chapter 2. Other kinetic analysis data were 
measured as follows: 
Proportion of Diffusive Particles   
Measuring particle  diffusion across various time intervals allows for a description of 
the proportion of particles that are diffusive through the mucus matrix [1].  
Equation 4.1 was used to determine a Diffusivity Factor (DF) which expresses the 
effective diffusion coefficient for each individual particle (Deff) across the time 
intervals (Δt) of 1 sec. and 0.2 sec.  
DF = Deff Δt=1 sec / Deff Δt=0.2 sec         Equation 4.1  
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Where the individual particle Deff = MSD/ (4 * Δt).   Particles with a DF value of 0.9 
and greater were defined as diffusive.   The proportion of the diffusive particles within a 
given NP type under study was then calculated and expressed as % Diffusive particles. 
Heterogeneity in Particle Diffusion   
Profiling the diffusive properties of each particle within an entire population provides 
information on the heterogeneity of particle movement and the presence of outlier sub-
populations that may follow distinct pathways of diffusion through the matrix. Here the 
effective diffusion coefficient for each individual particle (Deff) was calculated at the 
time interval (Δt) of 1 sec, and for any NP type all 360 Deff Δt=1 sec were then ranked to 
allow comparison of the highest (90th) and lowest (10th) percentiles, where for example 
the 90th percentile is the Deff value below which 90% of the Deff observations may be 
found. 
Statistical Analysis 
One-way analysis of variance test was used to compare the percent of ratio of Deff vs 
D° for all the particles with significant value of p < 0.05.  
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3. RESULTS AND DISCUSSION 
In Chapter three, various strategies were examined including PEC NPs. However, all 
the PEC NPs that have been designed by the partners in the Alexander consortium did 
not express the critical points about using of PEC NPs as slippery surface nano-strategy. 
I.e, studies did not mimic the surface properties of the muco-inert capsid shell viruses in 
term of having neutrally charged surfaces (minimum zeta potential was +5 for the NPs 
synthesized by consortium partners). Moreover, studies did not show the effect of the 
charge variation on the diffusivity of these particles through the mucus (PEC NPs in 
chapter three were not synthesized with a wide range of zeta potentials). To overcome 
these issues, the study in this chapter was designed to examine the slippery surface 
properties of PEC NPs that mimicking the capsid shell viruses and having a wide range 
of highly negative and positive charged surface NPs.  
Specifically, MPT methodology was used to explore the PEC NPs diffusivity and how 
the diffusivity through the “Cardiff Native Mucus” Model is influenced by the variation 
of particle surface charge, where a series of PEC NPs composed of different ratios of 
the charged polymers PAA (-ve) and chitosan (+ve) were synthesized.  In particular, to 
mimic the neutrally highly charged capsid shell viruses, reasonably small sized PEC 
NPs with near neutral charged was formulated and its diffusivity through the mucus 
barrier was studied.  To overcome the aggregation of neutrally surface charged particles, 
sonication technique was used to produce near neutral charged PEC NPs that is stable 
enough to be examined for its diffusivity.  
This aim was driven by the fact of the effectiveness of some viral particles to permeate 
through mucus not only as a result of their small particle dimensions, but also through 
possession of a highly charged near-neutral exterior facing surface. Hence, the kinetic 
                                                                                                                                                   Chapter Four 
 
172 
 
 
diffusivities of the PEC NPs were compared to the diffusion kinetics of a capsid virus 
represented by AD5 with a near neutral surface charge. Also, the comparisons of the 
kinetics of diffusion include the use of the non-charged hydrophilic particle represented 
by PEGylated PLGA. Lastly, muco-adhesive lipophilic NP represented by PLGA NP 
was used as a negative control since it is expected to have the lowest permeability 
through the mucus barrier. 
3.a PEC NPs Synthesis and Characterisation 
PEC NP based on chitosan and PAA has been widely studied in term of particle size 
and stability [17]. Fourier transforms infrared spectroscopy (FT-IR) analysis has shown 
an electrostatic interaction between the Chitosan NH3+ group and the PAA COO- 
group, this electrostatic interaction was found to be responsible for the self-assembly 
process associated with the formation of these PEC NPs [18]. In our study, low 
molecular weight chitosan was used which was reported to induce smaller particle size 
NPs as compared to the higher molecular weight [19]. Mixing of chitosan and PAA at 
various ratios enables the formation of NPs with a wide variety of surface charges 
extending form highly positive to near neutral charge up to highly negative charges. 
However, the mechanism of the PEC NPs formation requires that both polymers to be 
ionized to complete the self-assembly process. Hence, these polymers were mixed at pH 
6.5.  This pH value was selected to be close to the pH in the intestine and to induce the 
ionization of chitosan and PAA depending on their pKa values [20].  
Among all the types of buffers tried, MES buffer showed the best reproducibility and 
consistency of particle sizes and zeta potentials. Carboxylate containing buffers like 
citrate and phosphate precipitated chitosan when they were used as the buffer system. 
This was due to the ionic interaction of chitosan amino group and carboxylate group of 
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these buffers [21]. Accordingly, use of HEPES buffer generated unstable dissociated 
PEC NP which was attributed to the high salt content in HEPES buffer. It seems this 
high salt content initiated a screening effect on the functional groups of the oppositely 
charged polymers which eliminate the electrostatic interaction between the polymers 
[22].   Dissociation effect was similar when the highly ionic strength buffer, formic acid 
was used.  
Table 4.1 shows the zeta potential and particle size measurements of PEC NPs 
comprising formulations of various PAA to chitosan polymer mass ratios.  In the table, 
PEC NPs were classified into the negatively charged, neutral and the positively charged 
particles. A range of ratios of PAA:Chitosan extending from (5:1) to (1:8) was 
examined in this study to achieve the highest possible positively and negatively charged 
PEC NPs. It can be seen that a broad range of surface charges was obtained ranging 
from -30 mV (PAA: chitosan mass ratio of 5:1) to +20 mV (PAA: chitosan mass ratio 
of 1:8). Also, PEC NPs were given symbol of F that is increasing from F1 to F14 in 
accordance with the change of the PAA:Chitosan ratios from (5:1) to (1:8).  
A zeta potential value close to neutral (i.e. -0.5 mV) was attained at a PAA: chitosan 
mass ratio of 1:2.2 indicating higher charge density of PAA than that of the chitosan. 
This could be attributed to the higher number of the small acrylic acid units (72.06 
gm/mole) per the chain of the PAA polymer as compared with the chitosan polymer 
chain which has less number of the large glucosamine units (179.17 gm/mole) [22].   
Accordingly, Table 4.1 shows that at the maximum level of zeta potentials (30 to +20), 
any decrease or increase in the ratio of PAA-chitosan did not affect the final zeta 
potentials. That is, increase the ratio of PAA:Chitosan from (1:5) (F11, +19.2) to (1:8) 
(F14, +19.2) did not change the zeta potential value, similarly, when the ratio increased 
                                                                                                                                                   Chapter Four 
 
174 
 
 
in the other direction from (4:1) (F2, -30.6) to (5:1, -29.1) (F1), no change was observed 
for the zeta potential of these NPs. This is in contrast for NPs with lower zeta potential 
where any change in the ratio of PAA:Chitosan is accompanied by a change in the zeta 
potential value. For example, changing the ratio of PAA:Chitosan from (1:2.2) (F7) to 
(1:1) (F6) resulted in the change of zeta potential from -0.5 (F7) to -15.2. This was 
interpreted in previous study based on the mechanism of the formation of PEC NPs 
where the further increase in one polymer resulted in mutual presence of PEC NPs and 
that free polymer, i.e, extra polymer content will not be self-assembled with the 
oppositely charged polymer but remain free in the solution which keeps the final zeta 
potential of PEC NPs unchanged [17]. 
Table 4.1: Particle sizes and zeta potentials of various PEC NPs including the 3 
different sonicated particles (*).  
Nature of  NPs PAA:Chitosan 
Mass ratio 
Code Zeta Potential 
(mV) 
Mean (± s.d.) 
Particle Size   
(nm) 
Mean (PDI) 
Negatively 
charged  
Polyelectrolyte  
5:1 F1 -29.1 (±3.6) 104 (0.14) 
4:1 F2 -30.6 (±4.4) 149 (0.10) 
3:1 F3 -25.0 (±4.0) 204 (0.21) 
2:1 F4 -18.9 (±1.3) 225 (0.13) 
1:1 F5 -15.4 (±0.8) 357 (0.21) 
1:1* F6 -15.2 (±1.2) 365 (0.21) 
Neutral  
Polyelectrolyte 
1:2.2 F7    -0.5 (±1.9)  1244 (0.32) 
1:2.2* F8 +1.1 (±2.4) 334 (0.19) 
Positively 
charged  
Polyelectrolyte 
1:3 F9 +6.0 (±1.1) 144 (0.18) 
1:4 F10 +14.3 (±0.3) 104 (0.09) 
1:5 F11 +19.2 (±0.5) 180 (0.17) 
1:6 F12 +19.5 (±0.9) 293 (0.17) 
1:8 F13 +19.2 (±0.6) 359 (0.11) 
1:8* F14 +19.5 (±2.3) 373 (0.23) 
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For particles formulated at a PAA: chitosan mass ratio either greater or equal to 1 (i.e. 
negatively charged particles) or less or equal to 0.33 (i.e. positively charged particles), 
the particle size varied in a pattern between 104 to 359 nm. Specifically, for negatively 
charged particles, the particle size increased from 104 to 357 nm in line with the 
approach of zeta potential toward neutrality and the relative reduction in PAA and 
increase in chitosan content.  Accordingly, for the positively charged particles, the 
relative increase in chitosan content led to increasing of particle size from 144 to 359 
nm. This increase of particle sizes in response to increase of chitosan content could be 
due to the alignment of the spatially large chitosan polymer at the surface of NP, 
swelling of these chitosan units at the surface of particles will enlarge the hydrodynamic 
sizes of NPs [23].  
At near neutral charge (mass ratio 1:2.2) (F7), the particle size increased dramatically to 
greater than 1µ due to a predictable aggregation arising from the lack of electrostatic 
repulsion or steric hindrance [24]. The 3-dimensional study design, however, required a 
comparatively small particle size that possessed a neutral charge. Besides that, small 
neutral charged particle is required to mimic the surface properties of capsid shell 
viruses. To achieve this, large neutral particle F7 (1244 nm, +1.1 mV) was subjected to 
probe sonication and filtration to achieve a particle size of 334 nm.   
The stability of the smaller sonicated particle was confirmed over a period (up to 2 hr) 
that would allow for setup of MPT diffusion experiment for the NP. The absence of re-
aggregation of these particles in the mucus was confirmed visually during the MPT 
experiment by the Epifluorescence microscopy. Stability of neutral particles for long 
time was not the subject in this chapter since these PEC NPs were used as proof of 
concept for being slippery surface particles. As controls, the largest sized negative 
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particle F5 (1:1 ratio, -15.2 mV, 357 nm) and the largest sized positive particle F13 (1:8 
ratio, +19.2 mV, 359 nm) were also subjected to probe sonication and filtration to 
ensure that the sonication process did not artificially increase mucus diffusion of the 
particular particle formulation. 
3.b Multiple Particle Tracking (MPT) in “Cardiff Native Mucus” Model 
Table 4.2 shows, besides the physicochemical properties, the Effective Diffusion 
Coefficient (<Deff>) in mucus and the respective Diffusion Coefficient in water (D °) 
for each NP type. Moreover, the ratio of these two parameters expressed as (% ratio 
<Deff> / D°), provides a measure of the relative efficiency of particle diffusion through 
“Cardiff Native Mucus” Model when the particles’ intrinsic free Brownian motion in 
water is taken into account.  As such it affords comparison of particle diffusion in 
mucus after accounting for the impact of the particle’s size upon its unrestricted 
diffusion in solution.  It is essentially a measure that more directly addresses the relative 
impact between particles of differing surface physicochemical properties and the 
interactions with, and the steric hindrance of, the mucin network.  
While more generally there was no obvious pattern between PEC particle diameter and 
<Deff> (Figure 4.3A), it is clear that size had a significant role in restricting the 
movement of F7 compared to its smaller derivative particle F8 (+1.1 mV, 334 nm), the 
latter  displaying an approximate 12-fold greater <Deff> (Figure 4.3B).  The F8 particle 
was derived by sonication and filtration of F7 specifically with the aim to provide a 
neutral particle whose size was consistent with the other polyelectrolyte NP 
formulations. The size stability of F8 in water was confirmed over a time period of 2 hr, 
sufficient to allow its physical characterisation and the conduct of the MPT 
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experiments; the absence of re-aggregation of these particles in mucus during the MPT 
experiment itself was confirmed by fluorescence microscopy. 
To address if the  sonication process may have led to an increase in particle diffusion by 
mechanisms beyond a reduction in particle size per se,  the largest +ve particle,  F5,  
and largest -ve particle, F13, were also subjected to the sonication process;  neither of 
the respective derived particles, F6 and F14, showed enhanced diffusion.  
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Table 4.2: physical characteristics and diffusion kinetics in “Cardiff Native Mucus” Model of various PEC NPs including sonicated particles (*), 
PLGA, PEG-PLGA and AD5. 
Nature of  NPs PAA:Chitosan 
Mass ratio 
Code Zeta Potential 
(mV) 
Mean (± s.d.) 
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% Ratio 
<Deff> / D° 
% Diffusive 
particles 
Negatively 
charged  
Polyelectrolyte  
5:1 F1 -29.1 (±3.6) 104 (0.14) 43.21 0.00163 (±0.00031) 0.0038 1 
4:1 F2 -30.6 (±4.4) 149 (0.10) 30.16 0.00366 (±0.00067) 0.0121 2 
3:1 F3 -25.0 (±4.0) 204 (0.21) 22.03 0.01781 (±0.00378) 0.0809 6 
2:1 F4 -18.9 (±1.3) 225 (0.13) 19.97 0.01574 (±0.00329) 0.0788 4 
1:1 F5 -15.4 (±0.8) 357 (0.21) 12.59 0.02286 (±0.00534) 0.1816 5 
1:1* F6 -15.2 (±1.2) 365 (0.21) 12.31 0.01749 (±0.00365) 0.1421 - 
Neutral  
Polyelectrolyte 
1:2.2 F7    -0.5 (±1.9)       1244 (0.32)  3.61 0.00239 (±0.00064) 0.0661 1 
1:2.2* F8 +1.1 (±2.4) 334 (0.19) 13.46 0.02887 (±0.00501) 0.2146 13 
Positively 
charged  
Polyelectrolyte 
1:3 F9 +6.0 (±1.1) 144 (0.18) 31.21 0.03182 (±0.00650) 0.1019 9 
1:4 F10 +14.3 (±0.3) 104 (0.09) 43.21 0.00849 (±0.00213) 0.0196 2 
1:5 F11 +19.2 (±0.5) 180 (0.17) 24.97 0.00104 (±0.00018) 0.0042 1 
1:6 F12 +19.5 (±0.9) 293 (0.17) 15.34 0.00084 (±0.00014) 0.0055 1 
1:8 F13 +19.2 (±0.6) 359 (0.11) 12.52 0.00031 (±0.00009) 0.0024 1 
1:8* F14 +19.5 (±2.3) 373 (0.23) 11.92 0.00032 (±0.00006) 0.0030 - 
Lipophilic PLGA - -29.2 (±2.1) 161 (0.03) 27.91 0.00013 (±0.00002) 0.0005 1 
Hydrophillic PEG-PLGA - -8.3 (±1.2)  54 (0.03) 83.22 0.46889 (±0.09343) 0.5634 32 
Capsid Virus AD5 - -0.5 (±2.3) 146 (0.18) 30.78 0.04391 (±0.00891) 0.1426 19 
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Figure 4.3: Relationships between particle size/zeta potential with particle diffusion 
kinetics in mucus.  (A) Plot of particle size of the PEC NPs versus <Deff>;  (B) Plot of  
particle size of the PEC NPs, the PEG-PLGA and the capsid virus AD5 versus <Deff>;  
(C) Plot of zeta potential of the PEC NPs versus <Deff>; (D) Plot of  zeta potential of 
the PEC NPs, the PEG-PLGA and the capsid virus AD5 versus <Deff>;  (E) Plot of zeta 
potential of the PEC NPs versus %ratio <Deff>/D°, (F) Plot of  zeta potential of the 
polyelectrolyte NPs, the  PEG-PLGA and the capsid virus AD5 versus  %ratio 
<Deff>/D°.   
                                                                                                                                                   Chapter Four 
 
180 
 
 
The more general issue of size-dependency in particle diffusion through mucus appears 
to be more discernible for particles of a consistent surface chemistry. For example, 
Dawson et al. (2003)  [25] using either amine or carboxylate terminated polystyrene 
NPs showed size-dependency (range 100 nm to 500 nm) in particle diffusion within 
cystic fibrosis sputum. Similarly, the movement of DNA through cervical mucus has 
been shown to be dependent upon DNA particle diameter in the range 115 to 310 nm 
[26].  Nevertheless, the effect of particle size upon diffusion within mucus is just one 
variable and, depending upon context; the surface properties can potentially be more 
significant.   
The polyelectrolyte particles in the current work displayed zeta-potentials ranging 
between -30 mV [F1] to +20 mV [F14] (Table 4.2). An essentially neutral  zeta 
potential was obtained at a PAA:chitosan mass ratio of 1:2.2 (F7, F8), a mass ratio  
consistent with the PAA polymer possessing a relatively  higher density of  negatively 
charged groups compared to the density of positive charges on each chitosan molecule  
[22].  Particles less than 365 nm and which displayed the greater <Deff> (Figure 4.3C, 
Table 4.2) were those which bore negative (-25 mV and greater) (i.e. particles F3-F6) or 
near neutral surface charge (i.e. F8 and F9).  For example, the F5 particle (-15.4 mV) 
showed an approximate 14-fold greater <Deff> than the F1 particle (-29.1 mV) despite 
the former being of a larger size (357 nm vs 104 nm).  Positively charged particles of 
greater than +14 mV displayed a <Deff> that was at least x10-fold lower than the 
neutral F8 formulation.  
Generally the positively charged particles displayed a much reduced diffusion compared 
to the negatively charged species.  For the positive particles the increasing content of 
chitosan provides greater opportunity for mucin to interact through both electrostatic 
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and hydrophobic forces with the chitosan polymer  [27]. While the carboxylate groups  
of the PAA polymer  provide opportunity for H-bonding interactions [28].   
Figure 4.4 uses the data from Table 4.2 to show a 3-dimensional response surface of 
polyelectrolyte NP diffusion <Deff> through mucus as a function of both particle size 
and zeta potential. The crucial impact of zeta-potential is clear with a ‘backbone of 
greatest diffusion’ corresponding with particles of neutral surface charge.   Figure 4.3E 
shows the relative permeation of the polyelectrolyte particles in mucus expressed as 
%ratio <Deff>/ D° and plotted against zeta-potential.  Here, after accounting for the 
impact of a particle’s size upon its unrestricted diffusion in solution, the superior 
performance of the neutral (F8, +1 mV) is more profound, with this particle displaying a 
significantly greater (P<0.05) diffusion ratio than any other polyelectrolyte formulation.   
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Figure 4.4: 3D plot showing the multi-variate relationship between particle size and 
zeta potential to polyelectrolyte particle diffusion kinetics in mucus.   
Moreover, tracking of particle transport at sequential time intervals enables us to 
determine the change in the diffusion of these particles as they come in contact with 
more restricted mucus environments over time. Thus, by determining the Effective 
Diffusion Coefficient (Deff) for each individual particle among the 360 tested particles 
across the time intervals of 1 sec  and 0.2 sec,  we were able to calculate the proportion 
of the entire population of particles that can be defined as diffusive through the “Cardiff 
Native Mucus” Model [1]. Figure 4.5 illustrates individual Deff measurements for 20 
randomly selected particles from the neutrally charged sonicated F8 PEC NP across the 
time intervals of 0.2 sec and 1 sec. The vast majority of these measurements show a 
decline in Deff as the monitoring interval is extended to 1 sec compared to the 0.2 sec 
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interval. This is interpreted as the occurrence with time of increased interactions of a 
particle with the micro-domains of the mucin network. Some particles, however, display 
a rise in Deff across the 1 sec interval indicative of free diffusive transport, and it is 
those particles that display such an increase that are taken to represent the proportion of 
diffusive particles for any particle type, i.e. for F8 the proportion of diffusive particles 
was 13% (Table 4.2) and was significantly greater (P<0.05) than for all other 
polyelectrolyte particles despite its greater size of 334 nm.  
 
Figure 4.5: Effective Diffusion Coefficients (Deff) for 20 randomly individual 
particles. The profile shows 20 particles from formulation F8 across the time intervals 
of 1 sec and 0.2 sec. Some particles display a rise in Deff across the 1 sec interval 
indicative of diffusive transport; those particles that display such an increase represent 
the proportion of diffusive particles.  The online source random.org was used to 
randomly select the particles. 
Examining particle diffusion over these short time scales substantially eliminates the 
effect that the contractile and stretching behaviour of the mucin fibres themselves may 
have on particle movement [29].  It is noteworthy that the difference in <Deff> between 
the neutrally charged F7 and F8 particles (i.e. an approximate x12-fold difference) was 
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directly proportional to their respective proportion of Diffusive particles, i.e. 1% to 
13%, respectively.  
The PEGylation of particles is aimed at providing  a uniform uncharged hydrophilic 
external layer that minimises hydrophobic and electrostatic interactions of the particle’s 
surface with, for example, the hydrophobic  domains or glycosidic linkages of  the 
mucin fibres [30].  Indeed  PEGylated NPs have been shown to display high permeation 
through cervical-vaginal mucus [31] and within sputum from cystic fibrosis patients  
[32]. Not surprisingly on most measures of particle diffusion through mucus we found 
the PEG-PLGA particle was superior to any other particle examined. For example, the 
<Deff> of the PEG-PLGA particle was approximately x15-fold greater than that of the 
neutral F8 particle (Table 4.2, Figures 4.3B and D).  
Similarly, the proportion of diffusive particles in the PEG-PLGA formulation was 
substantially greater (P<0.05) at 32% than for any other particle type examined (Table 
4.2).  Nevertheless, when accounting for the impact of particle size and unrestricted 
particle diffusion in solution, then the advantage of PEG-PLGA particle over the neutral 
F8 PEC particle is less pronounced, i.e. the %ratio <Deff>/D° was only x2.6-fold 
greater (Figure 4.3F, Table 4.2), despite the size of the PEG-PLGA particle (54 nm) 
accommodating a reduced steric hindrance with the mucin network (Figure 4.3F, Table 
4.2). 
Some capsid virus particles can display  rapid permeation through a mucus gel, e.g. 
Norwalk virus and human papilloma virus [11]. Of importance in this context is the lack 
of significant steric effects facilitated by the virus’ relatively small geometry (typically 
<100 nm).  However,  as  for synthetic particles, the electrostatic stability of the virus 
particle  in extracellular conditions is critical [33] and capsid viruses that permeate 
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mucus effectively tend to possess an external facing surface that comprises a high 
density of positive and negative charges while presenting an essentially electrically 
neutral or near-neutral character, i.e. properties that minimising hydrophobic and 
electrostatic interactions. For example,  Siber et al  [34]  analysed the spatial 
distribution of positive and negative charges across the capsid wall of 130 viral capsids 
and reported the majority to possess an external charge close to zero, or slightly 
negative.  Consistent with this, Michen and Graule (2010) [35] evaluated the isoelectric 
points (IEP) of  a number of  viruses species, some of which are known to infect 
through intestinal or pulmonary mucus. They reported, for example, the IEP for the 
Norwalk virus to be 5.5 - 6.0, for the Polio virus to be 6.6 -7.4, for the Rotavirus A to 
approximate 8.0, and the Influenza A virus to be 6.5 -7.0.  
In this study we tracked the diffusion of the neutrally charged (-0.5 mV) AD5 particle 
(size 145 nm) through “Cardiff Native Mucus” Model. The determined <Deff> of the 
AD5 particle indeed ranked highly, second only to the much smaller  PEG-PLGA 
particle (54 nm) but only some 1.5-fold  greater than the much larger sized neutral PEC 
F8 formulation (334 nm) (Figures 4.3B and D, Table 4.2).  However,  when accounting 
for the impact of unrestricted particle diffusion in solution, then the neutral PEC F8 
particle now showed a slightly improved (x1.5 fold greater) mucus permeation over the 
AD5 particle  despite the greater size and likelihood of steric hindrance in the mucus 
(Figure 4.3F, Table 4.2). Clearly, while the AD5 particle displayed a neutral surface 
charge other determinants such as interaction of the capsid proteins will have likely 
impacted, at least in this study, on mucus permeation. Indeed glycocalyx and tethered 
mucin within the respiratory tract have been shown to  inhibit adsorption of certain 
adenovirus serotypes to  lung tissue [36,37].  
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The heterogeneity in the movement of individual particles through mucus can provide 
an insight into how different subpopulations within a given formulation (particle) type 
may exploit divergent permeation pathways.  Here we assessed such heterogeneity by 
measuring over a time interval of 1 sec. the effective diffusion coefficient Deff for each 
of 360 individual particles from any given particle type, and ranking this Deff data into 
percentiles. Figure 4.6 shows the percentile data for four different particle types.  
Generally, the more positively or negatively charged the particle type then the less 
heterogeneous was the diffusion data.  For example, for the highly negative (104 nm 
sized) F1 NP, some 90% of the particles displayed a Deff (cm2. S-1 x10-9) below 0.024, 
while 10% of the particles had a Deff below 0.00015 (Figure 4.7A). The resulting ratio 
90th/10th percentile was 150.  For the highly positive (373 nm sized) F14 particle, the 
corresponding ratio was 180 (Figure 4.6B). It is not unreasonable that the more highly 
charged polyelectrolyte particles will display a more homogenous physical character 
(size, charge), and as such the variability in forces influencing particle diffusion through 
the mucus will be determined predominantly by the structure of the mucus mesh itself 
rather than any distinct particle subpopulations [25].  
Similarly, the PEG-PLGA particle (54 nm sized) exhibited a 90th/10th percentile ratio of 
200 (Figure 4.6D), consistent with previously published  PEGylated particle diffusion 
through mucus [1].   In contrast, the sonicated (334 nm sized) neutrally charged F8 
particle displayed a marked heterogeneity with a 90th/10th percentile ratio of 11,000 
(Figure 4.6C). This is not readily attributable solely to the heterogeneous structure of 
the mucus mesh but must reflect additional diversity involving particle subpopulations 
and differential forces hindering their movement. Creating a charged but neutral 
synthetic particle through the simple process of self-assembly of polyelectrolyte 
polymers will inevitably lead to opposing surface charges that are not uniformly 
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distributed with the result of forming surface ‘hotspots’ or surface domains of a 
particular electrical sign that will have differential interactions with the mucin network. 
Indeed, the spatial arrangement of charge on a particle’s surface, even for particles of 
the same overall net surface charge, has been shown to be influential in particle 
transport through a mucin gel [38]. Such heterogeneity reflects one of the limitations of 
creating a charged but neutral synthetic particle through the simple process of self-
assembly of polyelectrolyte polymers. Nevertheless, the fastest particles (90th 
percentile) seen for the neutral polyelectrolyte F8 NP (i.e. Deff of  5.81; Figure 4.6C)  
were at least as fast as  the 90th percentile particles  recorded for the much smaller  
PEG-PLGA (i.e.  Deff of 4.06; Figure 4.6D).  
The abovementioned results revealed a broad and meaningful relationship between 
particle diffusion in mucus (x1000 difference between slowest and fastest particle 
types), particle size (104 nm to 373 nm) and particle surface charge (-29 mV to + 19.5 
mV).  In particular the crucial impact of zeta-potential was clear, with highest diffusion 
in mucus (from amongst the series of polyelectrolyte particles) observed for those of a 
neutral surface charge (e.g. particle [F8] at +1.1 mV, 334 nm).  The diffusion of the 
neutral polyelectrolyte particle compared favourably with that of a highly diffusive 
PEGylated-PLGA particle (54 nm) despite the size of the latter accommodating a 
reduced steric hindrance with the mucin network. Assessment of the heterogeneity of 
diffusion within a given particle type  revealed the most diffusive neutral PEC NPs 
formulation F8 to display a x11,000-fold difference in particle diffusion between the 
fastest 10% sub-population  and the slowest 10% sub-population; a finding likely 
reflecting a non-uniform distribution of surface charge expected for a neutral particle of 
this type.  Of significance, the most diffusive 10% sub-population for this neutral PEC 
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NP was faster than that of the most diffusive 10% sub-populations obtained for both the 
PEGylated-PLGA particle as well as for a capsid adenovirus particle. 
 
Figure 4.6: Heterogeneity of (PAA:Chitosan) PEC NPs movement through mucus.  For 
each particle type a Deff was calculated for each of 360 individual particles over a time 
interval of 1 sec. The data was ranked into percentiles from the 90th through to 10th 
percentile, where the 90th percentile is the Deff value below which 90% of the Deff 
observations may be found. (A) data for the negatively charged [F1] polyelectrolyte 
formulation; (B) data for the positively charged [F14] polyelectrolyte formulation; (C) 
data for the neutrally charged [F8] polyelectrolyte formulation; (D) data for the PEG-
PLGA particle. Figure presents data of from three separate experiments, i.e. ≥ 360 
individual particles examined for each particle type. 
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4. SUMMARY AND CONCLUSION 
While this study has used a simple self-assembly PEC system to explore the impact of 
particle size and charge upon “Cardiff Native Mucus” Model permeation, it has 
revealed in a robust manner the clear benefits for a particle possessing a neutral or near 
neutral surface.  Beyond polyelectrolyte systems exploitation of polymer synthesis 
approaches such as living free radical chemistry should deliver stable, size-controlled 
nanoparticles possessing a uniform and balanced high density distribution of positive 
and negative surface charges, ultimately yielding particles with a net neutral surface 
potential that will provide an additional strategy to that of PEGylated systems when 
seeking to avoid interactions with the mucus barrier.  
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1. INTRODUCTION 
1.a Polymer and Polymerization 
The term polymer is originally a Greek word in which poly means many and meros 
means parts [1]. The polymer definition is not far from the source of the word. Polymers 
are chains of repetitive units, namely, monomers linked together by covalent bonds to 
form  macromolecules with a molecular weights reaching to millions Da [2]. The 
process of polymer synthesis is called polymerization, wherein, the monomers are 
driven to react with themselves under certain circumstances and in the presence of 
reactivating agents. A few monomers are linked together in the early stage of the 
polymerization process to produce small chains of monomers which are called 
oligomers. As the process is continued, longer chains are produced.  
Polymers can be classified depending on their skeletal structure into linear, branched or 
cross-linked polymers (Figure 5.1) [3]. Polymers can also be classified into semi-
crystalline or amorphous depending on their microstructure, where the chains look 
semi-arranged within the semi-crystalline type or randomly ordered in the amorphous 
type [4]. Chemically, polymers can be classified depending on the chemical nature of 
the monomers into either homopolymers which consist of one type monomer or 
copolymers which consist of different types of monomers (Figure 5.2). Accordingly, 
these copolymers can be sub-classified depending on the arrangement of the monomers 
into: block, random and alternating (Figure 5.2). Moreover, polymers can be classified 
depending on their (i) origin into natural or synthetic, (ii) nature into biodegradable or 
non-biodegradable [5], (iii) thermal properties into thermoplastic or thermosetting, (iv) 
tacticity into atactic or isotactic or (v) mechanism of the polymerization [6]. 
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Figure 5.1: Skeletal structure of polymer: (A) Linear polymer (B) Branched polymer 
and (C) Cross-linked polymer. 
 
Figure 5.2: Polymer classification depending on the type and the structural 
arrangements of monomers within the polymer chain. 
1.b Methods and Mechanisms of Polymerization  
Polymers can be classified based on the method of polymerization into condensation or 
addition polymerization [7]. Polymers synthesized by condensation process are formed 
of repetitive units which lack, or have more, chemical entities than that of the monomers 
synthesized from. That is to say, condensation of (XAAX, YBBY) molecules to form 
the repetitive unit (AABB) with the release of a by-product (X,Y) is a condensation 
polymerization process [8], this can be exemplified by the condensation of alcohol and 
acid to produce a simple polymer with the release of water. Condensation 
polymerization has been the pathway to synthesize different types of polymers, such as 
linear and cyclic aromatic peptides [9] and ketonic resin [10].  
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On the other hand, Polymers synthesized by addition polymerization hold exactly the 
same structural unit of the monomer. In other words, synthesized polymers are just 
repetition of the monomer units synthesized from. Addition polymerization is 
characterized by the quick consecutive addition of hundreds or thousands of pre-
activated monomers into the growing chain polymer [3]. Hence, the terms addition 
polymerization and chain growth polymerization are used interchangeably. Addition 
polymerization is preferable over condensed  polymerization, due to the high yield and 
quick formation of polymers with no need to the gradual step-growth process [11]. 
Addition polymerization starts with activating the monomers into an active unsaturated 
centre, to which the other unsaturated monomers are added successively to from a chain 
polymer. The activation of monomer is called the initiating step in which unsaturated 
molecules, namely, initiator is added into the monomers to form new unsaturated 
species.  Addition polymerization can be sub-classified depending on the type of 
desaturation of the reactive centre into radical, cationic or anionic addition 
polymerization [11]. Among the three types of addition polymerization, radical 
polymerization (RP) has been shown to be suitable for most types of monomers and is 
therefore mostly used.  
1.c Radical Polymerization 
RP was first described by Flory in 1937 who described vinyl polymerization as a chain 
growing process characterized by consecutive addition of monomers [12]. RP is three 
steps process starts with initiation step followed by propagation and ended with 
termination step [13]. The initiator is most likely an organic compound with an unstable 
group such as Azo (-N=N-) or Peroxide (-O-O-), which at certain temperature and/or 
pressure conditions is hydrolyzed into two radicals; each of them can attack monomer 
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and activate it [14]. Radicals should have an adequate half-life in order to remain active 
during the polymerization process [15].  
Monomers that are suitable for initiation and propagation are molecules having a pi- 
bond susceptible to consequent activation. After the initiation step (opening of the pi-
bond), the monomer is activated and propagation step starts in which monomers are 
added consequently into the activated monomer to grow into a polymer chain [16]. RP 
is terminated through the binding of two radical species in the reaction media, these 
radical species could be two propagating polymers or an initiator and propagating 
polymer [3]. Nowadays, RP has become of high industrial importance with 50% of the 
rubber and plastic are produced nowadays through this process [17].  
1.d Controlled Polymerization 
One of the main concerns with addition polymerization (RP) is the short half-life of the 
growing chain. This issue has been the main obstacle in controlling the molecular 
weight and block copolymerization of propagating polymers [16]. Controlled 
polymerization was first achieved by Szwarc in 1956 through the use of an anionic 
polymerization technique to eliminate the un-controlled termination step and to produce 
a living polymer [18]. Decades after, control of the RP was achieved based on the 
formation of dormant species and the concurrent initiation and propagation [15].  
The main differences between conventional RP and controlled radical polymerization 
(CRP) is the turning of the unsaturated active propagating polymer into a dormant 
species which can not be propagating or reacting to any other radical till it turned back 
to its unsaturated active species. This difference affects the steps of polymerization as 
follows. Firstly, the half-life of the propagating process is prolonged from a few seconds 
in RP to several hr in CRP due to the formation of dormant species. Secondly, in the 
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RP, most chains are dead due to radical-radical termination while only 10% of chains 
are dead in CRP due to the coexistence of dormant species which are very inert to be 
terminated by another radical interaction. Lastly, in RP, a steady state is achieved by the 
equilibration between the initiation and the termination steps, while, in CRP, this 
equilibration is achieved through the exchange of the active and dormant species [15]. 
Generally, there are two main pathways for CRP. These are, firstly, reversible 
termination of the propagating radical (Pm
.
, Pn
.
 or Rm
.
) (Figure 5.3A) through 
reversible coupling/uncoupling with a stable agent such as a stable radical (nitroxide 
radical) [19] or transition metal complex (copper complex) [20].  Secondly, radical 
polymerization can be controlled through the ‘reversible addition fragmentation chain 
transfer’ (RAFT) of the propagating radical (Figure 5.3B). Both techniques depend on 
the equilibrium between the active propagating radical and the inactive centre, in which 
the radical addition and propagation is immobile [21]. In this work, RAFT technique 
will be used to synthesize controlled molecular weight polymers.  
 
Figure 5.3: Mechanism of CRP (A) reversible activation/ deactivation of the 
propagating radical, (B) reversible addition fragmentation chain transfer of the 
propagating radical.  
 
 
 
A 
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1.e Reversible Addition Fragmentation Chain Transfer (RAFT) 
This technique depends on the use of an active unsaturated agent, namely, a chain 
transfer agent (CTA) which can reversibly hold the propagating radical to retard its 
growing [22]. The RAFT technique was firstly introduced by Gaynor et al. (1995) in the 
mid-nineties who used alkyl iodide as a CTA for the control polymerization of styrene 
polymer [23]. However, this technique did not show acceptable polydispersity 
(acceptable polydispersity should be <1.4). Subsequently, the patent of the Phuong et al. 
which was published in 1998 paved the way for a controlled radical polymerization 
process through the use of thiocabonylthio compounds as a CTA agent (Figure 5.4) 
[24]. These Thiocabonylthio agents are characterized by suitability to be used with 
various types of monomers to yield polymers with predictable molecular weights and 
low polydispersity (usually <1.2) [25].  
 
Figure 5.4: Functional groups responsible for the activity of the Thiocabonylthio CTA 
agent.  
The chain transfer process is controlled by the three main functional groups in the CTA 
agent, these are: the carbon-thiol double bond, Z and R groups (Figure 5.4). Each of 
these functional groups has its own role in the RAFT technique. The carbon-thiol 
double bond is the site to which the propagating radical is added to form an intermediate 
radical. Z groups should activate and stabilize the addition of propagating radical and 
formation of the radical intermediate. As will be seen in Figure 5.6, stability of the 
intermediate is essential to hold the growing polymer and control the overall 
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polymerization. Depending on the types of Z groups, thiocabonylthio agents can be 
classified into four types. These types and their order of activity are as follows: 
Dithiobenzoates > trithiocarbonates > xanthates > dithiocarbamates (figure 5.5) [26].  
 
Figure 5.5: Types of thiocarbonylthio transfer agents. 
Accordingly, R group in the CTA agent should be a fast leaving group to form a new 
radical (R˙), so the Thiol-R bond should be weak so as to allow fast homo breaking of 
the bond to release the R˙ (Figure 5.4). This formed R˙ should be stable enough to 
reinitiate and propagate again. Similar to the variety of Z groups, CTAs exist with a 
variable withdrawing efficiency R˙ group [27].  
The mechanism of RAFT polymerization is described in Figure 5.6 [28]. RAFT 
polymerization shares the same initiation (Ki) and termination (Kt) steps (step 1 and 5, 
Figure 5.6) with conventional RP. The reversible addition/fragmentation step (step 2) 
involves the addition (ka) of the propagating radical (Pm˙) to the CTA agent to 
reversibly form an intermediate agent holding the propagating radical (Pm˙-CTA) 
(compound X). The (Pm˙-CTA) could either degrade back (K-a) into the original 
propagating radical (Pm˙) and the CTA or it could fragment (kf) into the dormant 
species (Pm-CTA) with the breaking of the (S-R) bond and releasing of the radical (R˙). 
Then, (R˙) undergoes reinitiation and propagation (Kp) to form new propagating radical 
(RPm˙) (step 3).  
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With the appropriate type and concentration of the CTA agent, the pre-equilibrium 
addition should dominate over the conventional propagation. The equilibration step 
(step 4) involves the reversible re-addition of the propagating radical (RPm˙) to the 
dormant Pm-CTA (compound Y) to form a new intermediate radical (Pm-CTA˙-RPm) 
(compound K). This radical intermediate undergoes a reversible fragmentation to form 
propagating radical Pm˙ and dormant species (RPm-CTA) [28,29].  Each of the 
propagating radicals at either side of the equilibration step (step 4) has the chance to 
propagate for few milliseconds before it is held by the intermediate radical (compound 
K) for a few seconds. Hence, each polymer grows by a few monomers before it 
becomes dormant again. The equilibration step allows all the chains to grow equally 
with a min chance  to produce dead polymers [15]. CTAs with a very high addition 
constant can produce polymers with very low polydispersity since the addition will be 
totally dominant over the propagation step. Termination (step 5) is responsible for the 
formation of dead polymers, although it counts for less than 10% of the total 
polymerization. 
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Figure 5.6: Mechanism of RAFT polymerization by the CTA agent. This Figure was 
modified from the original figure in [28]. 
1.f Zwitterionic Sulfobetaine Polymer 
The Zwitterioinc (co)polymer is defined as the polymer possessing both anionic and 
cationic groups. At certain pH value, namely, the isoelectric point, the net charge is 
approximately zero. There are two types of Zwitterionic polymer: (i) polyampholyte, in 
which the opposite groups exist in different monomer units and (ii) polybetaine which is 
characterized by the presence of the opposite groups in the same monomer unit [30]. 
Each betaine monomer unit possesses a terminal anionic group next to the cationic 
group (Figure 5.7 While the cationic ion is usually amino group, the terminal anionic 
group could be either sulphate group (Figure 5.7A) or carboxylate groups (Figure 5.7B) 
[31]. Betaine monomer is called sulfobetaine when the anionic species is sulphate group 
(Figure 5.7A), and called carboxybetaine when the the anionic species is carboxylate 
groups (Figure 5.7B). The first synthesised carboxybetaine polymer was reported  in 
1957, while the first synthesis of sulfobetaine polymer was in 1958 [32].  
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Figure 5.7: (A) Structure of sulfobetaine unit, (B) Structure of carboxybetaine unit, (C) 
1,3-propane sultone structure, (D) Substituting groups in the sulfobetaine structure. 
The betainisation of DMAEMA to form sulfobetaine polymer was firstly reported in the 
mid-eighties where the reaction of DMAEMA with 1,3-propane sultone (Figure 5.7 C)   
was carried out under an extremely high temperature (120 °C) and propylene carbonate 
as the solvent [33].  However, the betainisation of the DMAEMA polymer under a mild 
condition of 25 °C and tetrahydrofuran (THF) solvent was introduced in the late nineties 
which enabled the synthesis of the (DMAEMA)sulfobetaine by a one step 
akylsulfonation process of the tertiary amine group with a 100% yield [34].  
Physicochemical properties of sulfobetaine polymer are affected by the molecular 
weight of this polymer. For example, the water solubility of this polymer was found to 
increase when the molecular weight of sulfobetaine polymer decrease [35]. 
Microscopically, examination of sulfobetiane polymer revealed a collapsed coil 
conformation in aqueous phase due to the intra-groups interaction,  however, the low 
molecular weight sulfobetaine polymer exhibited a random coil configuration in better 
solubilizing solvents such as 2,2,2-trifluoroethanol (TFE) where the conformational 
dimensions was dependent on the polymer molecular weight [36]. 
1.g Biological Activity of Zwitterionic Polymer: Sulfobetaine Polymers 
Polymers can be immobilised onto biological or chemical surfaces to form coating 
films. A coating film comprised of zwitterionic polymer is characterised by a densely 
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charged outer layer which serves as an anti-adherent layer minimising electrostatic or 
lipophilic interactions [37]. For example,  immobilisation of Poly(3-trimethoxysilyl-
propyl-methacrylate)-co-poly(2-methacryloyloxyethyl phosphoryl choline onto the 
surface of contact lenses is one of the techniques to enhance anti-adherent properties 
against micro-organisms and protein adsorption while retaining  high wettability  [38].  
Accordingly, the anti-adherent properties of sulfobetaine polymers have been widely 
reported. For example, sulfobetaine polymer cross-linked onto a hollow membrane of 
poly(vinylidene-fluoride) showed considerably higher protein anti-fouling and 
hydrophilicity as compared to the non-modified hollow membrane [39]. Similarly, 
covering of  vinylidene-fluoride membrane with grafted sulfobetaine highly improved 
the anti-adherent properties of the membrane such as reduced surface protein 
adsorption, platelet activation, plasma clotting and blood cell haemolysis [40].   
Chemically, the sulfobetaine structure has various functional groups available for 
substitution. Specifically groups R1, R2, R3 and R4 (Figure 5.7D) can be substituted 
with either more lipophilic or more hydrophilic groups so as to have new compounds 
with modified properties. Developing new sulfobetaine compounds by modifying the 
sulfobetaine structure has been the subject for several patents. For example, Ballschuh 
et al. (1992) synthesized a patented sulfobetaine compound in which either R1, R2 or 
R4 was substituted with  α-sulfonylcarboxylic acids and R3 was replaced with a highly 
lipophilic 20 alkyl unit chain [41].  Patented sulfobetaine compounds have been used 
for various applications such as drug delivery and chemical industries. 
Substituting of R1 (Figure 5.7D) with up to a 30 alkyl unit chain and modifying of R2, 
R3 and R4 with small alkyl chains was the basis of a  patented antibacterial layer 
applied onto contact lenses [42].  Coating contact lenses with modified sulfobetaine 
layers to improve wettability and biocompatibility was the subject of another patent 
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published in 2013 (Broad et al. 2013). Additionally, sulfobetaine was blended with a 
range of  polymers to form a patented filter for blood purification, haemodialysis, 
hemofiltration and for water purification [44]. Sulfobetaine-co-acrylic acid copolymer 
has been used to cover blood contacting devices to prevent platelet adhesion and 
fibrinogen adsorption [31]. Similarly, sulfobetaine polymer  has also showed impact as 
an anti-adherent layer in non-medical applications e.g. as in an electroplating 
suspension to improve the mechanical strength and appearance of nickel surfaces [45]. 
The Ben-Sasson group has modified R1, R2, R3 and R4 groups in the sulfobetaine 
polymer with a range of substituents from highly lipophilic to highly hydrophilic 
functional groups (Ben-Sasson & Dagan 2009). This patent showed that sulfobetaine is 
an excellent template to load various range of hydrophilic and lipophilic drugs such as 
cyclophosphamide, NSAIDs, betamethasone, cimetidine and rapamycin. Accordingly, 
Xiu et al (2013) studied the impact of sulfobetaine polymer on a gene delivery [47].  
The target DNA was loaded into a comb-shaped vector consisting of dextran backbone 
with a comb-like surface consisting of either DMAEMA or sulfobetaine. The DNA 
stability and cellular uptake was much higher for the gene loaded into the sulfobetaine 
comb vector as compared with the DMAEMA comb vector.  
The sulfobetaine polymer has also shown to be a promising nano-carrier for DNA 
delivery  in the study by  Dai et al (2008) [48]. Here the DNA was loaded into a NP 
fabricated from an (ABA) tri-block copolymer in which the A-block is sulfobetaine 
polymer and the B-block is 2-(2-methoxyethoxy)ethyl methacrylate. Ethidium bromide 
displacement assay showed that the sulfobetaine block in the NPs was responsible for 
the binding of the DNA with a very high efficiency, and an increase of sulfobetiane 
ratio resulted in an increase of DNA condensation by the NP [48].  
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As described above, the biological activity of the sulfobetaine polymer or NPs is due to 
the sulfobetaine moiety rather than any other copolymer included in the structures of 
these copolymers. This means that sulfobetaine NPs should have the sulfobetaine 
moiety at the surface of NPs (as a shell) to exert the desired effect. In this NP type, the 
zwitterionic sulfobetaine moiety is a very hydrophilic block polymer, this causes it to be 
localised at the shell of NPs when it is assembled in the presence of a lipophilic core 
[49] (Figure 5.8). This is in agreement with the principle of self-assembly of 
amphiphilic di-block copolymers, where the hydrophilic block will form the shell of the 
NP and the lipophilic block will accumulate in the core of the NP [50,51]. Thus, 
sulfobetaine NP with a lipophilic core should have the same anti-adherent effect as the 
sulfobetaine polymer since the zwitterionic block should be in contact with the 
biological media.  
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1.h Aim of the Study 
The aim of this study is to produce novel zwitterionic sulfobetaine NPs having a 
densely charged surface but with a net neutral zeta potential at the physiological pH 
(Figure 5.8). These NPs will have a BMA lipophilic core and sulfobetaine as the highly 
charged zwitterionic shell. Moreover, these novel NPs should exhibit small particle size 
and be stable for at least the time required for the particles to deliver the therapeutic 
active agent to the required site of the body. Lastly, these sulfobetaine NPs should have 
a high diffusivity through the intestinal mucus barrier. The hypothesis is that the 
densely charged but net neutral shell with opposing charges on the same polymer chain 
will result in high mucus-diffusion of the respective NPs. 
The purposes of this study are as follows: 
  To synthesize a low molecular weight butyl methacrylate (BMA) lipophilic 
block polymer by the RAFT technique to serve as the lipophilic core for the 
shell-core sulfobetaine NP.  
 To copolymerize the BMA block with various ratios of N,N-
Dimethylaminoethyl Methacrylate (DMAEMA) copolymer to from a di-block 
copolymer of BMA-DMAEMA with the following ratios: 70:30, 60:40, 50:50, 
40:60 and 30:70. 
 To form BMA- sulfobetaine at the same above ratios of 70:30, 60:40, 50:50, 
40:60 and 30:70 by reacting of each BMA-DMAEMA copolymers synthesized 
in step 2 with 1, 3 propane sultone. As a result, the synthesized block BMA-
sulfobetaine will have BMA as the lipophilic block and the sulfobetiane as the 
zwitterionic hydrophilic block.  
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 To synthesize zwitterionic sulfobetiane NPs from the BMA-Sulfobetaine 
polymer by the nano-precipitation technique in which the BMA will form the 
lipophilic core and the sulfobetaine will form the hydrophilic shell (Figure 5.8). 
These sulfobetaine NPs will be fluorescently labelled with the lipophilic dye 
Lumogen red. 
 To characterize all the synthesized polymers and NPs where the structures of 
polymer will be identified by IR, NMR and GPC while the particle size and zeta 
potential of NPs will be measured by DLS.  
 Sixth is to investigate the mucus permeability of the novel synthesized 
zwitterionic sulfobetaine NPs. Specifically, studies here are to address the ability 
of sulfobetaine to form a muco-inert layer on the NP surface to reduce the 
interaction of NP particles with mucus components. On this basis, the kinetics of 
sulfobetaine particles transport through the “Cardiff native mucus” model will 
be studied to reveal the potential of the characteristic of sulfobetaine NPs. 
 
Figure 5.8: Diagram showing the aim of this study to synthesize sulfobetaine 
Zwitterionic NPs by successive steps starting with the synthesis of BMA, followed by 
the copolymerization of BMA-DMAEMA, then the synthesis of BMA-Sulfobetaine and 
finally the nano-precipitation to form the Zwitterionic NPs.  
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2. MATERIALS AND METHODS 
2.a Materials 
All the chemicals used in control polymerization were purchased from Sigma-Aldrich. 
These chemicals are: Butyl methacrylate (BMA), 2-Dimethylaminoethyl methacrylate 
(DMAEMA), 1,3-Propanesultone, 2-Cyano-2-propyl dodecyl trithiocarbonate (CTA), 
2,2′-Azobis(2-methylpropionitrile) (AIBN) and tetrahalose. Methanol, Dioxane, 
dimethyl sulfoxide (DMSO), Hexane, THF and other solvents used to measure the 
solubility were purchased from Fisher scientific. Lumogen red was a gift from Nanomi, 
Netherland. Other chemicals like NaCl, KCl, Na2HPO4, KH2PO4, NaOH and HCL 
were also purchased from Fisher scientific. Similarly, dialysis tubing of molecular 
weight cut off (MWCO) 20 KDa and 12 KDa were bought from Sigma-aldrich. 
Lumogen Red-305 (LR) was supplied by Nanomi (Netherlands). Glass bottom imaging 
dishes (35 mm diameter dish with a glass coverslip at 1.5 mm thick and 10mm 
diameter) were from MatTek Corporation (USA).   
2.b Synthesis of the Novel Zwitterionic Polymer 
Synthesis of the Lipophilic BMA Block Polymer 
RAFT control polymerization technique was used to polymerize the BMA block 
polymer. This polymerization was carried out using AIBN initiator, 2-Cyano-2-propyl 
dodecyl trithiocarbonate as the CTA and dioxane as the solvent of reaction (Figure 5.9). 
Prior to the synthesis, the initiator was purified by recrystallizing AIBN powder in cold 
methanol. BMA monomer was also purified prior to the polymerization by passing the 
monomer solution through aluminum oxide Pasteur tube to remove the anti-
polymerizing agent (hydroquinone). The ratios of each of the reactants 
(BMA:CTA:AIBN) was calculated following the RAFT equation (Equation 5.1). Since 
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a final desired number of BMA monomers in each polymer chain was 25 units, 
BMA:CTA:AIBN were reacted at the ratio of (25:1:0.1) respectively [52]. 
 
Mn = aimed molecular weight of the polymer,  
(mol monomer/ mol CTA) = molar ratio of monomer to the CTA agent,  
MWmonomer = molecular weight of the monomer and  
MW (CTA) = molecular weight of the CTA agent. 
Thus, following equation 5.1, 3.52 x 10-3 mole BMA monomer, 1.40 x 10-4 mole CTA 
and 1.40 x 10-5 mole AIBN were added in a dry borosilicate glass tube and dissolved in 
2 ml dioxane (solvent of reaction). The solution in the glass tube (BMA, AIBN and 
CTA) was flushed with nitrogen gas for 30 min before the reaction; the container was 
kept under the nitrogen flushing during the polymerization process. The reason to 
evacuate the glass tube with an inert gas was to deoxygenate the container to allow the 
continuation of radical polymerization. Polymerization was started by moving the 
borosilicate glass tube containing the reactants into a preheated silicon oil bath at 70 °C, 
the polymerization was continued under heating (70 °C) and stirring (100 rpm) until the 
end of the synthesis. 
The polymerization was carried out at three different polymerization times (6, 12 and 24 
hr) to assess the effect of time on the degree of polymerization of BMA polymer. At the 
indicated time, the sealed rubber was removed and the mixture of polymer, unreacted 
monomer and other ingredients was exposed to the air to stop the polymerization 
process. BMA polymer was separated from other ingredients by precipitating in excess 
cold methanol and centrifugation at 3500 rpm for 20 min. The precipitate was washed 
twice with cold methanol.  The supernatant was removed and the precipitated polymer 
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was dried under vacuum at room temperature. The dried polymer was used for further 
analysis and copolymerization with DMAEMA monomer in the next step [53].  
 
Figure 5.9: RAFT polymerization of BMA polymer by using CTA agent. 
Copolymerization of BMA-DMAEMA Di-Block Copolymer 
Following the synthesis of BMA block co-polymer in the previous section, in this 
section, the lipophilic block BMA polymer was copolymerized with DMAEMA 
monomers by the RAFT control polymerization technique (equation 5.1). Herein, BMA 
polymer holding CTA agent was served as the macro-CTA agent for controlling the 
RAFT polymerization of DMAEMA monomers. In other word,  the block BMA-CTA 
was counted as the CTA agent in the calculations (equation 5.1) for the control 
polymerization of the DMAEMA monomers [54]. BMA was copolymerized with 
DMAEMA at different ratios so as to obtain BMA-DMAEMA copolymers with 
versatile hydrophilic-lipophilic properties.  For this purpose, BMA:DMAEMA was 
copolymerized with the following aimed ratios (70:30, 60:40, 50:50, 40:60, and 30:70). 
Table 5.1 shows all the calculations including the molar ratios of DMAEMA monomer 
to CTA and AIBN ratios. As illustrated in Table 5.1, the (BMA: DMAEMA) ratios of 
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(70:30, 60:40, 50:50, 40:60, and 30:70) were symbolized as P1, P2, P3, P4 and P5 
respectively. 
Table 5.1: Calculations (DMAEMA monomer/CTA), BMA monomer and AIBN ratios 
to synthesize BMA-DMAEMA polymer at various block copolymers ratios.  
Formula PBMA: DMAEMA 
Calculated ratio 
Ratio 
(DMAEMA /CTA) 
PBMA-CTA 
Moles  
DMAEMA 
Moles  
AIBN 
Moles 
P1 (70:30) 16.35 7.5 x10-5 1.23 x10-3 7.5 x10-6 
P2 (60:40) 25.50 6.6 x10-5 1.70 x10-3 6.6 x10-6 
P3 (50:50) 38.17 5.8 x10-5 2.22 x10-3 5.8 x10-6 
P4 (40:60) 57.25 5.0 x10-5 2.86 x10-3 5.0 x10-6 
P5 (30:70) 89.05 4.2 x10-5 3.71 x10-3 4.2 x10-6 
Polymerization was carried out under the same conditions of polymerization of BMA 
except that the polymerizations of BMA:DMAEMA di-block copolymers was carried 
out for one polymerization time (24 hr), i.e. the effect of polymerization time was not 
studied for this copolymerization step. BMA-DMAEMA di-block copolymers were 
precipitated in cold hexane and the precipitates were washed twice in cold hexane prior 
to drying under vacuum pressure at room temperature. Figure 5.10 shows the structural 
copolymerization of BMA-DMAEMA copolymer where the BMA-CTA was served as 
the macro-CTA agent.  
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Figure 5.10: Copolymerization of BMA-DMAEMA in which BMA-CTA served as the 
macro-initiator to control the polymerization of DMAEMA monomers. 
Synthesis of BMA-Sulfobetaine Di-Block Copolymer 
In this step, BMA-DMAEMA di-block copolymers were betainised to form zwitterionic 
di-block BMA-Sulfobetaine. To do so, each of the BMA-DMAEMA di-block 
copolymers (P1, P2, P3, P4 and P5) were reacted with 1,3 propane sultone at a molar 
ratio of 1:2 receptively. The reactions were carried out in THF for 3 days under mild 
stirring and nitrogen supply [55]. Same reactions were also performed in DMSO under 
the same conditions. After 72 hr, BMA-Sulfobetaine polymers were precipitated in 
excess acetone then centrifuged at 3500 rpm. The precipitate was washed twice with 
acetone before left to dry under vacuum at room temperature. Figure 5.11 shows the 
reaction of the DMAEMA tertiary amine group with the propane sultone leading to the 
opening of the sultone ring and formation of the negatively charged sulfonate group 
next to the quaternary amino group on the same unit. The synthesized BMA-
sulfobetaine di-block copolymers were symbolized following the same order used to 
symbolize BMA:DMAEMA di-block copolymers. Thus P1S, P2S, P3S, P4S and P5S 
were the synthesized copolymers from P1, P2, P3, P4 and P5 respectively, and 
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consisting of BMA:sulfobetaine ratios of (70:30, 60:40, 50:50, 40:60 and 30:70) 
respectively (table 5.2).   
  
Figure 5.11: Synthesis of BMA-sulfobetaine where the tertiary amino group of the 
DMAEMA unit was reacted with the γ carbon of the 1,3 propane sultone. 
NMR Analysis of the Synthesized Polymers 
NMR proton (1H-NMR) analysis was used to identify structures, degree of 
polymerization and purity of the synthesized polymers. NMR spectra were recorded in a 
400 MHz (Varian NMR Instruments, Claredon Hills, IL) and auto-calibrated to the 
deuterated solvent reference peak. For BMA polymer, degree of polymerization was 
detected by measuring the NMR spectrum peak representing the number of BMA 
monomers in each chain polymer versus the reference peak representing the one CTA 
agent molecule within each chain polymer. Accordingly, the diminishing of any 
unreacted BMA monomers within the separated BMA polymer was confirmed by the 
disappearance of peaks of unreacted BMA monomers (BMA with double bonds) in the 
NMR spectrum of BMA polymer. In other words, these peaks of unreacted BMA 
monomers (double bonds) were shown in the NMR spectrum of BMA monomer but 
disappeared for the BMA polymer. Deuterated Chloroform (CDCL3) was used as the 
NMR solvent for the NMR analysis of both BMA polymer and monomer. 
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Similarly, CDCL3 was used to run the NMR analysis of BMA-DMAEMA polymer and 
DMAEMA monomer. Reference peak from BMA block polymer versus reference peak 
from DMAEMA block polymer were compared to identify the degree of polymerization 
of DMAEMA and the BMA:DMAEMA ratios within each di-block BMA-DMAEMA 
copolymer. Also, NMR spectrum was used to confirm the inexistence of any unreacted 
DMAEMA monomers in the final BMA-DMAEMA di-block copolymer by comparing 
the NMR spectrum of DMAEMA monomer and the BMA-DMAEMA polymer. 
Moreover, the degree of betainisation of BMA-DMAEMA and structures of BMA-
sulfobetaine polymers were detected by the NMR analysis using Deuterated DMSO 
(DMSO-d6) as the NMR solvent [56]. 
Infrared (IR) Structural Analysis  
IR structural spectra were performed to identify the structures of BMA, BMA-
DMAEMA and BMA-Sulfobetaine using a Nicolet Magna 560 (Thermo Fisher 
Scientific, Waltham, MA) with a KBr beam splitter in evaporated film.  
Gel Permeation Chromatography (GPC) Analysis of the Molecular Weight 
Molecular weight was determined on an HPLC Elite LaChrom system (VWR-Hitachi) 
equipped with a GPC Shodex KF-603 column, 6,0 mm ID, 150 mm, and THF as the 
mobile phase. The average molecular weight (Mwa) was calculated by comparing the 
retention time of each assessed polymer with the retention times of polystyrene 
standards. The polymer polydispersity index (PDI) was calculated following equation 
5.2:  
 
Mwa = average weight molecular weight, Mna = number average molecular weight. 
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2.c Synthesis of the Novel Zwitterionic NPs  
Polymer Solubilisation 
In previous sections, di-block copolymers of BMA-sulfobetaine were synthesized at 
ratios of 60:40 (P2S), 50:50 (P3S), 40:60 (P4S) and 30:70 (P5S) (Table 5.2). These 
copolymers were insoluble in water. To solubilize these copolymers, various organic 
solvents, mixture of organic solvents and mixture of aqueous and organic solvents were 
used. Among all the mixtures of aqueous and organic solvents tested, the mixture of 2 
M NaCL + methanol was used to solubilize BMA-sulfobetaine di-block copolymers. 
Each of the BMA-sulfobetaine copolymers (P2S, P3S, P4S and P5S) was dissolved in a 
solvent with different ratios of methanol to 2M NaCL. In other words, the ratios of the 
aqueous to the organic phase (methanol to 2 M NaCL) were varied depending on the 
ratios of BMA to the Sulfobetaine in each copolymer. Table 5.2 shows the solubilisation 
ratios (2M NaCL:methanol) for each sulfobetaine di-block copolymer. For example, for 
P2S, a 250 µl of 2 M NaCL and 250 µl of methanol were added into a tube containing 5 
mg of P2S then the sample was sonicated for 10 min. 
Fabrication of NPs by Nano-Precipitation Method 
Sulfobetaine NPs were formulated by a modified nano-precipitation method in which 
the solubilisation media involved the usage of a co-solvent (2 M NaCL) rather than the 
usage of one organic solvent [57]. Simply, 5 µg of the Lumogen red and 5 mg of BMA-
sulfobetaine di-block co-polymer (P2S, P3S, P4S or P5S) were dissolved in 500 µl of 
the specified solubilisation media (2M NaCL: methanol) (Table 5.2). Afterward, each 
solubilised polymers was added drop wise at a rate of 20 µl/min into a 10 ml external 
aqueous phase (PBS pH 6.8 or PBS pH 7.4) (table 5.2) using a programmable syringe 
pump (Razel, USA). Each of the formed NP suspension was further stirred for 45 min to 
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ensure the evaporation of the methanol before the physiochemical characterisation of 
these NPs.  
 Then, sulfobetaine NPs were freeze dried and stored for further studies. To do so, NPs 
suspensions were dialysed (dialysis tubing, MWCO: 20000) against 500 ml PBS 6.8 for 
24 hr followed by collecting of NP suspension in the dialysis tube. Cryo-protectant 
(Tetrahalose) was added at a weight ratio of 5:1 to the total NPs weight [58]. The 
sample was freeze dried for 24 hr and particle size was measured to confirm the 
retaining of the original physicochemical properties of sulfobetaine NPs after freeze 
drying.  
  
 218 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 5.2: The conditions of nano-precipitation of Zwitterionic polymer: the ratios of solvents 
solubilisation, weight of solubilised polymer, rate of polymer precipitation and volume of buffer media 
used for nano-precipitation of the Zwitterionic polymer. 
Code 
BMA:Sulfobetaine 
Ratios 
Solubilisation media 
µl 
Polymer 
weight (mg) 
Rate of  
nano-precipitation 
µl/min 
Volume of the 
buffer aqueous 
phase (ml) 
2 M NaCL Methanol 
P1S (70:30) The yield of sample was low 
P2S (60:40) 250 250 5 20 10 
P3S (50:50) 275 225 5 20 10 
P4S (40:60) 350 150 5 20 10 
P5S (30:70) 400 100 5 20 10 
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Table 5.3 shows the concentrations of chemicals dissolved in DDW to prepare PBS 
buffers of pH 6.8 and pH 7.4.  
Table 5.3: Concentrations of the ingredients used to prepare the PBS buffers of pH 6.8 
and pH 7.4. 
Ingredients  pH 7.4 pH 6.8 
NaCl (mM) 137 137 
KCl (mM) 2.7 2.7 
Na2HPO4 (mM)  10 4.3 
KH2PO4 (mM) 1.8 1.4 
2.d Characterization of NPs: Stability of NPs against Aggregation  
Particle size and zeta potential were measured for the freshly prepared sulfobetaine NPs 
and at time intervals of 0.5, 1, 2, 3, 4 and 6 hr at 25 and 37 °C to assess the stability of 
these particles against aggregation at the physiological and the room temperatures. Also, 
particle sizes and zeta potentials were measured before and after freeze drying and 
loading of the Lumogen red to assess the effect of freeze drying and loading of 
hydrophobic cargo on the physicochemical properties of particles.  
2.e Loading Capacity and in Vitro Release of Lumogen Red (Lipophilic Cargo) 
Lumogen red has been used throughout this thesis as the fluorescent dye which is 
needed to be loaded at concentration of 0.1% w/w. In this study, the loading capacity of 
sulfobetaine NPs for lipophilic cargo was studied by using Lumogen red as the 
lipophilic model with the aimed loading capacity of 50%. As was described above, 
Lumogen red and sulfobetiane copolymers were dissolved in the solubilisation media of 
2 M NaCL:methanol then NPs were prepared by the nano-precipitation method. 
However, to load Lumogen red at a concentration of 50%, 2.5 mg Lumogen red and 5 
mg sulfobetaine copolymers were dissolved in the solubilisation media.  
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After the formation of NPs, 5 ml of the each of the NPs suspensions was added into the 
dialysis tube (MWCO: 20000) and the suspension was dialysed against an external 
media consisting of 500 ml PBS pH 6.8 for 24 hr. At the specified time, NPs suspension 
was collected and the concentration of Lumogen red in the NPs suspension before and 
after the dialysis was measured in triplicate using the fluorescence micro-plate reader 
(Fluostar Optima, BMG, Germany) [59]. Here, the quantity of Lumogen red was 
measured in the NPs suspension and not in the external media (500 ml PBS pH 6.8) due 
to the instability of Lumogen red in the buffer external media. This is based on the 
HPLC quantification analysis of Lumogen red which showed a self-quenching of 
Lumogen red in the PBS pH 6.8 and a high stability and concentration-absorbance 
correlation in the NPs. The entrapment efficiency (EE%) [60] and the loading capacity 
(LD%) [61] of sulfobetaine NPs were detected by the following equations: 
 
Accordingly the in vitro release of the Lumogen red was studied as follows. Freeze 
dried NPs loaded with Lumogen red were re-suspended in phosphate buffer pH 6.8. 
Suspension was divided into 1 ml aliquots, each aliquot was added into dialysis tube 
(MWCO: 20000) then dialysed against 500 ml PBS 6.8. NP suspension from each 
dialysis tube was collected at the specified time interval and concentration of Lumogen 
red was measured in triplicate in each suspension before and after the dialysis. 
Suspension samples were collected at time intervals of 30 min, 1, 2, 3, 4, 6, 8, 16 and 24 
hr.  
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2.f Study of Sulfobetiane Kinetics Diffusion through the “Cardiff Native Mucus” 
Model 
All the experimental work to study the kinetics of particles’ diffusion through the mucus 
was carried out following the same MPT methodology in chapter four.  
Statistical Analysis 
One-way analysis of variance test was used to compare the % ratio of <Deff> vs D° for 
all the sulfobetaine NPs with significant value of p < 0.05.  
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3. RESULTS AND DISCUSSION 
3.a Synthesis of the Novel Zwitterion Polymer 
RAFT technique was used to synthesize BMA lipophilic block polymer and BMA-
DMAEMA di-block copolymers prior to the synthesis of the zwitterionic sulfobetaine 
polymer. This technique allows tailoring the molecular weight of the lipophilic and the 
hydrophilic block polymers. Thus, for sulfobetaine NPs, controlling the molecular 
weight of BMA block polymer will allow controlling the size of the lipophilic BMA 
core in the NPs and the same for the sulfobetaine hydrophilic shell [62,63]. This enables 
to design the NPs in response to the purpose it is synthesized for. This will be illustrated 
in the next section.  
The other reason to use the RAFT technique is the presence of the CTA agent within the 
polymer synthesized by RAFT technique which introduces another opportunity to 
covalently bind targeting agents into the NPs [64]. In other words, targeting agent could 
be attached to the NPs through a replacement reaction in which the CTA is removed and 
replaced with the targeting agent. This replacement technique could be used in this work 
later to introduce any targeting agent.  
Synthesis of the Lipophilic BMA Block Polymer  
In this section, BMA block polymer was synthesized by RAFT technique with the 
purpose of producing low molecular weight lipophilic block. This lipophilic block 
polymer will be copolymerized in the next sections with a zwitterionic hydrophilic 
polymer where this block will be the lipophilic core in the NPs. The low molecular 
weight lipophilic polymer is supposed to form a small lipophilic core in the NP [65] 
which in turn leads to form a small NP size [66]. In this work, producing NPs with 
small lipophilic core was essential so as to reduce the lipophilic interaction with the 
mucus lipophilic component and to reduce the NP size which in turn will eliminate 
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trapping of NPs by mucus steric effect (explained in chapter 3). Hence, a ratio of 25:1 of 
the monomer to the CTA agent was selected to synthesize polymers with only 25 BMA 
units in each chain. 
Figure 5.12 shows the 1H-NMR spectra of the BMA polymer in which A, B and C show 
the spectra of BMA polymers after 6, 12 and 24 hr polymerization time. These NMR 
spectra were used to detect the number of BMA units in each polymer chain by 
comparing the area under the curve of the peak signal at 3.95 ppm representing two 
protons from the BMA monomer to the area under the curve of the peak signal at 3.2 
ppm representing two protons in the CTA agent (Figure 5.12). To be more specific, 
Figure 5.12 shows that the peak signal at 3.95 ppm is related to the two protons of the 
methyl groups next to the ester group in the BMA monomer. Since in the RAFT 
polymerization, each polymer chain possesses a one CTA unit, so comparing of these 2 
peaks reveals the number of the BMA units in each polymer as compared to the one 
CTA unit. (Note: 1H-NMR spectra of the CTA agent and BMA monomer is presented in 
Appendix F). 
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Figure 5.12: 1H-NMR spectrum of the BMA polymer in which the peaks showing the number 
of BMA units in polymer chain was highlighted. (A) BMA polymerized for 6 hr. (B) BMA 
polymerized for 12 hr. (C) BMA polymerized for 24 hr. (Solvent: CDCL3). 
It can be seen that BMA polymerized for 6, 12 and 24 hr were grown up to 24, 39 and 
56 units respectively (Figure 5.12 A, B and C). Polymerization of BMA for 6 hr 
achieved the aimed number of units (25 monomers per polymer chain). However, 
stopping the polymerization of BMA after 6 hr could affect the PDI of this polymer 
since some chains could be still growing at this time interval (6 hr). This expectation 
could be true since the number of BMA monomers in each BMA chain was doubled 
after 24 hr. Hence, the PDI of BMA polymer should be assessed to assess the suitability 
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of the trithiocarbonate CTA agent for BMA polymerization. For this reason, GPC 
technique was used to detect the PDI of the BMA polymer that was polymerized for 6 
hr, also, the PDI of the BMA polymer that was polymerized for 12 hr was also 
measured as a reference for a well grown polymer. Figure 5.13A shows that the PDI of 
the 6 hr polymerized BMA was 1.28 while Figure 5.13B shows that the PDI value for 
the 12 hr polymerized BMA was 1.19.  
 
Figure 5.13: GPC profile of BMA showing the molecular weight and the PDI. (A) 
BMA polymerized for 6 hr. (B) BMA polymerized for 12 hr. 
The pattern of polymer growing (Figure 5.12) indicates that time of polymerization had 
important impact on the degree of polymerization of the BMA, where only 6 hr 
polymerization achieved the aimed 24 units BMA polymer with a molecular weight of 
3750 gm per mole, while, polymerization of BMA for 24 hr doubled the number of 
BMA monomers up to 56 per polymer chain. Previous studies showed that time can 
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play important role in the degree of polymerization of active monomers [28]. Hence, 
time effect here is predictive since BMA is an active monomer that can grow quickly up 
to tens of thousands of grams per mole with very high polydispersity when it is 
subjected to uncontrolled polymerization [67]. Like any active monomers, high activity 
is gained from the presence of high donating functional groups which stabilize the 
propagating radicals to grow up to thousands or millions Da [68,69]. In BMA monomer, 
butyl group is the donating species which stabilize the propagation of BMA. For this 
reason, obtaining low molecular weight BMA polymer have required various control 
polymerization techniques such as atomic transfer radical polymerization (ATRP) [70] 
and the use of chelating agent [71]. 
Moreover, obtaining the aimed 24 units BMA polymer at short time interval (6 hr) 
elucidates the suitability of trithiocarbonate CTA agent for RAFT polymerization of 
BMA polymer. This could also be confirmed by having PDI value of 1.28 for 6 hr 
polymerized BMA polymer which is within the acceptable limit (≤1.3) (Figure 5.13) 
[72,73]. In literature, 2-Cyano-2-propyl dodecyl trithiocarbonate has been defined as the 
CTA of choice for the control polymerization of highly active methacrylate monomers 
like BMA [28,74]. The cyano propyl trithiocarbonate CTA agent was modified by 
Moad and co-workers to control the polymerization of very active monomers like 
styrene and methacrylate [75]. Accordingly, CTA agent with cyano R group was widely 
reported for the RAFT polymerization of BMA polymer [76–78].  
For all the above mentioned reasons, trithiocarbonate was selected as the CTA agent to 
polymerize BMA polymer for which it showed an acceptable suitability. With this 
achievement, BMA polymer that polymerized for 6 hr was selected to be the macro-
CTA agent for copolymerization with DMAEMA. 
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Copolymerization of BMA-DMAEMA Di-Block Copolymer 
As was described in previous section, BMA-CTA was used as the macro-CTA agent to 
copolymerize DMAEMA at various ratios. The codes P1, P2, P3, P4 and P5 were used 
to describe the di-block BMA:DMAEMA copolymer at ratios of (70:30, 60:40, 50:50, 
40:60 and 30:70) respectively. At this stage, these various ratios cannot be considered as 
ratios of hydrophilic to lipophilic polymers since DMAEMA block polymer is not a 
hydrophilic polymer. However, DMAEMA itself will be the source of the hydrophilic 
block in the next step after the betainisation of DMAEMA.  
Figure 5.14 A, B, C, D and E show the 1H-NMR spectra of the 5 BMA-DMAEMA 
polymers (P1, P2, P3, P4 and P5) respectively. These spectra were used to detect the 
ratios of BMA to DMAEMA block polymers in each BMA-DMAEMA di-block 
copolymer by comparing the area under the curve of the signal peaks from BMA to that 
of DMAEMA. In Figure 5.14, symbols A and B were donated for the methyl groups 
next to the ester groups in BMA and DMAEMA units respectively (Note: structures of 
BMA-DMAEMA di-block copolymers with symbols A and B are presented to the left 
in Figure 5.14). Each of these methyl groups possesses two protons which makes the 
ratio between their signal peaks representative to the ratio of the number of units of 
BMA and DMAEMA in each block polymers. The signal peak for the BMA methyl 
group was at 3.95 ppm and for DMAEMA methyl group was at 4.1 ppm (1H-NMR 
spectrum of the DMAEMA monomer is presented in Appendix F).  
To assess the suitability of the CTA agent in this study, the ratios of each block polymer 
detected by NMR was compared to the calculated ratio by the RAFT equation 5.1. 
Thus, if the detected ratios by NMR are equal to the calculated ratios then this indicates 
the suitability of the macro BMA-CTA agent on the polymerization of DMAEMA. To 
clarify the ratios obtained by NMR versus the calculated ones, Table 5.4 shows the 
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ratios of BMA and DMAEMA blocks in the copolymers that were detected by 
comparing the peaks in the NMR spectra. 
It can be seen that the detected ratios of BMA:DMAEMA are very close to the 
calculated ratios indicating the successful control polymerization of DMAEMA by the 
RAFT technique (Figure 5.14, Table 5.4). For example, P1 was aimed to be 
copolymerized at a ratio of 70:30 (BMA:DMAEMA) which is very close to the detected 
ratio by NMR (69:31) which indicates that trithiocarbonate is the proper CTA agent for 
the copolymerization of DMAEMA with BMA. This finding is consistent with previous  
study showed the successful use of trithiocarbonate for the di-block copolymerization of 
DMAEAM with styrene [79]. Additionally, trithiocarbonate as a macro-CTA agent was 
widely reported as a good source for di-block and tri-block control copolymerization 
[80,81].  
Moreover, Table 5.4 shows the molecular weight of each di-block copolymer measured 
by calculating the sum of the molecular weight of monomers in each copolymer. In this 
study, only NMR analysis was used to detect the molecular weight due to the technical 
issue associated with the use of GPC to measure the molecular weight of DMAEMA, 
where the DMAEMA amino group was found to interact with the GPC column. 
However, NMR analysis showed that the number of DMAEMA monomers that 
copolymerized to BMA was precisely correlated to the calculated one which indicates 
the well control on the degree of polymerization of DMAEMA polymer. 
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Table 5.4:  Calculated and detected ratios of BMA block polymer to DMAEMA block 
polymer and the molecular weights of each BMA-DMAEMA di-block copolymer. 
Symbol 
BMA-DMAEMA 
Calculated ratio 
BMA-DMAEMA 
Detected ratio by 
NMR 
BMA-DMAEMA 
Monomer ratio 
detected by NMR 
Molecular 
weight of 
detected by the 
NMR gm/mole 
P1 70:30 69:31 24:10 5370 
P2 60:40 58:42 24:16 6265 
P3 50:50 49:51 24:24 7517 
P4 40:60 39:61 24:36 9396 
P5 30:70 28:72 24:56 12528 
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Figure 5.14: 1H-NMR spectrum of the BMA:DMAEMA di-block copolymer in which 
the peaks showing the ratios of number of units of BMA to DMAEMA was highlighted. 
(A) (P1) BMA:DMAEMA (70:30). (B) (P2) BMA:DMAEMA (60:40). (C) (P3) 
BMA:DMAEMA (50:50). (D) (P4) BMA:DMAEMA (40:60). (E) (P5) 
BMA:DMAEMA (30:70). (Solvent: CDCL3). 
 
                                                                                                                                                   Chapter Five 
 
231 
 
Synthesis of BMA-Sulfobetaine Block Copolymer 
The main aim in this section is to synthesize an amphiphilic polymer in which the 
hydrophilic block is zwitterionic highly charged polymer. This aim was approached by 
the betainisation of the DMAEMA block polymer in the BMA-DMAEMA di-block 
copolymer. Structurally, each DMAEMA tertiary amino group was aimed to be attached 
to the γ methyl group of the propane sultone. This leads to the formation of a positively 
charged quaternary amino group and negatively charged sulfonate group on the same 
polymer chain. That is, on the same chain, there will be two oppositely charged 
functional groups that are separated by three methyl groups. This zwitterionic 
sulfobetaine polymer, could form a NP mimicking the muco-inert capsid shell virus in 
term of the densely charged surface with a net neutral charge [82].  
The reaction as described in the method section was carried out in THF for 72 hr 
followed by precipitation process. As a trial to facilitate the reaction between the 
propane sultone and BMA-DMAEMA, reaction was also carried out in DMSO which 
exhibited fast precipitation (24 hr) with no need for precipitating step. Visually, the 
precipitate formed from the reaction of the propane sultone and BMA-DMAEMA in 
DMSO seemed bulky and oily and soluble in most organic and aqueous solvent (visual 
appearance is described below in Figure 5.19). NMR analysis of the compound resulted 
from the reaction of BMA-DMAEMA with propane sultone in DMSO showed no 
structural indication of the presence of di-block copolymers, instead, NMR analysis 
showed the formation of dimethyl(sulfopropoxy) sulfonium salt (Figure 5.15A and 
5.15B). These findings made doubts about the reaction of BMA-DMAEMA with 
propane sultone.  
Hence, another reaction was carried out in which only DMSO and propane sultone were 
reacted so as to investigate the probability of the reaction of propane sultone with the 
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DMSO rather than BMA-DMAEMA. A bulky oily powder is formed which is visually 
similar to the one formed in the presence of BMA-DMAEMA. NMR analysis showed 
that the product of the reaction of propane sultone and DMSO alone was structurally 
similar to the product formed in the presence of BMA-DMAEMA (Figure 5.16A).The 
formation of dimethyl(sulfopropoxy) sulfonium salt by reacting DMSO with propane 
sultone was described early by Natus and Goethals (1965) [83]. However, our study, 
showed that DMSO and propane sultone could react preferably even with the prersence 
of other ingredients like BMA-DMAEMA di-block copolymer to form the same 
sulfonium salts (Figure 5.15B and Figure 5.16B). 
 
Figure 5.15: (A) 1H-NMR spectrum of the sulfonium salt resulted from the reaction of 
DMSO with propane sultone in the presence of BMA-DMAEMA. (B) Formation of 
dimethyl(sulfopropoxy)sulfonium salt when propane sultone was reacted with DMSO in 
the presence of BMA-DMAEMA (Solvent: CD3OD). 
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Figure 5.16: (A) 1H-NMR spectrum of the sulfonium salt resulted from the reaction of 
DMSO with propane sultone in the absence of BMA-DMAEMA. (B) Formation of 
dimethyl(sulfopropoxy)sulfonium salt when propane sultone was reacted with DMSO in 
the absence of BMA-DMAEMA (Solvent: CD3OD). 
On the other hand, the 5 BMA-DMAEMA di-block copolymers (P1, P2, P3, P4 and P5) 
were reacted with propane sultone in THF for 72 hr [55]. It was observed that the rate of 
the formation of BMA-sulfobetaine was directly correlated to the ratio of DMAEMA in 
the BMA-DMAEMA copolymer. Thus, for the polymers with higher DMAEMA ratios 
(P5 and P4), the products were started to precipitate after 24 hr. This fast precipitation 
was not observed for P3 with 50% DMAEMA, where the BMA-sulfobetaine polymer 
was started to precipitate within the last 24 hr of the reaction. Oppositely, for polymer 
with lesser DMAEMA ratios than BMA represented by P2 and P1, there was no 
precipitation even after 72 hr and products precipitated in excess acetone. The 
synthesized zwitterionic BMA-sulfobetaine copolymers were given symbols related to 
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the polymer they formed from. So, P2S, P3S, P4S and P5S were the BMA-sulfobetaine 
polymers that are formed from P2, P3, P4 and P5 respectively. 
Precipitation by acetone increased the yield (precipitation) of all polymers with the 
highest yield obtained for P5S followed by P4S then P3S and the lowest P2S. 
Alternatively, P1S showed very low yield made the use of this polymer in the 
formulation of NPs is unreasonable. To explain the reason for the correlation between 
the DMAEMA ratio and degree of betainisation, yield results could be described the 
opposite way, where the yield of BMA-sulfobetaine was inversely correlated with the 
ratio of BMA. In other words, increase in the ratio of the copolymer (BMA) induced a 
reduction or retardation of the reaction between DMAEMA and propane sultone.  
This is consistent with Bütün et al. (1997) study who showed that the increase in the 
ratio of the block polymer (2-diisopropylamino ethyl methacrylate) copolymerized to 
DMAEMA from 20% to 40% resulted in high reduction in the betainisation of 
DMAEMA [84]. Bütün explained the correlation between the ratio of the copolymer 
and the degree of betainisation of DMAEMA based on the steric effect of the 2-
diisopropylamino ethyl methacrylate that minimize the ability of tertiary amine of 
DMAEMA to react with propane sultone. This also explains our data and the reason for 
the massive reduction in the yield of the BMA-sulfobetaine when the BMA ratio 
increased reaching to 70%.  
Moreover, to confirm the synthesis of BMA-sulfobetaine, IR analysis was used to study 
the synthesis of BMA-sulfobetaine copolymers by investigating step by step structural 
transformation of the BMA to BMA-DMAEMA reaching to the synthesis of BMA-
sulfobetaine. Figure 5.17 shows consequently the IR spectra of BMA block polymer 
(Figure 5.17A), BMA-DMAEMA di-block copolymer (Figure 5.17B) and BMA-
sulfobetaine copolymer (Figure 5.17C) in which groups representing the structures of 
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BMA, BMA-DMAEMA and BMA-sulfobetaine polymer were highlighted (functional 
groups associated with CTA and AIBN initiator were not highlighted).  
Figure 5.17A shows the main functional groups of the BMA block polymer including 
the methyl, ether and the ester groups at 2850-3000, 1210-1320 and 1750-1820 cm-1 
respectively. Accordingly, Figure 5.17B shows the functional groups of DMAEMA 
polymer that is copolymerized to the BMA including the methyl, ether, ester and amino 
group at 2850-3000, 1210-1320, 1750-1820 and 1080 cm-1 respectively. Consequently, 
Figure 5.17C shows the formation of the sulfonyl group at 1030-1060 cm-1 and the 
sulfanol at 3200-3550 cm-1 besides the main functional groups of BMA. Thus, IR 
proved the formation of BMA-Sulfobetaine di-block copolymer; however, IR analysis 
could not confirm the total betainisation of the DMAEMA group and further NMR 
studies were required to show the ratio of BMA to sulfobetaine in the polymer.  
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Figure 5.17: IR spectrum showing the structural formation of BMA-sulfobetaine step 
by step where step (A) shows the functional groups of the BMA, step (B) shows the 
functional groups of BMA-DMAEMA while step (C) shows the functional groups of 
BMA-sulfobetaine. 
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On the other hand, NMR structural analysis of BMA-sulfobetaine faced technical 
difficulties associated with the solubility of the BMA-sulfobetaine in NMR solvents. 
That is, all the BMA-sulfobetaine copolymers were insoluble in most of the organic or 
aqueous solvents due to the very high water solubility of the sulfobetaine block polymer 
which makes the copolymers insoluble in most organic solvent used for NMR analysis. 
Only the copolymers P1S and P2S which contains 70% and 60% BMA showed some 
solubility in DMSO-d6 (not totally dissolved), this low solubility in DMSO made NMR 
spectra of P1S and P2S very noisy. Nevertheless, noisy NMR spectra enabled to run a 
structural comparison of the BMA-sulfobetaine polymers (P1S and P2S) with BMA-
DMAEMA polymers which was partly soluble in DMSO-d6 (comparison before and 
after the step of betainisation).  
NMR spectrum of BMA-DMAEMA copolymer (before the betainisation step) shows no 
signal peak at 4.5 ppm but 2 signal peaks at 3.9 and 4.1 ppm representing the BMA and 
DMAEMA signal peaks respectively (Figure 5.18A). On the other hand, Figure 5.18 B 
and C for P1S and P2S show the BMA signal peak at 3.9 ppm with disappearance of the 
DMAEMA signal peak at 4.1 and appearance of a signal peak at 4.5 ppm indicating 
structural change in the DMAEMA block copolymer. This structural change (peak at 
4.5 ppm) is associated with the formation of methyl group next to the quaternary amino 
group of DMAEMA indicating the betainisation of DMAEMA.  
Moreover Figure 5.18 B and C show correlations between the ratios of the signal peaks 
at 3.9 ppm (BMA methyl group) and the signal peak at 4.5 ppm (methyl group next to 
the quaternary amino group) in P2S and P1S. Thus, for P2S, the ratio of the BMA signal 
peak to the sulfobetaine signal peak was 60% to 40% (Figure 5.18B) which is the same 
ratio for the original P2 BMA:DMAEMA copolymer. Similarly, for P1S, the ratio of the 
BMA signal peak to the sulfobetaine signal peak was 70% to 30% (Figures 5.18C) 
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which is the same ratio for the original P2 BMA:DMAEMA copolymer. These NMR 
spectra indicate the complete betainisation of DMAEMA block and formation of BMA-
Sulfobetaine at the same original ratio of BMA-DMAEMA for both P1S and P2S.  
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Figure 5.18: 1H-NMR spectrum. (A) BMA-DMAEMA polymer. (B) BMA-
sulfobetaine (60:40) P2S. (C) BMA-sulfobetaine (70:30) P1S. 
Accordingly, the physical appearance of BMA-sulfobetaine copolymers formed in THF 
was entirely different from that of the sufonyl salt formed from reaction of propane 
sultone with DMSO. As was described earlier, sufonyl salt was oily white powder. 
Oppositely, pure crystals were formed for all BMA-sulfobetaine polymers resulted from 
the reaction in THF. The colour of these crystals varied from yellowish white for the 
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polymers with high BMA ratio (P1S and P2S) to white for the polymers with low BMA 
ratios (P4S and P5S). This yellowish appearance for P1S and P2S reflects the high 
content of the BMA polymer which has physical appearance of yellow brown oil.  
3.b Synthesis and characterization of the Novel Zwitterionic NPs  
Polymer Solubilisation 
All the methods for the synthesis of polymeric NPs require polymers to be dissolved in 
a suitable organic or aqueous solvents [85]. BMA-sulfobetaine is characterized by a 
very lipophilic block polymer (BMA) that is soluble in highly lipophilic organic solvent 
and a very hydrophilic block sulfobetaine that is insoluble in any organic solvent but 
water. Any attempt to solubilize this zwitterionic hydrophilic-lipophilic copolymer in 
either organic solvent or aqueous phase alone did not work and polymer underwent 
micellization. Based on previous solubility studies on zwitterionic hydrophilic-
lipophilic di-block copolymers, mixtures of organic and hydrophilic solvents were used 
to dissolve these types of polymers [86].  
Thus, various mixtures of organic solvents and DDW were used to solubilize this 
zwitterionic polymer (Figure 5.19). These BMA-sulfobetaine polymers were insoluble 
in all tested mixture except the mixture of methanol and 1 N HCL which solubilized the 
polymer at a desired concentration (1 mg per 100 µl). However, the use of 1 N HCL 
was not suitable due to the high acidity of the medium which can affect the NPs 
themselves and it was necessary to replace HCL with another highly ionised hydrophilic 
solvent. This highly ionized media should be a highly concentrated electrolyte solvent 
that can be mixed with methanol to replace HCL acid. Thus, highly concentrated NaCL 
(2 M NaCL) solution was used due to its high ions content.  
                                                                                                                                                   Chapter Five 
 
241 
 
This mixture of 2 M NaCL and methanol showed a high solubilisation tendency towards 
all BMA-sulfobetaine copolymers. As was described in Table 5.2, the ratio of the 
organic phase to the hydrophilic phase (mtheanol to 2M NaCL) was varied depending 
on the ratio of the BMA to sulfobetaine with an average solubility of 10 mg/ml. As 
example, the ratio of the methanol:NaCL increased from 50:50 for P2S (BMA: 
sulfobetaine (60:40)) to 20:80 for the P5S (BMA:sulfobetaine) (30:70).  
The solubilizing effect of 2 M NaCL was explained depending on the theory of the anti-
polyelectrolyte effect [30]. This theory describes the conformation of the zwitterionic 
polymer in the aqueous phase as a collapsed globular structure due to dipolar 
interactions between the opposite charges. Addition of low molecular weight 
electrolytes such as NaCL will screen these dipolar interactions making the polymer 
having more extending conformation. This extended conformation enables the organic 
solvent like methanol to solubilize the lipophilic block that was originally hidden in the 
collapsed globular structure.  
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Figure 5.19: Solubilisation process of the BMA-sulfobetaine polymers including the 
use of various organic and hydrophilic mixtures.  
Fabrication of NPs by Nano-Precipitation Method 
Nano-precipitation technique is a one-step simple and reproducible method for 
formulation of NPs; therefore, it was selected for the fabrication of Sulfobetaine NPs 
[87]. Before analysing the data of sulfobetaine NPs, it is important to clarify the 
conditions at which sulfobetaine NPs were nano-precipitated. As was seen in Table 5.2, 
all BMA-sulfobetaine copolymers were nano-precipitated following the same 
parameters of polymer concentration in the solubilisation medium (5 mg/0.5 ml) and the 
rate of nano-precipitation (20µl/min). It is known that the solubilisation conditions of 
polymers prior to the nano-precipitation process affect the sizes of the particles. For 
example, changing the solubilisation solvent can reduce the solubility of polymer which 
in turn can increase the particle sizes of NPs [88]. However, in this section, studying the 
impact of solubilizing condition on the particle sizes was restricted by the limited 
solubility of the BMA-sulfobetaine copolymers (5 mg/0.5 ml) and the inability to 
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change the solvents in the medium since the polymer was soluble only in the mixture of 
methanol: 2 M NaCL.  
Accordingly, the volume of the external phase (10 ml) and the rate of precipitation 
(20µl/min) were selected depending on the reproducibility and consistency of the 
results. Also, NPs were fabricated using 2 buffers (PBS pH 6.8 and pH 7.4) as the 
external phases to mimic the intestinal and physiological pH. The formulated NPs were 
characterised for their particle sizes and zeta potentials to ensure the formation of 
Zwitterionic NPs with small particle sizes at the intestinal and physiological pH. Also, 
particle sizes and zeta potentials were measured at a consequent time intervals of 0.5, 1, 
2, 4 and 6 hr at temperatures of 25 and 37 °C to ensure the stability of these particles 
against aggregation during the time required for particles administered orally to reach 
the site of action [89,90]. 
Table 5.5 shows the effect of loading of Lumogen, freeze drying process, type of 
external media and storage time on particles sizes and zeta potentials of sulfobetaine 
NPs. All studies on the physicochemical properties were carried out on NPs suspensions 
with external phase PBS pH 6.8 which is the intestinal mucus pH, while, the effect of 
the external phase (PBS pH 7.4) was also summarized in the table by the term (no 
change). Accordingly, the effect of storage time on the particle sizes and zeta potential 
of sulfobetaine NPs at various time intervals (0.5, 1, 2, 3, 4, 6) hr and at (25 and 37) °C 
was summarized in Table 5.5 by the term (no aggregation) since these values were 
measured at consequent time intervals.  
Table 5.5 shows that all the sulfobetaine NPs expressed a particle size below 50 nm. 
The smallest particles size was 28 nm for P2S with 60% BMA and the largest particle 
size was 48 nm for P5S with 30% BMA. Accordingly, polydispersity of these particles 
were within the range of (0.42-0.48) which is within the high acceptable limit (<0.5). 
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This high polydispersity was observed for all the NPs formulated by the nano-
precipitation method, for example, Figure 5.20 shows the polydispersity obtained for 
P2S NP where the particle size was small and the polydispersity was 0.42. Moreover, 
zeta potentials of these NPs were near neutrality with slightly negative charges ranging 
from -0.57 to -2.26. As example, Table 5.6 shows the three zeta potential readings of 
P3S in the Malvern Nano ZS, it can be seen that this NP has slightly negative charge. 
Moreover, all the zeta potential and particle size values did not change for these NPs 
when the external phase was changed from PBS pH 6.8 to 7.4. 
Also, Table 5.5 shows the effect of Lumogen loading on the particle sizes and zeta 
potential of these sulfobetaine NPs. It can be seen that Lumogen loading did not have 
any impact on the particle size and zeta potential of all sulfobetaine particles. Figure 
5.20 shows the particle size of P2S loaded with 0.1% Lumogen which was the same size 
of the P2S without Lumogen. Accordingly, Table 5.5 shows the particle sizes of 
sulfobetaine NPs after freeze drying process. It can be seen that there were no changes 
in the particle sizes of sulfobetaine NPs before and after the freeze drying process 
indicating that sulfobetaine NPs were re-suspendable after freeze drying and retained 
the original particle size. Lastly, Table 5.5 shows that there was no aggregation of 
particles after 6 hr at 25 °C and 37 °C. The stability of these particles against 
aggregation is also presented in Table 5.7 which shows no changes in the particle size 
of one of the sulfobetaine NPs at consequent time intervals of 0.5, 1, 2, 3, 4 and 6 hr.  
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Table 5.5: Particle sizes and zeta potentials of sulfobetaine NPs at external phase PBS pH6.8 and after Lumogen loading, freeze drying, at PBS pH 7.4, and after 
6 hr aggregation studies at 37 °C and 25 °C. 
Code 
(BMA:Sulfobetaine) 
pH 6.8 Lumogen loading Freeze drying Change of particle 
size and zeta 
potential 
when external 
phase changed to 
PBS pH 7.4 
Change of particle 
size and zeta potential 
after 6 hr storage at 
25 °C and 37 °C 
Zeta Potential (mV) 
Mean (± s.d) 
Particle Size   
(nm) 
Mean (PDI) 
Zeta Potential 
(mV) 
Mean (± s.d) 
Zeta Potential 
(mV) 
Mean (± s.d) 
Zeta Potential 
(mV) 
Mean (± s.d) 
Zeta Potential 
(mV) 
Mean (± s.d) 
P2S (60:40) -2.13 (±1.59) 28 (0.42) -0.73 (±2.33) 28 (0.34) -4.99 (±4.12) 26 (0.31) No change No aggregation 
P3S (50:50) -1.82 (±1.12) 47 (0.48) -2.12 (±3.19) 45 (0.46) -2.78 (±2.52) 46 (0.36) No change No aggregation 
P4S (40:60) -2.26 (±0.36) 45 (0.43) -1.31 (±1.20) 43 (0.33) -3.45 (±2.31) 39 (0.44) No change No aggregation 
P5S (30:70) -0.57 (±0.06) 49 (0.47) -2.44 (±1.59) 48 (0.47) -1.08 (±2.01) 51 (0.48) No change No aggregation 
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Figure 5.20: Particle size and polydispersity of P2S NPs indicating the high polydispersity of 
these particles. 
 
Table 5.6: Zeta potential values of P3S NP showing the near neutral negatively charge nature 
of these NPs. 
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Table 5.7: Particle size of a sulfobetaine NP showing the particle sizes at consequent time 
intervals up to 6 hr and at 25 and 37 °C. 
 
It can be observed that these NPs have very small particle sizes. These small particles sizes 
are consistent with previous studies which showed that zwitterionic sulfobetaine NPs had 
particle sizes smaller than 50 nm [56,91] . This finding can be interpreted depending on the 
chemical nature of the synthesized di-block copolymer. That is, the size and type of NPs 
formed from pre-synthesized di-block copolymers is highly affected by the molecular weight 
of the lipophilic and the hydrophilic block polymers [92].  If the lipophilic block polymer is 
smaller than 9000 Da, micelles-like NPs are formed which are characterised by particle sizes 
as small as micelles [93,94]. This is in agreement with the synthesized BMA-sulfobetaine in 
this study in which the molecular weight of the BMA lipophilic block polymer is 3500 Da 
(much less than 9000 Da). Hence, these sulfobetaine NPs should have small particle sizes 
(less than 50 nm). Accordingly, the high polydispersity of these NPs is mainly due to the 
mechanism of formation of these particles by the nano-precipitation technique where the 
solubilised polymer is added drop-wise into the external phase [95]. After dropping into the 
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external phase, the solubilisation media (methanol and 2 M NaCL) diffuses quickly into the 
external phase leaving the polymer to undergo fast precipitation. This precipitation is very 
quick and not homogeneous leads to the formation of nano-sized particles with high 
polydispersity.  
Accordingly, zeta potentials of these particles were shown to be slightly negative near neutral 
charge. These near neutral zeta potential values indicate the complete betainisation of the 
DMAEMA polymer where each positively charged amino group was neutralized by a 
negatively charged sulfonate group that existed on the same polymer chain [96]. The slightly 
negative charge of these particles is the result of the adsorption of anions from the external 
media onto the surface of the sulfobetaine polymer [97]. The phenomenon of anions 
adsorption onto the zwitterionic sulfobetaine NPs is called chameleon effect [98]. Also, this 
probably could be due to the position of the charged groups where the negatively charged 
sulfonate is located at the terminal position on the polymer chain making these groups in 
direct contact with the interface inducing slightly negative charge at the surface of the NPs. 
Table 5.5 also showed that the change of the external phase did not affect the 
physicochemical properties of these particles. This is not surprising since both of the 
functional groups of sulfobetaine polymer (positively charged quaternary amine and 
negatively charged sulfonate) do not undergo protonation at any pH value [99]. In other 
words, the magnitude of the negative value of sulfonate and the positive value of quaternary 
amine will not change when pH of the media slightly changed from 6.8 to 7.4. As a result, no 
change on the nature of the surfaces of sulfobetiane NPs can be obtained at PBS pH 7.4 
which leads to no change in the zeta potential and particle sizes of these sulfobetaine NPs. 
The other factor which was studied in this section was the effect of Lumogen loading on the 
particle sizes and zeta potential of NPs. Previous studies showed the same lack of influence 
of lipophilic cargo on the sizes of NPs when it is incorporated into the lipophilic core of these 
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particles [100,101]. As example, the very lipophilic and highly molecular weight agent 
(docetaxel) did not increase the particle size of PLGA when it was loaded at a concentration 
of 20% [102]. Accordingly, the Lumogen red was incorporated into the lipophilic core of the 
sulfobetaine NPs at much lower concentration (0.1%) which eliminates any chance to 
increase particle sizes of these NPs.  
Moreover, these sulfobetaine NPs were shown to be re-suspendable after the freeze drying 
process when trehalose was used the cryo-protectant at 5:1 weight ratio. This is in accordance 
with previous studies which showed the efficiency of trehalose at this weight ratio to re-
suspend NPs to its original particle sizes after freeze drying [103,104]. The results from 
freeze drying make these particles practically suitable for in vivo and other pharmacological 
studies since these particles can be easily re-suspended in the buffer phase. 
Lastly, it was shown in Table 5.5 and Table 5.7 that these particles were stable for the time 
and temperatures that they studied for. This stability was due to the highly charged nature of 
these particles where both of the quaternary amine and sulfobetaine are totally ionized at all 
pH values [105]. That is, these groups do not form H-bonding so when particles approached 
each other, the highly negatively charged sulfonate and the highly positively charged amino 
group will prevent any aggregation of particles due to the high repulsion forces they exert 
against approaching particles [106,107] .  
3.c Loading Capacity and in Vitro Release of Lumogen Red (Lipophilic Cargo) 
As was described in previous chapters, all the tested NPs were loaded with 0.1% Lumogen 
red and they were successfully tracked by the MPT technique to measure their diffusion 
coefficient through mucus barrier. This is in accordance with a previously reported work 
which showed no aggregation or self-quenching of Lumogen red  when it is loaded in NPs at 
a concentration less than 1% [108]. This means that sulfobetaine NPs should be successfully 
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loaded with 0.1% Lumogen red to be tracked by the MPT technique. Hence, to meet this 
requirement, loading capacity and the in vitro release of Lumogen red was studied for 
sulfobetaine NPs loaded with 0.1% Lumogen red.  
On the other hand, as novel NPs, the maximum loading capacity of sulfobetaine NPs to 
lipophilic cargo could reveal the nature of these NPs. Lumogen red is very large lipophilic 
molecules (Figure 5.21) with a molecular weight of 1079 gm which makes the loading of it to 
be very challenging  [109].  Among the four sulfobetaine NPs, NP with the biggest lipophilic 
core (60%, P2S) and NP with the smallest lipophilic core (30%, P5S) were selected to be 
studied for their maximum loading capacity of Lumogen red. To study the maximum loading 
capacity for P5S and P2S, Lumogen was aimed to be loaded at very high concentration 
(50%).  
  
Figure 5.21: Chemical structure of Lumogen red 305.  
Table 5.8 shows the EE% and LD% of the sulfobetiane NPs for the Lumogen red. The data in 
Table 5.8 was divided into 2 sections, second and third columns show the loading data of 
0.1% Lumogen red, while, columns four and five show the loading data for 50% Lumogen 
red. Firstly, for the trial to load 0.1% Lumogen red, it can be seen that all the sulfobetiane 
NPs showed 100% EE% and 0.1% LD%. In other words, Lumogen red was loaded 
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completely into the sulfobetaine NPs at the concentration of 0.1% which was not surprising at 
this low concentration to be incorporated into the BMA core.  
Table 5.8: Entrapment efficiency and loading capacity of sulfobetaine NPs to Lumogen red 
lipophilic dye at concentrations of 0.1% and 50%. 
Sulfobetaine 
NPs 
 (0.1%) Lumogen   (50 %) Lumogen  
Entrapment 
Efficiency %  
Loading 
Capacity %  
Entrapment 
Efficiency % 
(± s.d.) 
Loading 
Capacity % 
(± s.d.) 
P2S 100 0.1 82.26 (7.40) 40.33 (3.15) 
P3S 100 0.1 - - 
P4S 100 0.1 - - 
P5S 100 0.1 4.53 (0.92) 2.26 (0.46) 
On the other hand, for loading of 50% Lumogen red, Table 5.8 shows a big variation between 
the EE% and the LD% of P2S and P5S. While, P2S showed very high EE% (82.26%) and 
LD% (40.33%), P5S showed much lower EE% and LD% for Lumogen red (4.53 % and 2.26 
% respectively). This reveals the very high capacity of sulfobetaine NP to load lipophilic 
cargo, where the very small (25 nm) P2S NPs showed very high loading capacity to the very 
large lipophilic molecule. Moreover, reasonably, this loading capacity for sulfobetaine NPs 
was associated with the ratio of the lipophilic BMA core, i.e, the loading capacity increased 
from 2.26% to 40.33% when the BMA ratio increased from 30% to 60%. This is in 
accordance with previous studies which showed positive correlations between the loading 
capacity for lipophilic cargos and the ratio of the lipophilic core in the NPs [110,111].  
Moreover, in vitro release was studied for Lumogen red from sulfobetaine NP formulae 
loaded with 0.1% and 50%. Firstly, for sulfobetaine particles loaded with 0.1%, this study 
revealed no release of Lumogen red for all sulfobetaine particles (P2S, P3S, P4S and P5S) at 
all the time intervals, i.e, no release was detected even after 24 hr meaning that Lumogen red 
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was located in the NPs for 24 hours. These characteristics indicate the photo-stability of 
sulfobetaine NPs loaded with 0.1% during the release conditions which make the Lumogen 
red sufficiently stable to be tracked by the MPT technique. In other words, high and fast 
release of Lumogen red from the particles results in inadequate dye content in the particles 
and inability to track them. Also, high release of the dye is associated with high noise which 
affects the accuracy of tracking of these particles.  
On the other hand, in vitro release of Lumogen red from particles loaded with 50% was 
carried out to ensure the release of the lipophilic cargo from sulfobetaine NPs. These 
sulfobetaine NPs loaded with 50% Lumogen red exhibited a release profile dependent on the 
ratio of the BMA core. Figure 5.22 shows the in vitro release profile of Lumogen red from 
formulae P2S and P5S loaded with 40.33% and 2.26% Lumogen red respectively. It can be 
seen that both particles exhibited incomplete release profile of Lumogen red after 24 hr, 
where P5S and P2S showed 80% and 48% release after 24 hr. P5S NP exhibited fast release 
(33%) within the first 2 hr followed by a gradual release within the time intervals between 2 
and 8 hr. Oppositely, P2S showed a gradual release reaching to 30% after 8 hr. Both formulae 
showed almost a plateau release profile after 8 hr up to 24 hr. That is, P2S showed only 7% 
release within the time interval between 8 and 24 hr, while P5S showed 13% release for the 
same time interval. This indicates that for both formulae, 83% of the total release was 
occurred within the first 8 hr and 16% within the time interval between 8 and 24 hr.   
                                                                                                                                                   Chapter Five 
 
253 
 
 
Figure 5.22: In vitro release profile of Lumogen red from sulfobetaine NPs (P2S and P5S). 
The release profile of sulfobetaine particles loaded with 0.1% Lumogen red shows that that 
Lumogen red was preferably retained in the BMA lipophilic core and have not been released 
into the hydrophilic medium (PBS pH 6.8). This was also observed in the Epifluorescence 
microscopy (next section), where no released dye was viewed during the measurement of 
diffusion coefficient of sulfobetaine particles. This is in agreement with previous study on the 
release of a lipophilic drug (amiodarone) encapsulated at low concentration in a lipophilic 
core (solid lipid NP), where no release was detected into the phosphate buffer media even 
after 4 days of the in vitro dialysis study [112]. This indicates the suitability of loading of 
Lumogen at 0.1% concentration since the dye release is not preferred in the study of diffusion 
of particles through the mucus where the tracking of particles depends on the stability of the 
dye within the labelled particles. 
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Accordingly, the release profile of P2S loaded with 40% Lumogen and P5S loaded with 
2.26% Lumogen was low for both formulae. Specifically, P2S showed only 48% Lumogen 
release after 24 hr.  This low release is consistent with previous study which showed very low 
release of a lipophilic dye (Coumarine 6) from NPs with lipophilic core (polystyrene or 
PLGA NPs) in a buffer medium pH 6.8 (intestinal pH) [113]. The low release of Coumarine 6 
was attributed to the high solubility of the lipophilic dye in the lipophilic NP and low 
solubility in the hydrophilic external medium.  Similarly, in this study, the release is affected 
by the very hydrophilic nature of the external medium (PBS pH 6.8) which limits the release 
of the very lipophilic molecules like Lumogen. Use of co-solvents during the in vitro release 
should improve the release of the lipophilic molecule, however, this technique can damage 
the NPs [114].  
3.d Study of diffusion of sulfobetaine NPs through the Cardiff Native Mucus” Model 
As described in previous chapters, the capsid shell virus represents with an electrically neutral 
high charge density surface represents a model in nature inspirational for the construction of 
synthetic particles able to permeate mucus with high efficiency. However, the synthesis of 
particles replicating such properties is compromised by issues of particle aggregation.  
Sulfobetaine NPs exhibited relatively small particle sizes (ca 50 nm). While sulfobetaine is 
well-known for anti-bioadherant properties, the literature (both basic and patent) has to date 
not revealed evidence of any studies addressing the permeability through mucus of 
sulfobetaine NPs or NPs formed from the BMA-sulfobetaine copolymer.  
Table 5.9 shows for the various  sulfobetaine NPs  synthesised the: physicochemical 
properties of the particle (Zeta potential and particle size); MPT diffusion data [cm2 S-1 x 10-
9] in the Cardiff mucus model < Deff>   and in water  D°  (calculated by Stocks Einstein 
equation); the ratio of < Deff>   to D° expressed as a %; and in the last column the % of 
diffusive particles. The <Deff> is a measure of the absolute diffusion of the NPs through 
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mucus reflecting both surface chemistry and particle size, while the % ratio <Deff>/D°  is a 
measure of the diffusion of the NPs through mucus reflective of surface chemistry 
characteristics alone, i.e. normalised against differences in particle size.  Figure 5.23A shows 
the ensemble effective diffusion coefficient < Deff>   versus the particle size for each of the 
sulfobetaine particles, while Figure 5.23B shows the zeta potential of each sulfobetaine 
particle versus the % ratio < Deff>  to D°.  
Table 5.9 shows that apart from the 60:40 BMA:sulfobetaine (P2S) particle, the increase in 
the proportion of sulfobetaine has essentially no effect upon particle size. Similarly, as would 
be predicted by the combined +ve and -ve charge within the same polymeric monomer there 
are no noticeable differences in zeta potential.  As a result the diffusion data for the P3S, P4S, 
P5S particles is mainly dependent on the ratio of BMA to sulfobetaine. Since the particles are 
characterized by the distribution of the highly charged sulfobetaine on the surface and the 
lipophilic BMA in the core, any increase in the ratio of sulfobetiane indicates the increase of 
the highly charged sulfobetaine at the NP surface. Hence we are able to identify, essentially 
independently of zeta potential and particle size, the influence of charge density at the particle 
surface upon particle diffusivity through the mucus. 
Particle diffusivities measured by both <Deff> and <Deff>/D° were greater as the ratio of the 
sulfobetaine increased (Table 5.9 and Figures 5.23A and 5.23B). Statistical analysis showed 
that % ratio <Deff>/D° was increased significantly with each increase of sulfobetaine ratio by 
10%.  These findings strongly support the influence of surface chemistry and in this particular 
case overall density of matched +ve and –ve surface charges on their ‘slippery properties’ 
through mucus. This is put into some perspective when the data is referenced to the P2S 
(60:40 ratio BMA:sulfobetaine) formulation which despite the smaller size (28 nm) resulted 
in an ensemble effective diffusion <Deff>  of only approximately 30% of the P5S value 
(30:70 ratio), and with the <Deff>/D°  of the P2S some x6-7 fold lower than the P5S particles. 
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Hence from this data it would appear, it is the increase of sulfobetaine content rather than 
particle size which is a dominant factor to drive mucus permeability of the particles (Figure 
5.23A).  
This is also a reasonable conclusion to reach when the diffusion data is viewed with respect to 
particle zeta potential.  While all the particles were close to neutral they did display an overall 
net –ve value (from -2.26 to -0.57).  However, comparing P4S (40:60 ratio) and zeta potential 
of -2.26 mv to the P2S formulation, zeta potential -2.13 mv, once again shows the importance 
of the overall density of matched +ve and –ve surface charges in eliciting improved mucus 
permeation (Figure 5.24B).  
These findings are consistent with the work of Lowe et al on the anti-adherent activity of the 
BMA-sulfobetaine polymer [55] which involved BMA-DMAEMA polymerised at two 
different ratios (90:10) and (70:30) with sulfobetaine to form BMA-sulfobetaine polymers 
coating Poly (methyl methacrylate) discs. Both polymer ratios exhibited high antibacterial and 
anti-macrophage adhesion and dirt resistance but with the BMA-sulfobetaine with the ratio of 
70:30 displaying a significantly higher anti-adherent properties than that of the 90:10 ratio.  
The impact of sulfobetaine on the anti-adherent properties of polymer films has also been 
reported by Li et al [39]. Li grafted poly(vinylidene fluoride) hollow membrane surfaces with 
various ratios of sulfobetaine polymer and found that the increased of grafting sulfobetaine 
from 153.2 µg/cm2 to 244 µg/cm2 was associated with a 90% reduction in protein adsorption 
from 21.4 µg/cm2 to 2 µg/cm2 which was further reduced when sulfobetaine coating was 
increased to 600 µg/cm2.  
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Figure 5.23: (A) Mucus diffusion <Deff> versus particle size of various sulfobetaine NPs in 
the “Cardiff Native Mucus” model. (B) % ratio <Deff>/D° versus zeta potential of various 
sulfobetaine NPs in the “Cardiff Native Mucus” model. 
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Table 5.9: Physicochemical characteristics and diffusion kinetics through the “Cardiff native mucus” barrier of the various sulfobetaine NPs. 
Statistical analysis carried out by One-way analysis of variance test (n=3). 
BMA:Sulfobetaine Code 
Zeta Potential 
(mV) 
Mean (± s.d.) 
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  
(mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% Ratio 
<Deff> / D° 
% Diffusive 
particles 
60:40 P2S -2.13 (±1.59) 28 (0.42) 160.50 
0.2828 
(±0.0768) 
0.1762 35 
50:50 P3S -1.82 (±1.12) 45 (0.48) 99.87 
0.3447 
(±0.0683) 
0.3452 44 
40:60 P4S -2.26 (±0.36) 45 (0.43) 99.87 
0.5747 
(±0.1019) 
0.5754 54 
30:70 P5S -0.57 (±0.06) 49 (0.47) 89.88 
1.0692 
(±0.1861) 
1.1895 70 
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Table 5.9 also shows for each of the formulations, the % diffusive particles within the 
mucus. This parameter is determined by measuring a particle’s diffusion at discrete 
points over a1 second duration. A particle that shows a Deff at 1 second equal to or 
greater than 90% of the Deff at the 0.2 second point is defined as ‘diffusive’. The 
principle relies on the probability that as the contact time between a particle and mucus 
increases, e.g. 0.2 second to 1 second, then the trapping by the mucus will increase. 
Hence, only diffusive particles possess a Deff at the longer time point of 1 second that is 
equal to or greater than 90% of the <Deff> at shorter period 0.2 second.  Figure 5.24 
illustrates this behaviour for 20 randomly selected particles from a total of 360 particles 
of formula P3S; these particles were tracked by the MPT technique.  It can be seen that 
11 (45%) of the randomly selected 20 particles showed an increase of the diffusion at 
the  longer time point as compared to the shorter time point. For each NP species, the 
percent of diffusive particles was measured for 360 particles. On this basis, for P3S 
formula, 45% of particles were identified as the proportion of the diffusive particles.  
 
Figure 5.24: Deff for each of 20 randomly individual particles Selected from P3S. The 
online source random.org was used to randomly select the particles. 
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Table 5.9 shows a gradual increase in the % of diffusive particles as the sulfobetaine 
content increases. That is, the percent of diffusive particles increase by 1.2 times with 
each 10% increase in the ratio of sulfobetaine. For example, percent of diffusive 
particles was increased from 44% to 54% and from 54% to 70% when sulfobetaine ratio 
was increased from 50% 60 60% and from 60% to 70% respectively. In general, all the 
sulfobetaine particles showed a high % diffusive particles as compared with the 
respective data obtained from all other particles analysed by consortium partners 
(Chapter Four),  this includes PEG-PLGA hydrophilic particles which is known to 
readily permeate mucus  and which displayed a % diffusive particles of 32% (Chapter 
Four) lower than any of the sulfobetaine  particles reported here.   
The mathematical correlation of the increase in the particle diffusivity with the increase 
in sulfobetaine content is consistent with the hypothesis of this study which is the direct 
correlation between the diffusion behaviour of NPs and the ratio of sulfobetaine at the 
NPs shell.  Figure 5.25 summarizes the effect of the increase of the sulfobetaine ratio on 
particle behaviour in the mucus. Specifically, the gradual increase of sulfobetaine ratio 
to the BMA is associated with an increased covering of the lipophilic BMA core by the 
densely charged sulfobetaine.  The P2S particle has a ratio of 60:40 (BMA:Sulfobetaine) 
which makes the lipophilic core (BMA) relatively large compared to the content of the 
sulfobetaine (40%) which is insufficient to prevent some contact of BMA with the  
mucus lipophilic components and hence the introduction of hydrophobic-hydrophobic 
interactions.  With the gradual increase of sulfobetaine to 50% (P3S), the exposed area 
of BMA is reduced such that a BMA interaction with the mucus components is reduced. 
It is also notable that with the relatively greater sulfobetaine content, the charge density 
at the surface of particles increases.  As a result of the above, the <Deff>, %<Deff>/D° 
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and the % diffusive particles increase in gradual manner with the increase of 
sulfobetaine ratio.  
 
 
Figure 5.25: Effect of charge density on the surface of sulfobetaine NPs and the 
exposed area of the BMA core on the particles’ interaction with mucus. 
Figure 5.26 shows the heterogeneity of particle diffusion through mucus. Specifically, 
for each  sulfobetaine NP species, it shows the ranking of 360 particles (all the same 
formulation) based on their diffusion in mucus (Deff), with the fastest particles in the 90 
percentile, the definition of which is the Deff value below which 90% of the Deff values 
within the particle population occur.  The correlation of the increase in the diffusivities 
of particles with the increase of sulfobetaine ratios is again consistent within this 
particular set of data. The Deff values associated with 50 percentile for each 
sulfobetaine NP formulation displayed a relatively high diffusion through the mucus (> 
2x10-9 cm2s-1) as compared to   the data obtained for NPs in Chapter Four and 
encouragingly the formulations showed a low degree of heterogeneity (ratio of Deff for 
90% vs Deff for 10%).  
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In particular it is noteworthy that the heterogeneity decreases as the sulfobetaine ratio 
increases, i.e. particles with a more complete shell of sulfobetaine covering the 
lipophilic BMA core. In other words, the highest ratio of sulfobetaine is the more 
compact distribution of sulfobetaine at the surface of particles which makes the surface 
distribution of sulfobetaine uniform and facilitates good particle diffusion. This may be 
realised by considering the difference between the fastest 90 percentile and slowest 10 
percentile is only 28-fold for the P5S (Figure 5.26D). Accordingly, difference in 
diffusion between the fastest 90% and slowest 10% for P4S (Figure 5.26C) and P3S 
(Figure 5.26B) were 1090 and 1731 times respectively. For P2S (Figure 5.26A) where 
the lipophilic BMA ratio (60%) is higher than the hydrophilic sulfobetaine ratio (40%), 
the difference between the fastest 90% and slowest 10% was much higher (4755 times) 
than other sulfobetaine NPs.  
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Figure 5.26: Heterogeneity of particle movement through mucus.  For each particle 
type, an effective diffusion coefficient (Deff) was calculated for each of 360 individual 
particles over a time interval of 1 sec. The data was ranked into percentiles from the 90th 
through to 10th percentile, where the 90th percentile is the Deff value below which 90% 
of the Deff observations may be found. (A) P2S, (B) P3S, (C) P4S and (D) P5S. 
 3.e Comparison of Sulfobetiane NPs Diffusion through the “Cardiff Native 
Mucus” Model with other Nano-Strategies. 
The main aim of synthesizing this novel zwitterionic sulfobetaine NPs is to produce 
viral like NPs with densely charged surface but with net neutral charge and with proper 
physicochemical properties for clinical uses. However, all the above-mentioned 
properties is a pathway to reach to the main aim of this work which is producing highly 
mucus permeable NPs. Previous section showed the comparison of diffusivities of the 
various synthesized sulfobetaine NPs through the mucus. It was shown that sulfobetaine 
ratio is the critical factor for the diffusion of particles through the “Cardiff native 
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mucus” model barrier. In this section, sulfobetaine NPs are compared with all other NPs 
representing various strategies to overcome the mucus barrier (chapter three). 
Figure 5.27A shows the <Deff> versus particle size of the various sulfobetaine NPs 
marked in red as compared with all other NPs which have shown high diffusivities in 
Chapters three (SMEDD systems and PEG-PLGA NPs). Figure 5.27B illustrates the 
%<Deff>/D° versus the zeta potential of the same groups of particles in figure 5.27A. 
For better clarification of the data of <Deff> versus particle size and %<Deff>/D° 
versus zeta potential, figure 5.28 A and B show these values presented in histogram 
where more attention was given to the particles having high diffusion through the 
mucus barrier (sulfobetaine NPs, SMEDD systems and PEG-PLGA NPs).  
Figure 5.27A and 5.28A show that all the sulfobetaine NPs exhibited high <Deff>(s) as 
compared to other particles. In specific, P5S and P4S showed superior diffusions 
coefficients through the mucus barrier as compared with other particles specifically the 
known highly mucus permeable PEG-PLGA NP. Only SMEDD system A in which a 
combination of SMEDD system and mucolytic agent was used, showed higher <Deff> 
than P4S but not P5S. Accordingly, P2S and P3S were within the fastest 6 particles 
among the 113 particles that were tested for their diffusion through the “Cardiff native 
mucus” model.  
Regarding the comparison based on %<Deff>/D°, figure 5.27B and 5.28B demonstrates 
that P5S showed the highest %<Deff>/D° among all the tested particles made the 
particle with compacted sulfobetaine surface as the particle with best surface chemistry. 
This sulfobetaine particle showed double the %<Deff>/D° value of PEG-PLGA NP. 
P4S also showed higher diffusivity than that of PEG-PLGA and mucus permeability 
comparable to that of SMEDD systems. P3S ranked within the fastest 10 particles for its 
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%<Deff>/D°.  Even the slowest sulfobetaine NP (P2S) showed a comparatively high 
%<Deff>/D° as compared with other strategies.  
 
Figure 5.27: Comparison of diffusivities of sulfobetaine NPs (defined by PXS 
abbreviation) as compared to 113 other NPs comprising various surface chemistries and 
permeation strategies. (A) Mucus diffusion <Deff> versus particle size. (B) % ratio 
<Deff>/D° versus zeta potential.   
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Figure 5.28: Histogram comparison of diffusivities of sulfobetaine NPs (defined by 
PXS abbreviation) as compared to 113 other NPs comprising various surface 
chemistries and permeation strategies. (A) <Deff> of various sulfobetaine NPs. (B) % 
ratio <Deff>/D° of various sulfobetaine NPs.  
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The superior mucus permeability results for sulfobetaine particles are not surprising and 
in accordance with the hypothesis and with the previous studies which have shown a 
very strong anti-adherent properties to proteins (introduction part of this chapter). Since 
mucin is simply a protein, then sulfobetaine at the shell of particles should not adhere to 
the mucin fibres and let particles to slip through the mucus network. The anti-adherent 
properties of sulfobetaine to the proteins (mucin) can be explained depending on two 
distinctive physicochemical properties of sulfobetaine.  
Firstly, sulfobetaine moiety at the terminal position has a unique chemical 
characteristic. This is related to the quaternary amino and sulfonate groups which are 
characterized by the disability of protonation at any pH [105]. Unlike carboxybetiane in 
which carboxylate group can be protonated at certain pH, sulfobetaine will never lose its 
negative or positive charges [115]. This makes sulfobetaine moiety to be fully charged 
with the oppositely charges on nthe surface at any pH in mucus. Hence, mucus 
components have no chance to form H bonds to sulfobetaine particles. H bonding is one 
of the main mucus pathway to trap hydrophilic particles that come in contact with 
mucus [116].  Also, the retaining of the positive and negative charges by the sulfonate 
and quaternary amine groups at any pH value will prevent the electrostatic interaction of 
the negatively charged mucin to the particles due to the repulsion by the negatively 
charged sulfonate group. The third pathway through which mucus can trap particles is 
the lipophilic interaction to the lipophilic core which is also diminished by the covering 
of the BMA lipophilic core with the sulfobetaine shell.  
Secondly, the anti-protein characteristic of some polymers is widely attributed to the 
hydration capability of these polymers [117]. As example, the tendency of PEGylated 
polymer to be hydrated is the reason for the non-specific protein-repulsion properties of 
PEG polymer and is known as water barrier theory [118]. According to this theory, the 
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water layer surrounding ethylene glycol molecules is thermodynamically stable and 
serves as a barrier that sterically prevents any interaction of protein molecules to the 
hydrated PEG polymer [119]. On the same basis, the efficient resistance to the protein 
adsorption to the eye lenses by the phosphorylcholine coating layer was explained on 
the high capacity of phosphorylcholine to hold water molecules which makes it very 
efficient protein-barrier [38].  
Wu and Chen studied the water holding capacity of sulfobetaine and PEG polymer 
using low-field NMR [120]. This study showed that while each ethylene glycol 
molecule holds one water molecule, on the other hand, each sulfobetaine moiety holds 
up to 8 water molecules indicating 8 times higher efficiency to form steric water layer to 
resist protein adsorption as compared to PEG. For this reason, a monolayer formed by 
self-assembly of zwitterionic molecules (phosphorylcholine) exerted an efficient protein 
resistance layer on gold surface [121] as compared with protein resistance properties of 
PEG layer which showed a limited protein resistance layer when ethylene glycol 
molecules were self-assembled on gold surface [122]. For self-assembled PEGylated 
layer, only the 6 units ethylene glycol has shown sufficient protein resistance properties 
in comparison with 2 and 4 units ethylene glycol. This is in agreement with the water 
holding capacity of the zwitterionic polymer and PEG polymer.  
From the abovementioned, the higher water holding capacity of sulfobetaine and 
diminished probability of sulfobetiane to form H bonds with the mucin are reasonable 
reasons for the high mucus permeability of these sulfobetaine NPs as compared with the 
known muco-diffusive PEG NPs. The only site within these novel NPs that can bind the 
mucus is the lipophilic BMA core. Ensuring a non-exposed BMA surface will ensure a 
lack of mucus interaction and slippery behaviour of these particles when they come in 
contact with mucus. For this reason, sulfobetaine NPs could be very promising NPs to 
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be investigated for in vivo studies and for the oral delivery of protein and peptides to 
permeate through the intestinal mucus barrier. 
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4 SUMMARY AND CONCLUSION 
In this study, RAFT technique was used to synthesize novel zwitterionic sulfobetaine 
co-polymers in which BMA is served as the lipophilic block polymer and sulfobetaine 
served as the hydrophilic block polymer. Various serial ratios of the zwitterionic BMA-
Sulfobetaine co-polymers were synthesized with controlled molecular weight. Then 
zwitterionic sulfobetaine NPs were formulated in which the BMA block polymer 
became the lipophilic core and the hydrophilic sulfobetaine the shell of these particles. 
The stability of these particles was studied to ensure the stability of these particles to 
exert their biological action. Also, re-suspendability after freeze drying of these 
particles was studied to assess the stability of these particles for the long storage term. 
The capacity of these particles to encapsulate big hydrophobic molecules exemplified 
by Lumogen red was examined in this chapter. Lastly, the diffusivity of these novel 
particles through the intestinal mucus barrier was studied. 
It was shown that by using proper techniques, it was possible to produce NPs possessing 
densely charged surface with an overall net neutral charge and excellent stability at 
physiological pH (biological fluid). Moreover, in contrast to the currently available 
neutrally charged surface NPs, these novel sulfobetaine NPs exhibited relatively small 
particle size (ca 50 nm) that were stable to be used to for mucus delivery. Also, these 
particles were re-suspended successfully after freeze drying with reproducing of their 
original particle sizes and zeta potential. The encapsulation efficiency for Lumogen red 
was dependent on the ratio of each block polymer with relatively high encapsulation 
efficiency for particles with highest BMA ratio (P2S). Moreover, the techniques 
involved in the synthesis of these particles are relatively simple and at lower costs than 
other techniques involved in the synthesis of other “BIO-Inert” NPs such as PEGylated 
NPs. Lastly, these sulfobetaine NPs were found to be highly diffusive through the 
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intestinal mucus barrier as compared with other particles synthesized by the partners in 
the consortium. 
Conclusions obtained from this study can be summarized as follows: 
 Trithiocarbonate was found to be a suitable CTA agent for the control 
polymerization of BMA and copolymerization of BMA-DMAEMA. 
 Particles with neutral surface charge, still can be very stable and having small 
particle size (<50 nm) if the oppositely charged groups are arranged on the same 
monomer (polybetaine polymer). This is unlikely to be obtained when neutrally 
charged NPs are prepared from polyampholyte polymer in which the opposite 
groups are on different monomers.  
 Moreover, the loading capacity and in vitro release of the lipophilic molecule 
was detected to be directly correlated to the size of the lipophilic core in shell-
core NPs.  
 The betaine shell on NP core can form muco-inert surface that can highly 
minimize the interaction of NPs with the mucus components leading to highly 
diffusive NPs. 
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1 General Conclusive Discussion 
Oral delivery of certain types of therapeutic agents like peptides and proteins is very 
limited due to the environmental and enzymatic degradation. These therapeutic agents 
need to be protected from the GIT environment to be delivered in effective therapeutic 
level. This issue was found to be possible through the incorporation of these therapeutic 
agents into suitable nano-delivery systems which provides enzymatic protection and 
sustained drug release to improve their bioavailability. For intestinal mucosal delivery, 
NPs need to permeate through the mucus layer covering the mucosa.  
All studies that have been carried out showed that mucus permeation is the limiting step 
for NPs to be absorbed through the intestinal mucosa. Some promising results have 
been obtained in terms of in vitro NPs permeation and in vivo drug bioavailability. 
However, nano-delivery through intestinal mucus is still one of the most challenging 
tasks in the world of drug delivery due to many reasons such as the trapping of the 
majority of NPs in the intestinal mucus and selecting of the improper techniques to 
measure NPs permeation through mucus barrier. 
The ultimate aim of the Alexander European consortium was to synthesize muco-
diffusive NP that can be used to for oral delivery of certain peptides such as insulin. For 
this reason, this thesis aimed to synthesize novel NPs that can highly diffuse through the 
intestinal mucus barrier. This was achieved step by step through the preparation of the 
elements enabling by the end to obtain novel highly permeable NPs through the 
intestinal mucus barrier. These elements were: the suitable pig intestinal mucus barrier 
model, the proper technique to measure NPs diffusion through the mucus and 
understanding the factors affecting NPs diffusion through the intestinal mucus barrier.  
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In the second chapter, two pig intestinal mucus models were introduced, one is native 
and collected from the pig intestine with no further processing steps; ”Cardiff native 
mucus”, while the other was squeezed from the pig intestine followed by washing steps 
“Consortium mucus gel” model. These mucus models were studied biophysically to 
identify their structural and physical properties. Thus, the water content, pH and 
rheological properties of each mucus model were examined; also, AFM imaging was 
used to study the structural properties of each model. These biophysical tests were used 
to identify differences between each model and to use these differences to interpret the 
diffusion of NPs through the both mucus models. 
The MPT technique was exploited to study particles diffusion through the both pig 
intestinal mucus models. To do so, the MPT technique was validated to ensure that the 
diffusion data is valid for all the tested particles. Hence, carefully selected NPs in which 
Lumogen red dye was encapsulated were used so as to validate the fluorescent dye, the 
fluorescent microscopy, the mucus and the tracking software so as to limit any error 
associated with the measurement of particles diffusion through the mucus by this 
technique. The diffusion of particles through the two mucus models were studied by the 
MPT technique to identify the best mucus model that can used to study the diffusion of 
other NPs.  
In chapter three, the diffusion coefficients of various NPs representing different nano-
strategies to overcome the mucus barrier were tested. These nano-strategies included 
slippery surface PEG NPs, slippery surface polymer mixture, slippery PEC NPs, 
SMEDD systems, mucolytic NPs and thiomer NPs. These NPs were synthesized and 
fluorescently labelled by the partners in the Alexander consortium. The diffusivities of 
all these NPs were compared through both mucus models. Particles were ranked 
depending on their diffusivities through the mucus barrier, to identify the promising 
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muco-diffusive nano-strategy. Also, the nano-strategy that was not covered adequately 
by the partners in the Alexander consortium was identified for further studies.  
In chapter four, determined by the outcomes of Chapter three where the PEC nano-
strategy was found to not be studied properly by our partners, this PEC NP strategy was 
studied and compared with other slippery surface nano-strategies. PEC NPs were 
synthesized in which chitosan and PAA polymers were the source of the positively and 
negatively charged polymer respectively. Chitosan and PAA were mixed at serial ratios 
to produce densely surface charge particles with zeta potential ranging from highly 
negative to neutral up to highly positive charges and with various particle sizes. The 
diffusivity through the mucus was increased as the surface charge of these particles 
approached neutrality; oppositely, the diffusivity through mucus was decreased as the 
charge of these particles was increased either positively or negatively. However, even 
with the promising diffusivities of these particles through mucus barrier, the low 
stability of these particles limited the use of these particles. Hence, developing particles 
with neutral surface charge and high stability was the next aim in the thesis.  
In chapter five, novel NPs with densely surface charge but with overall neutral zeta 
potential and with very small particle sizes were synthesized. To achieve this goal, the 
reversible addition fragmentation chain transfer (RAFT) technique was used to 
synthesize co-polymers with lipophilic and zwitterionic hydrophilic block. NPs were 
made from these polymers in which the lipophilic core was the butyl methyl 
methacrylate (BMA) and the hydrophilic shell was the hydrophilic slufobetaine 
polymer. These novel small particles (< 50 nm) were highly charged with overall 
neutral zeta potential and very stable. These physicochemical properties should enable 
these particles to be highly muco-diffusive and stable enough to exert their biological 
activity. 
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Following the synthesis of these novel NPs, the diffusivity of these sulfobetaine 
particles through the mucus was studied. These particles were found to be highly 
diffusive through the intestinal mucus when they were compared with other strategies 
that were adopted by the other partners in the Alexander consortium. The ability of 
sulfobetaine NP to cross mucus barrier will allow more ready access to the underlying 
epithelial surface for the absorption of material released from the NP as cargo. With this 
discovery, the main aim of this thesis was achieved through the obtaining of these novel 
zwitterionic muco-diffusive NPs.  
2 Future Works 
 Sulfobetaine NPs 
Besides the promising in vitro diffusion data through mucus barrier, these sulfobetaine 
NPs are inexpensive, biocompatible and easy to prepare. Hence, these NPs could be 
exploited for wider therapeutic applications for which further studies are required. 
These further studies and exploitations can be summarized as follows: 
(i) In vivo and toxicity studies could be performed in the future to prove the 
suitability of these NPs to improve the bioavailability of orally administered 
peptide with low bioavailability such as insulin and to correlate the in vivo 
and in vitro data to prove the concept of the mucus permeability of these 
NPs.  
(ii)  Chemical modification of these NPs could be done by altering the size or 
the type of the lipophilic core or the zwitterionic hydrophilic shell. For 
example, BMA could be replaced by another lipophilic block polymer. 
Further studies could be performed to investigate the effect of new chemical 
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entities on the physicochemical properties and diffusion behaviour of these 
sulfobetaine NPs.  
(iii) Further chemical and physical analytical studies such as scanning electron 
microscopy and differential scanning microscopy are required in the future 
for better understanding and explanation of the formation of sulfobetaine 
NPs.  
(iv) Due, to the densely charged nature, Sulfobetaine NPs could have long 
circulating properties following intravenous, intramuscular, sub-cutaneous or 
intra-dermal administration. Hence, further pharmacokinetic studies could be 
done in the future to study the suitability of these NPs for other clinical 
applications and pharmaceutical devices. 
(v) Following the high diffusion data through the mucus biopolymer barrier, the 
permeation of these NPs through the biopolymer barrier of bacterial biofilms 
is a promising area to be studied in the future. 
  MPT Technique 
(i) Further studies are required in the future for better understanding of the 
process involved in the measurement of NPs diffusion through the mucus 
barrier by the MPT technique. Factors such as changing the mucus 
preparation steps and time of the addition of NPs suspension into mucus 
sample could reveal better explanation about the process of NPs mixing 
with, penetration across and diffusion through the mucus barrier. 
(ii) MPT technique could be exploited in the future to study NPs permeation 
through the biopolymer bacterial biofilm. 
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APPENDIX A 
AFM IMAGES OF THE PIG INTESTINAL “CARDIFF 
NATIVE MUCUS” MODEL AND THE “CONSORTIUM 
MUCUS GEL” MODEL 
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Figure A.1: AFM imaging of the surface morphology from different scanned areas within the 
“Cardiff native mucus” model. (A) Medium scale (15x15 µm) AFM image of one area within 
the mucus sample, (B) Medium scale (15x15 µm) AFM image of another area imaged within 
the mucus sample, (C) Large scale (25x25 µm) AFM image of another different area imaged 
within the mucus sample. 
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Figure A.2: AFM imaging of the surface morphology from different scanned areas within the 
“Consortium mucus gel” model. (A) Medium scale (15x15 µm) AFM image of one site 
within the mucus sample showing 5 and 2.5 micron pores, (B) Medium scale (15x15 µm) 
AFM image of another site imaged within the mucus sample showing 5 and 7.5 micron pores.  
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Figure A.3: AFM imaging of the surface morphology of the “Consortium mucus gel” model 
at medium scale of (15x15 µm) showing a (5 x 5) micron aggregated cluster of mucin fibres. 
 
Figure A.4: AFM imaging of the surface morphology of the “Consortium mucus gel” model 
at small scale of (2x2 µm) showing the mucin fibres bundling into thick cables. 
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APPENDIX B 
DIFFUSION OF NPS REPRESENTING NANO-
STRATEGIES ADOPTED BY THE ALEXANDER 
PARTNERS THROUGH THE “CONSORTIUM MUCUS 
GEL” MODEL (PROCESSED INTESTINAL MUCUS 
BARRIER) 
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Table B.1: Particles’ composition, physical characteristics and diffusion behavior of various PEGylated NPs in the “Consortium mucus gel” model. 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean (± s.d.) 
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% of  Deff 
to D°          
Ranking  
Fastest to 
slowest 
Nanomi 
PLGA-15% 
PEG (5000) 
PLGA coated with 15% methoxy PEG 
(MW: 5000). 
-18   35  127.8 
0.00702 
(±0.00167) 
0.0055 29 
PLGA-15% 
PEG (6000) 
PLGA coated with 15% PEG (MW: 
6000). 
-8.3 54  83.22 
0.01396 
(±0.00477) 
0.0168 9 
PLGA-10% 
PEG (5000) 
PLGA coated with 10% methoxy PEG 
(MW: 5000). 
-26   41  110.7 
0.00561 
(±0.00113) 
0.0051 31 
Nevara 
 
G-15% PEG 
(2000) 
Lipophilic polymer coated  with 15% 
PEG (MW: 2000) (Lyophilized NP) 
-45 178  25.21 
0.00100 
(±0.00013) 
0.0040 38 
G-15% PEG 
(6000) 
Lipophilic polymer  coated  with 15% 
PEG (MW: 6000) (Lyophilized NP) 
-47 230  19.54 
0.00026 
(±0.00005) 
0.0013 71 
AUTH 
RG502H- 
PEG2000 
Acidic PLGA (50:50) coated with 25% 
methoxy PEG (MW:2000) 
-20 300  15.01 
0.00023 
(±0.00004) 
0.0015 67 
RG502H- 
PEG5000 
Acidic PLGA (50:50) coated with 25% 
methoxy PEG (MW:5000) 
-14 287  15.64 
0.00038 
(±0.00007) 
0.0025 55 
RG752H- 
PEG2000 
Acidic PLGA (75:25) coated with 25% 
methoxy PEG (MW:2000) 
-11 301  14.91 
0.00047 
(±0.00009) 
0.0032 48 
RG752H- 
PEG5000 
Acidic PLGA (75:25) coated with 25% 
methoxy PEG (MW:5000) -9 261  17.21 
0.00031 
(±0.00006) 
0.0018 64 
 
 
 
 
PEC- 22.5% 
PEG 
 
 
(70:30) Negatively charged polymer+ 
Positively charged polymer conjugated to 
75% PEG (Total ratio of PEG is 22.5%) 
-28 250  17.98 
0.00088 
(±0.00015) 
0.0049 33 
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LEK 
PEC- 52.5% 
PEG 
(30:70) Negatively charged polymer+ 
Positively charged polymer conjugated to 
75% PEG (Total ratio of PEG is 52.5%) 
-12 250 17.98 
0.00306 
(±0.00039) 
0.0170 8 
PEC- 15.0% 
PEG 
 
 
(70:30) Negatively charged polymer+ 
Positively charged polymer conjugated to 
50% PEG (Total ratio of PEG is 15%) 
-27 250  17.98 
0.00035 
(±0.00009) 
0.0020 60 
PEC- 35.0% 
PEG 
(30:70) Negatively charged polymer+ 
Positively charged polymer conjugated to 
50% PEG (Total ratio of PEG is 35%) 
-15 250  17.98 
0.00287 
(±0.00052) 
0.0160 10 
 Mix 3 PLGA-PEG  
120 37.45 
0.00305 
(±0.00057) 
0.00814 21 
 Mix 4 PLGA-PEG  
342 13.13 
0.00066 
(±0.00011) 
0.00502 32 
Evonik Mix 10 PLGA-PEG  
424 10.58 
0.00464 
(±0.00171) 
0.04386 1 
 Mix 18 PLGA-PEG  
183 24.56 
0.00471 
(±0.00088) 
0.01916 7 
 Mix 19 PLGA-PEG  
171 26.28 
0.00516 
(±0.00118) 
0.01962 6 
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Figure B.1: (A) Mucus diffusion <Deff> versus particle size of PEGylated NPs in the 
“Consortium mucus gel” model. (B) % ratio <Deff>/D° versus zeta potential of 
PEGylated NPs in the “Consortium mucus gel” model. 
 
 
 
 297 
 
 
Table B.2: Particles’ composition, physical characteristics and diffusion behavior of slippery polymer mixture NPs in the “Consortium mucus gel” model. 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean (± s.d.) 
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% of  Deff 
to D°          
Ranking  
Fastest to 
slowest 
Nevara 
NPA-L-L Gantrez NP -53 217  20.71 
0.00110 
(±0.00018) 
0.0053 30 
1% D-M-L-L Lipophilic polymer coated with 1% D-
mannosamine hydrochloride 
-40 242 (0.11) 18.56 
0.00083 
(±0.00014) 
0.0045 35 
2.5% D-M-L 
-L 
Lipophilic polymer coated with 2.5% D-
mannosamine hydrochloride 
-35 271 (0.12) 16.56 
0.00064 
(±0.00016) 
0.0039 39 
5% D-M-L-L Lipophilic polymer coated with 5% D-
mannosamine hydrochloride 
-45 263 (0.12) 17.09 
0.00545 
(±0.00098) 
0.0319 2 
7.5% D-M-L 
-L 
Lipophilic polymer coated with 7.5% D-
mannosamine hydrochloride 
-49 332 (0.13) 13.54 
0.00151 
(±0.00025) 
0.0111 16 
10% D-M-L-
L 
Lipophilic polymer coated with 10% D-
mannosamine hydrochloride 
-39 367 (0.12) 12.25 
0.00265 
(±0.00050) 
0.0216 3 
1% CO-DM 
L-L 
Lipophilic polymer copolymerized with 
1% D-mannosamine hydrochloride 
-37 265 (0.12) 16.96 
0.00041 
(±0.00009) 
0.0024 56 
2.5% CO-D 
M-L-L 
Lipophilic polymer copolymerized with 
2.5% D-mannosamine hydrochloride 
-31 249 (0.13) 18.05 
0.00058 
(±0.00009) 
0.0032 47 
5% CO-DM 
L-L 
Lipophilic polymer copolymerized with 
5% D-mannosamine hydrochloride 
-37 242 (0.12) 18.57 
0.00161 
(±0.00024) 
0.0087 20 
7.5% CO-
DM L-L 
Lipophilic polymer copolymerized with 
7.5% D-mannosamine hydrochloride 
-45 254 (0.12) 17.69 
0.00028 
(±0.00005) 
0.0016 66 
10% CO-DM 
L-L 
Lipophilic polymer copolymerized with 
10% D-mannosamine hydrochloride 
-39 243 (0.14) 18.49 
0.00052 
(±0.00009) 
0.0028 51 
1% LMPEC-
L-L 
 
Lipophilic polymer coated with 1% low 
methoxylated pectin -49 340 (0.21) 13.22 
0.00280 
(±0.00072) 
0.0212 4 
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5% LMPEC-
L-L 
Lipophilic polymer coated with 5% low 
methoxylated pectin 
-59 237 (0.23) 18.96 
0.00203 
(±0.00032) 
0.0107 17 
5% LMPEC-
L-L- 0.5 
BSA 
Lipophilic polymer coated 5% low 
methoxylated pectin loaded with 0.5% 
BSA 
-47 174 (0.22) 25.83 
0.00029 
(±0.00001) 
0.0011 76 
5% LMPEC-
L-L- 1 BSA 
Lipophilic polymer coated with 5% low 
methoxylated pectin loaded with 1% BSA 
-43 161 (0.24) 28.00 
0.00134 
(±0.00008) 
0.0048 34 
5% LMPEC-
L-L- 1.5 
BSA 
Lipophilic polymer coated with 5% low 
methoxylated pectin and loaded with 
1.5% BSA 
-41 174 (0.24) 25.90 
0.00147 
(±0.00008) 
0.0057 28 
5% LMPEC-
L-L- 2 BSA 
Lipophilic polymer coated with 5% low 
methoxylated pectin and loaded with 2% 
BSA 
-42 163 (0.25) 27.62 
0.00112 
(±0.00007) 
0.0041 37 
10% LMPEC 
-L-L 
Lipophilic polymer coated with 10% low 
methoxylated pectin 
-53 251 (0.23) 17.90 
0.00116 
(±0.00021) 
0.0065 27 
1% Co-LMP 
EC-L-L 
Lipophilic polymer copolymerized with 
1% low methoxylated pectin 
-49 221 (0.24) 20.34 
0.00231 
(±0.00032) 
0.0114 15 
5% Co-LMP 
EC-L-L 
Lipophilic polymer copolymerized with 
5% low methoxylated pectin 
-35 221 (0.23) 20.34 
0.00072 
(±0.00012) 
0.0036 42 
10% Co-LM 
PEC-L-L 
Lipophilic polymer copolymerized with 
10% low methoxylated pectin 
-39 175 (0.22) 25.68 
0.00034 
(±0.00008) 
0.0013 70 
1% HMPEC-
L-L 
Lipophilic polymer coated with 1% high 
methoxylated pectin 
-45 239 (0.24) 18.80 
0.00079 
(±0.00016) 
0.0042 36 
5% HMPEC-
L-L 
Lipophilic polymer coated with 5% high 
methoxylated pectin 
-52 261 (0.23) 17.22 
0.00039 
(±0.00009) 
0.0023 57 
10% HMPE 
C-L-L 
Lipophilic polymer coated with 10% high 
methoxylated pectin 
-46 274 (0.25) 16.40 
0.00020 
(±0.00003) 
0.0012 73 
1% Co-HMP 
EC-L-L 
Lipophilic polymer copolymerized with 
1% high methoxylated pectin 
-43 178 (0.23) 25.25 
0.00164 
(±0.00033) 
0.0065 26 
5% Co-HMP 
EC-L-L 
Lipophilic polymer copolymerized with 
5% high methoxylated pectin 
-47 157 (0.24) 28.63 
0.00040 
(±0.00007) 
0.0014 69 
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10% Co-HM 
PEC-L-L 
Lipophilic polymer copolymerized with 
10% high methoxylated pectin 
-36 168 (0.23) 26.75 
0.00040 
(±0.00008) 
0.0015 68 
CO-TH- SD Lipophilic polymer copolymerized with 
thiamine (spray dried NP) 
-29 231 (0.21) 19.46 
0.00006 
(±0.00001) 
0.0003 80 
OA-SD -L Lipophilic polymer copolymerized with  
octadecyl- amine (spray dried NP) 
-57 227 (0.22) 19.80 
0.00023 
(±0.00007) 
0.0012 75 
NIC- SD Lipophilic polymer copolymerized with  
nicotin- amide  (spray dried NP) 
-40 297 (0.25) 15.13 
0.00049 
(±0.00008) 
0.0032 46 
HPCD-SD Lipophilic polymer copolymerized with  
2-hydroxypropyl-beta-cyclodextin (spray 
dried NP) 
-57 245 (0.23) 18.34 
0.00047 
(±0.00011) 
0.0026 53 
TH- SD Lipophilic polymer coated with thiamine 
NP 
-41 240 (0.12) 18.75 0.00019 
(±0.00005) 
0.0010 77 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                   Appendix B 
 
300 
 
 
Figure B.2: (A) Mucus diffusion <Deff> versus particle size of slippery polymeric mixture NPs 
in the “Consortium mucus gel” model. (B) % ratio <Deff>/D° versus zeta potential of 
various slippery polymeric mixture NPs in the “Consortium mucus gel” model. 
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Table B.3: Particles’ composition, physical characteristics and diffusion behavior of PEC NPs in the “Consortium mucus gel” model. 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean (± s.d.) 
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% of  Deff 
to D°          
Ranking  
Fastest to 
slowest 
Lek 
L1009 (90:10)  Unknown (+)  charged polymer + 
(-) Alginate 
16 250  17.98 
0.00031 
(±0.00006) 
0.0017 65 
L1010 (30:70)  Unknown (+)   charged polymer 
+ (-)  chondroitin 4-sulfate  
-22 250  17.98 
0.00022 
(±0.00005) 
0.0012 72 
L1011 (40:60)  Unknown (+)   charged polymer 
+ (-) chondroitin 4-sulfate  
-18 250 17.98 
0.00037 
(±0.00010) 
0.0019 62 
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Figure B.3: (A) Mucus diffusion <Deff> versus particle size of PEC NPs in the “Consortium 
mucus gel” model. (B) % ratio <Deff>/D° versus zeta potential of PEC NPs in the “Consortium 
mucus gel” model. 
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Table B.4: Particles’ composition, physical characteristics and diffusion behavior of NPs loaded with mucolytic agent in the “Consortium mucus gel” model. 
Partner NP Code Compositions Zeta Potential 
(mV) 
Mean  
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% of  Deff 
to D°          
Ranking  
Fastest to 
slowest 
Insbruck 
PAA-PAP 
PAA NP loaded with  25% Papaine 
(proteolytic agent) 
-27 352 (0.26) 12.77 
0.00034 
(±0.00006) 
0.0026 52 
PAA-BRO 
PAA NP loaded with   25%  Bromelaine ( 
proteolytic  agent) 
-20 304 (0.29) 14.78 
0.00099 
(±0.00018) 
0.0067 25 
 
Sagetis 
CSTGA360/-
CD3 
Chitosan-thioglycolic acid+ unknown (-) 
charged Poly(β-amino ester)s (PBAEs) 
(disulfide breaking agent). 
NA NA NA NA NA NA 
CSNAC177/
CD3 
Chitosan-NAC+ unknown (-) charged 
Poly(β-amino ester)s (PBAEs) (disulfide 
breaking agent). 
NA NA NA NA NA NA 
CSGSH188/
CD3 
Chitosan-Glutathione + unknown (-) 
charged Poly(β-amino ester)s (PBAEs) 
(disulfide breaking agent). 
NA NA NA NA NA NA 
Nevara 
0.3P-NPA-L-
L 
Muco-adhesive NP loaded with papain 
(0.3 %) (lyophilized NP)  
-45 315 (0.19) 14.27 
0.00150 
(±0.00031) 
0.0105 18 
0.3P-NPB-L-
L 
Muco-adhesive NP loaded with papain 
(0.3 %)  (spray dried NP) 
-46 216 (0.24) 20.80 
0.00045 
(±0.00007) 
0.0022 59 
20NAC-NPA 
-L-L 
Muco-adhesive NP loaded with NAC (5 
%) (lyophilized NP) 
-51 145 (0.32) 30.95 
0.00037 
(±0.00002) 
0.0012 74 
200NAC-NP 
A-L-L 
Muco-adhesive NP loaded with NAC (50 
%) (lyophilized NP) 
-53 189 (0.18) 23.77 
0.00047 
(±0.00003) 
0.0020 61 
20NAC-NPB 
-L-L 
Muco-adhesive NP loaded with NAC (5 
%) (spray dried NP) 
-28 231 (0.20) 19.49 
0.00075 
(±0.00004) 
0.0038 40 
200NAC-NP 
B-L-L 
Muco-adhesive NP loaded with NAC (50 
%) (spray dried NP) 
-23 440 (0.30) 10.21 
0.00075 
(±0.00004) 
0.0073 22 
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Figure B.4: (A) Mucus diffusion <Deff> versus particle size of NPs loaded with mucolytic 
agent in the “Consortium mucus gel” model. (B) % ratio <Deff>/D° versus zeta potential of 
NPs loaded with mucolytic agent in the “Consortium mucus gel” model. 
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Figure B.5: Structures of main polymers used by the partners in chapter 3. 
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APPENDIX C 
KINETIC STUDIES ON THE DIFFUSION OF SMEDD 
SYSTEMS LOADED WITH THIOL AND NAC AGENTS 
THROUGH THE PIG INTESTINAL “CARDIFF NATIVE 
MUCUS” MODEL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                   Appendix C 
 
 
307 
 
SMEDD systems that were studied in this work are as follows: SMEDD system loaded 
with TBA-dodecylamine was given the symbol SMEDD A, while the SMEDD system 
loaded with the other thiol agent (TGA-octylamine) was given the symbol SMEDD B. 
Accordingly, the SMEDD system loaded with NAC was given the symbol SMEDD 
NAC. Lastly, the blank SMEED system which was not loaded with any thiol or 
mucolytic agents was given the symbol SMEDD C.  
Table C.1: Zeta potential, particle size, Diffusion coefficient in water and mucus, % 
ratio of <Deff>/D
o
 and percentage (%) of diffusive particles of various SMEDDS 
preparations. 
 
 
 
 
 
 
 
SMEDDS 
Zeta 
potential 
(mV) 
Mean 
( + s.d.) 
Particle size 
(nm) 
Mean (PDI) 
D
o
 (water) 
cm
2
.S
-1 
x 10
-9
 
<Deff> 
(mucus) 
cm
2
.S
-1 
x 10
-9
 
Mean 
( + s.e.m) 
% Ratio 
<Deff>/D
o
 
% 
Diffusive 
particles 
A 
-2.1 
( + 0.5) 
44.42 
(0.04) 
101.18 
0.87123 
( + 0.1223) 
0.8611 59 
B 
-2.2 
( + 0.4) 
53.39 
(0.04 ) 
82.28 
0.05135 
( + 0.0089) 
0.0624 35 
C 
-0.8 
( + 0.9) 
36.91 
(0.05) 
122.12 
0.01318 
( + 0.0003) 
0.0108 16 
NAC 
 
-7.1 
( + 0.2) 
43.89 
(0.23) 
102.41 
0.24624 
( + 0.0376) 
0.2405 40 
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Figure C.1: Correlation of particle size and surface charge of various SMEDDS to their 
mucus diffusion. (A) Correlation of particle size of various SMEDDS versus <Deff>. 
(B) Correlation of zeta potential of various SMEDDS versus <Deff>. (c) Correlation of 
zeta potential of various SMEDDS versus the % ratio of <Deff>/D°.  Particle size of 
NPs is expressed in nm, Zeta potential is expressed in mV and Deff is measured in cm2. 
s-1 *109. 
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Figure C.2: Comparison of average Deff of SMEDDS A, SMEDDS B, SMEDDS C 
and SMEDDS NAC at a time scale of 1 sec in mucus of subclasses from the fastest to 
the slowest percentile. Figure presents data of 3 experiments each with n ≥ 120 
particles. 
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Figure C.3: Effective diffusivities Deff versus time scale of 20 randomly selected 
particles selected by (random.org). (A) SMEDDS A: high ratio of particles shows 
diffusivities. (B) SMEDDS C: Some particles are diffusive vs major restricted particles.   
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APPENDIX D 
KINETIC STUDIES ON THE DIFFUSION OF PEC NPS 
SYNTHESIZED BY SAGETIS GROUP THROUGH THE 
NATIVE PIG INTESTINAL MUCUS MODEL 
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Five PEC NPs were synthesized by Sagetis group to be studied for their kinetics of 
diffusivity through the native pig intestinal mucus model. PAA and unknown novel 
peptide agent were used as the source of the positively and negatively charged 
polymers.  Moreover, these PEC NPs were loaded with the mucolytic agent (papaine). 
These PEC NPs were symbolised as follows: RDPB0, 
RDPB0.17,RDPB0.33,RDPB0.67,RDPB1.33.  
Table D.1: Zeta potential, particle size, Diffusion coefficient in water and mucus, % 
ratio of <Deff>/D
o
 and percentage (%) of diffusive particles of various PEC NPs. 
RDPB 
 
Zeta 
potential 
(mV) 
Mean  
( +s.d.) 
Particle 
size 
(nm) 
Mean 
(PDI) 
D
o
 (water) 
cm
2
.S
-1 
x 10
-
9
 
<Deff> 
(mucus) 
cm
2
.S
-1 
x 10
-9
 
Mean  
( +s.e.m) 
% Ratio 
<Deff>/D
o
 
% 
Diffusiv
e 
particles 
0 20.2 143 31.4 
0.0283 
(+0.0081) 
0.0900 21 
0.17 19.3 134 33.4 
0.3281 
(+0.0683) 
0.9823 
 
61 
0.33 19.6 138 32.6 
0.0546 
(+0.0093) 
0.1675 34 
0.67 18.1 213 21.1 
0.0099 
(+0.0024) 
0.0471 2 
1.33 13.4 368 12.2 
0.0145 
(+0.0048) 
0.1188 24 
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Figure D.1: Correlation of particle size and surface charge of various RDPB to their 
mucus diffusion. (A) Correlation of particle size of various RDPB versus <Deff>. (B) 
Correlation of zeta potential of various SMEDDS versus <Deff>. (c) Correlation of zeta 
potential of various RDPB versus the % ratio of <Deff>/D°.  Particle size of NPs is 
expressed in nm, Zeta potential is expressed in mV and Deff is measured in cm
2
. s
-1
 
*10
9
. 
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Figure D.2: Comparison of average Deff of RD, RDPB0.17, RDPB0.33, RDPB0.67 
and RDPB1.33 at a time scale of 1 sec in mucus of subclasses from the fastest to the 
slowest percentile. Figure presents data of 3 experiments each with n ≥ 120 particles. 
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Figure D.3: Effective diffusivities Deff versus time scale of 20 randomly selected 
particles selected by (random.org). (A) RDPB0.17: high ratio of particles shows 
diffusivities. (B) RD: Some particles show diffusivity vs major restricted particles.   
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APPENDIX E 
DIFFUSION BEHAVIOUR OF (PAA:CHITOSAN) PEC NPs, 
PLGA, PEG-PLGA AND AD5 THROUGH THE 
“CONSORTIUM MUCUS GEL” MODEL (CHAPTER FOUR) 
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Table E.1: Diffusion coefficient measurements of various polyelectrolyte NPs, PLGA, PEG-PLGA and AD5 in gel-mucus and water obtained by 
using Epifluorescence microscopy and by Einstein-stokes equation. 
Nature of  NPs PAA:Chitosan 
Mass ratio 
Code Zeta Potential 
(mV) 
Mean (± s.d.) 
Particle Size   
(nm) 
Mean (PDI) 
D°  (water) 
cm2. S-1 x10-9 
<Deff>  (mucus) 
cm2. S-1 x10-9 
Mean (± s.e.m) 
% Ratio 
<Deff> / 
D° 
Negatively 
charged  
Polyelectrolyte  
5:1 F1 -29.1 (±3.6) 104 (0.14) 43.21 0.00131        (0.00022) 0.0030 
4:1 F2 -30.6 (±4.4) 149 (0.10) 30.16 0.00211        (0.00038) 0.0070 
3:1 F3 -25.0 (±4.0) 204 (0.21) 22.03 0.00334        (0.00057) 0.0152 
2:1 F4 -18.9 (±1.3) 225 (0.13) 19.97 0.00255        (0.00053) 0.0128 
1:1 F5 -15.4 (±0.8) 357 (0.21) 12.59 0.00198        (0.00033) 0.0157 
1:1* F6 -15.2 (±1.2) 365 (0.21) 12.31 0.00192        (0.00036) 0.01557 
Neutral  
Polyelectrolyte 
1:2.2 F7    -0.5 (±1.9)  1244 (0.32)  3.61 0.00024        (0.00005) 0.0067 
1:2.2* F8 +1.1 (±2.4) 334 (0.19) 13.46 0.00268        (0.00045) 0.0199 
Positively 
charged  
Polyelectrolyte 
1:3 F9 +6.0 (±1.1) 144 (0.18) 31.21 0.00319        (0.00054) 0.0102 
1:4 F10 +14.3 (±0.3) 104 (0.09) 43.21 0.00154        (0.00027) 0.0036 
1:5 F11 +19.2 (±0.5) 180 (0.17) 24.97 0.00082        (0.00014) 0.0033 
1:6 F12 +19.5 (±0.9) 293 (0.17) 15.34 0.00048        (0.00009) 0.0031 
1:8 F13 +19.2 (±0.6) 359 (0.11) 12.52 0.00041        (0.00007) 0.0033 
1:8* F14 +19.5 (±2.3) 373 (0.23) 11.92 0.00039        (0.00007) 0.00328 
Lipophilic PLGA - -29.2 (±2.1) 161 (0.03) 27.91 0.00021        ( 0.00005) 0.0008 
Hydrophillic PEG-PLGA - -8.3 (±1.2)  54 (0.03) 83.22 0.01396        ( 0.00425) 0.0168 
Capsid Virus AD5 - -0.5 (±2.3) 146 (0.18) 30.78 0.00449        (0.00090) 0.01458 
* indicates NPs sonicated after fabrication prior to diffusion measurement.  
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APPENDIX F 
1H-NMR SPECTRUM OF THE MONOMERS AND CTA USED 
TO SYNTHESIZE THE POLYMERS AND CO-POLYMERS IN 
CHAPTER FIVE (BMA, DMAEMA, 2-CYANO-2-PROPYL 
DODECYL TRITHIOCARBONATE) 
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Figure F.1: 1H-NMR spectrum of the BMA monomer (Solvent: CDCL3). 
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Figure F.2: 1H-NMR spectrum of the DMAEMA monomer (Solvent CDCL3). 
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Figure F.3: 1H-NMR spectrum of the 2-Cyano-2-propyl dodecyl trithiocarbonate (Solvent: 
CDCL3). 
 
 
